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QUILL ON SCALPEL
This section provides a medium through which Canadian 
surgeons can declare themselves, briefly and informally, on 
the day-to-day affairs of surgery.
Important Modification of the Jejunoileal Bypass 
Procedure for Morbid Obesity
The surgical management of the morbidly 
obese patient has been the subject of often 
bitter debate over the last 30 years. The 
jejunoileal bypass, championed by Payne, 
by Scott and by Salmon, has been 
associated with high morbidity and the 
occasional death. This has prompted a 
renewed interest in gastric procedures for 
such patients, procedures that also have 
had their share of failures and complica­
tions.
A novel approach to preventing bac­
terial overgrowth in the defunctioned 
loop, presented in this issue (pages 114 to 
116) by Cleator and Gourlay, introduces 
an innovation that may solve the 
problems related to the major morbidity 
of traditional jejunoileal bypass surgery.
In his monograph on intestinal 
bypass1 Mason stated, in 1981, “ If the 
bypassed bowel could be emptied into 
some sterile area so that it would not 
become a receptor for bacterial over­
growth, these problems would not arise.” 
He was referring to the effects of bacterial 
overgrowth in the bypassed segment
which resulted in excessive weight loss and 
diarrhea, and hepatic, joint, skin and 
electrolyte abnormalities. Cleator and 
Gourlay present a well-studied series of 
50 patients in whom the bypassed segment 
was drained through the anterior wall of 
the stomach, thus avoiding the bacterial 
environment Mason described. The 
weight loss in their series, together with 
the lack of major side effects, is a stimu­
lus to others interested in surgery for mor­
bid obesity to duplicate their results.
When I arrived in Vancouver to head 
the Department of Surgery at St. Paul’s 
Hospital and found that jejunoileal 
bypass procedures were still being done 
in my department, my initial impulse was 
to ask Dr. Gourlay to stop performing the 
operation forthwith! But after observing 
some of these patients on the wards and 
the end results in others, I was quickly 
convinced that the procedures, as modi­
fied, had considerable merit. Dr. Gourlay 
was encouraged to study a consecutive 
series of cases thoroughly in order to 
justify his enthusiasm for the procedure.
The results form the basis for the current 
paper.
The remaining problems to be solved 
with this procedure are related to the 
excretion of oxalates and the occasional 
patient who has low magnesium and cal­
cium levels, in spite of no diarrhea. Both 
problems appear, however, to be transient 
and are the subject of continued study by 
Dr. Cleator and his colleagues.
If these results can be duplicated by 
other surgeons, the operation will be an 
important addition to the armamentar­
ium of those treating morbid obesity.
Jo h n  K . M a c Fa r l a n e , m d , f r c s c , f a c s  
Head,
Department of Surgery,
St. Paul’s Hospital,
1081 Burrard St.,
Vancouver, BC 
V6Z 1Y6
Reference
1. Mason EE: Surgical Treatment o f  Obesity (Major 
Problems in Clinical Surgery, Vol. 26), Saunders, 
Philadelphia, 1981: 105
The Canadian Journal of Surgery 
1867 Alta Vista Dr.
Ottawa, Ont. K1G 3Y6  
Tel.: (613) 731-9331
The Canadian Journal o f Surgery is published by the Canadian Medical Association 
and sponsored by the Royal College o f Physicians and Surgeons of Canada. The es­
tablishment of editorial policy is the responsibility o f the Royal College. The objec­
tives o f the Journal, endorsed by the Council of the College, are: (1) to contribute 
to the effective continuing education o f Canadian surgical specialists, using innova­
tive techniques when feasible and (2) to provide Canadian surgeons with an effec­
tive vehicle for the dissemination of their observations in the area of clinical research.
Published every 2 months by the Canadian Medical Association, PO Box 8650, 
Ottawa, Ont. K1G 0G8. Printed by HarpeH's Press Cooperative, Gardenvale, PQ
HO A I BO. Second-class mail registration No. 5375. Return postage guaranteed. All 
reproduction rights reserved. Subscription rate for Canada and USA $30.00 per year 
($15.00 per year for trainees in surgery in Canada only), for all other countries $35.00 
per year. Single copies (current is
sue) available at $5.00 each, back 
issues at $6.00 each.
Detailed instructions to contribu­
tors, in English and French, appear 
on page 69 of the January 1988 
issue.
All prescription drug advertisements 
in the Journal have been precleared 
by the Pharmaceutical Advertising 
Advisory Board.
PAAB
CCPP
1*1
WARRANTY
"The publisher warrants 
that the deduction of ad­
vertising costs for advertis­
ing in this periodical is not 
restricted by Section 19 of 
the Canadian Income Tax 
Act."
"Advertisers who file Cana­
dian tax returns can claim 
the advertising costs of 
this publication as a busi­
ness expense "
Coeditors
L.D. MacLEAN, Montreal, PQ
C. B. MUELLER, Hamilton, Ont.
Consulting Editor
D. D. CURRAN 
Associate Editor 
G. PANCIROV
The Canadian Medical Association
President
A.L. ROBERTS, MD, FCFP
Secretary General 
LEO-PAUL LANDRY, MD
Director, Advertising Sales 
PAUL GRIFFIN - (416) 231-6633
Editorial Assistant
L. WILLIAMSON 
Editorial Researchers 
K. BEAUDOIN
M. McCART
Advertising Sales Representative,
Canadian Journal o f Surgery
McGOWN & ASSOCIATES INC. (514) 735-5191
Production Manager 
KATHRYN A. FREAMO
Editorial Advisory Board 
P.J.E. CRUSE, Calgary, Alta.
A.C.H. DURANCEAU, Montreal, PQ 
G.A. FARROW, Toronto, Ont.
D.M. GRACE, London, Ont.
R.G. KEITH, Toronto, Ont.
N. SCHMIDT, Vancouver, BC 
N.M. SHEINER, Montreal, PQ 
C. SORBIE, Kingston, Ont.
G.F.O. TYERS, Vancouver, BC 
C.J. WRIGHT, Saskatoon, Sask.
Assistant Production Manager 
NANCY POPE
Manager, Classified Advertising 
ANN ANDERSON
The Royal College of Physicians 
and Surgeons of Canada
President
R.W. GUNTON, MD, FRCPC
Executive Director
J.H. DARRAGH, MD, FRCPC
VOLUME 31, NO. 2, M ARC H  1988 /  THE CANADIAN JOURNAL OF SURGERY 75
Prophylactic Treatment of Stress Ulcers: First Do No Harm
Just when we thought we understood 
how to prevent stress ulceration in the 
stomach without unpleasant side effects 
in severely injured and septic patients, 
nagging doubts have arisen. In the past 
decade, clinicians from various disciplines 
have noted a marked decrease in the fre­
quency of stress ulcers and now surgery 
is rarely required.1 Large surgical serv­
ices operate on fewer than one patient 
annually for stress ulceration with bleed­
ing.2 Most agree that the effective 
prophylaxis — antacids and H2 blocking 
agents — account for this decrease. There 
has also been an improvement in general 
supportive care, but better overall survival 
of seriously ill patients in intensive care 
units has not been documented during 
this decade. In fact, the death rate may 
be higher in those receiving antacids or 
cimetidine.3
The routine use of antacids or cimeti­
dine in the intensive care unit is based on 
excellent studies4,5 that have implicated 
ischemia, with breakdown of the normal 
defence capability of the gastric mucosa, 
as the most important cause. These inves­
tigators have emphasized the need to raise 
the pH of gastric contents above 4 to 
avoid hemorrhage.6' 8 Randomized trials 
have been designed to evaluate the rela­
tive efficacy of antacids versus cimetidine. 
These therapies appear to be equally effi­
cacious in reducing the incidence of bleed­
ing and the requirement for transfusion.2
What information is there that ques­
tions our practice of neutralizing stomach 
acid in critically ill patients? In 1982 du 
Moulin and colleagues9 reported on 60 
patients in an intensive care unit, 52 of 
whom had the same organisms cultured 
simultaneously from both the upper air­
way and stomach. Pneumonia due to 
gram-negative organisms developed in 31 
patients, and in most instances the organ­
isms had been cultured from the stomach. 
No pneumonia developed in eight patients 
whose gastric and upper airway flora were 
different. The number of gram-negative 
bacilli in gastric aspirates in this study 
increased logarithmically as the pH rose. 
All patients were receiving antacids, 
which likely encouraged bacterial over­
growth in the stomach with colonization 
of the airway from that source. Over­
growth of pathogenic organisms in the
stomach with later transmission to the 
trachea and development of pneumonia 
has been reported previously.10
Patients who likely would have bled to 
death from stress ulcers 10 years ago will 
now survive for prolonged periods in the 
intensive care unit, but many will suc­
cumb to multiple organ failure. It has 
been known since the first descriptions of 
multiple system organ failure that this was 
related to infection — sometimes occult, 
usually intra-abdominal. Recently, it has 
become apparent that a focus of infection 
is not always found at the time of explora­
tory surgery in patients with bacteremia 
and multiple organ failure. The source is 
not always revealed even at autopsy. In 
other patients, adequate management of 
a septic focus does not necessarily reverse 
the organ failure or halt the bacteremia.
The microbial flora cultured from 
patients who died of organ failure in the 
absence of persistent peritonitis differs 
from the usual flora of bacterial perito­
nitis,11 suggesting that the phenomenon 
involves mechanisms more complex than 
the simple persistence of inadequately 
controlled infectious foci. Organ failure 
can develop in patients who enter the 
intensive care unit with peritonitis, for 
example after ruptured diverticulitis, and 
the infections are most commonly caused 
by Escherichia coli, Bacteroides fragilis 
and Enterococcus. On the other hand, 
infection acquired in the intensive care 
unit and organ failure, which occur later 
and are frequently not associated with pus 
in the abdomen, are due to quite a diffe­
rent group of organisms: Staphylococcus 
epidermidis, Candida albicans and Pseu­
domonas aeruginosa." Most deaths due 
to multiple system organ failure occur in 
patients with the latter group of organ­
isms. Cultures of the upper gastrointes­
tinal tract likewise reveal an overgrowth 
of these same organisms.12
Normal gastric acidity is an important 
component of the antibacterial defence of 
the upper gastrointestinal tract. Loss of 
this defence permits overgrowth of bac­
teria and fungi and has now been shown 
to predispose to pneumonia9 and multi­
ple organ failure.12 The magnitude of the 
overgrowth may cause translocation of 
viable organisms across the mucosal 
barrier.13
Altered proximal gastrointestinal flora 
and translocation of organisms may also 
contribute to the development of an 
abnormal systemic immune response and 
abnormal liver function. Marshall and 
colleagues14 have shown that gram­
negative pathogens entering the portal cir­
culation from the gut can suppress the 
immune response, rendering these infec­
tions potentially more lethal. This appears 
to be due to a direct stimulation of Kup- 
ffer cells.14 In a related experiment, a 
Kupffer-cell preparation, when stimu­
lated by endotoxin, markedly inhibited 
hepatocyte protein synthesis.15
Is there any way we could avoid neu­
tralizing acid in the stomach but protect 
it in other ways to see if this might 
decrease the frequency of ICU-acquired 
multisystem organ failure? The most 
promising avenue is the use of sucralfate, 
which acts through pepsin absorption, 
mucosal binding and cytoprotection, but 
leaves acid production by the stomach 
unimpaired.
Two prospective randomized trials on 
the use of sucralfate in the intensive care 
unit have now been completed. In the 
first,16 patients receiving mechanical ven­
tilation were randomly assigned to receive 
sucralfate or antacids. The investigators 
found that nosocomial pneumonia 
occurred in 3 of 29 patients (10%) treated 
with sucralfate, compared with 11 of 
34 (32%) treated with antacids. In a 
recent paper, Driks and colleagues17 
studied the rate of nosocomial pneumo­
nia in an intensive care unit among 130 
mechanically ventilated patients who were 
receiving as prophylaxis for stress ulcer 
either sucralfate (61) or conventional 
treatment with antacids or H2 blockers, 
or both (69). The two groups were simi­
lar in age, underlying disease and severity 
of acute illness. Patients in the sucralfate 
group had a significantly higher propor­
tion of gastric aspirates with a pH less 
than 4 and a significantly lower concen­
tration of gram-negative bacilli in gastric 
aspirates, pharyngeal swabs and tracheal 
aspirates than did patients in the 
antacid/H2 blocker group. The rate of 
pneumonia was twice as high in the 
antacid/H 2 blocker group as in the 
sucralfate group. Gram-negative bacilli 
were isolated more frequently from the
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tracheal aspirates of patients with pneu­
monia who were receiving antacids or H2 
blockers and the death rate was signifi­
cantly higher in this group.
Sucralfate may be given prophylacti- 
cally (1 g every 6 h), suspended in 20 ml 
of sterile water and administered by 
nasogastric tube, which is then flushed 
with 10 ml of sterile water to prevent clog­
ging. Heating the water may aid in this 
form of administration.
Pneumonia can occur in patients on 
sucralfate medication. Gastric pH above 
4 can also occur in this group and be 
associated with bacterial overgrowth. One 
of the reasons for this is enteral feedings 
which can increase gastric pH and thereby 
increase the risk of nosocomial pneumo­
nia or translocation of bacteria, even 
though the patient is not on antacids 
or H2 blockers.18
The beneficial effects of sucralfate in 
the intensive care unit have been 
documented by randomized trial only in 
respirator-dependent patients. Whether 
this encouraging result will hold for all 
patients in the surgical intensive care unit 
remains to be proven, but the results to
date strongly suggest that this break­
through will have wide application in the 
treatment of seriously ill patients.
Lloyd D. MacLean, md, frcsc 
Coeditor
Canadian Journal of Surgery 
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Blood Is Thicker (and More Dangerous) Than Water
The interesting observation that blood 
transfusion enhances tumour growth was 
first reported in 1955 in a mouse sarcoma 
model.1 Recently, many studies, includ­
ing that by Arnoux and colleagues in this 
issue (pages 121 to 126), have examined 
retrospectively the relation between blood 
transfusion and survival in various groups 
of cancer patients. The adverse effect of 
blood transfusions on survival after resec­
tion of rectal cancers is reported and the 
effect is found to be dose-related. The 
authors have previously demonstrated the 
same effect in patients with colorectal 
cancer, but the numbers in the previous 
study were insufficient to permit separate 
conclusions for those with cancer of the 
rectum.
The evidence must be examined criti­
cally, as important decisions for clinical 
management must be made. Readers will 
note the mounting evidence of the 
deleterious effect of blood transfusion on 
survival described in the literature review. 
Arnoux and colleagues note the evidence 
for decreased survival in patients with 
colorectal cancer, breast cancer, soft- 
tissue sarcomas and cancer of the lung. 
They could also have added similar evi­
dence for patients with renal adenocarci­
noma.2,3 In retrospective studies of this 
kind, one is heavily dependent on confir­
mation and consistency from study to 
study to raise the credibility of the 
hypothesis. In the case of colorectal 
cancer, multiple consistent studies are 
available as described by Arnoux and col­
leagues, but in the case of breast cancer, 
two other studies4,5 have failed to 
demonstrate any deleterious effect of 
transfusion on survival. The overall pat­
tern, however, is of lower survival rates 
in cancer patients receiving blood trans­
fusion perioperatively than in those not 
transfused. Transfusion has also been 
shown to increase the risk of postopera­
tive septic complications. The only good 
news is the improvement of kidney sur­
vival in patients given blood transfusion 
before renal allograft transplantation. All 
of these effects are consistent with the 
hypothesis of immune suppression.
The mechanisms are not clear, but the 
currently favoured hypothesis relates to 
a general suppressive effect on cell- 
mediated immunity. It has been shown 
that blood group antigens are present 
throughout the fetal colon, are usually
absent in distal colon in adults, but are 
frequently re-expressed by cancers of the 
distal colon.6 The indictment of blood 
transfusion makes biologic sense in this 
framework, but the major criticism of all 
the existing evidence is that those patients 
who were transfused may have had more 
aggressive disease or tumours that were 
technically more difficult to resect. These 
factors could be associated with increased 
risk of tumour spread during and after 
surgery. This criticism cannot be laid to 
rest without better stratification and 
choice of controls in the case control 
design of studies. It is common for 
authors to end with a plea for randomized 
prospective studies, but that is simply not 
a realistic option in trying to answer this 
particular question. It would be unethi­
cal and inappropriate to consider a ran­
domized prospective design to investigate 
the effect of blood transfusion on survival 
following resection for colonic cancer. It 
would be ethical and appropriate (but 
clinically impossible) to carry out a study 
comparing the effect of homologous and 
autologous blood. It is not unusual, 
however, to have a clinical question in 
which the use of a randomized controlled
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trial is impossible. Further retrospective 
case control studies are required, designed 
to eliminate bias as much as possible. A 
consistent trend in further studies would 
eventually lead to general acceptance of 
the hypothesis.
There are several reasons for the 
progressive reduction in the amount of 
blood transfused in surgery. We know 
now that in patients with healthy cardi­
ovascular systems hemodilution to a 
hematocrit as low as 20% to 25% can be 
tolerated as long as the blood volume is 
adequately maintained. Transmission of 
hepatitis virus is an ever-present risk and 
there is now a high level of anxiety con­
cerning transmission of the virus respon­
sible for the acquired immune deficiency 
syndrome (AIDS). Fear of AIDS has 
reached the point at which many patients 
make it clear that blood transfusion will 
not be accepted under any circumstances. 
We now have an additional reason to
minimize the amount of blood transfused 
in surgery, namely the probable adverse 
effect on survival from cancer. The 
association is not yet proven beyond the 
shadow of a doubt, but the evidence is 
strong enough to make us review our 
transfusion orders carefully. The extent 
of the blood loss in relation to the 
patient’s cardiovascular status may 
demand transfusion, but before reaching 
for the requisition, let us ensure that the 
indications are strong.
C h a r l e s  J. W r i g h t , m b , c h  b , m  s c , 
FRCSC
Member,
Editorial Board,
Canadian Journal o f Surgery
Department of Surgery,
University Hospital,
Saskatoon, Sask.
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SESAP V  Question
116. Which of the following statements about severe pelvic fractures is NOT true?
(A) Open pelvic fractures have a mortality of at least 50%
(B) Peritonitis due to perforation of the colon or rectum is the major cause of death
(C) At least two major fractures or ligamentous disruptions will generally be present
(D) When death results from hemorrhage, the usual bleeding source is from branches of the hypogastric arteries
(E) Blood at the penile meatus associated with pelvic fracture should be evaluated with urethrography
For the critique of Item 116 see page 109.
(Reproduced by permission from SESAP VSyllabus; Surgical Education and Self-Assessment Program No. 5. For enrol­
ment in the Surgical Education and Self-Assessment Program No. 5, please apply to the American College of Surgeons, 
55 East Erie St., Chicago, IL 60611.)
hydrocortisone -  zinc sulfate 
Available in ointment and suppositories
Anusol-HC
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Product monograph available upon request.
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Contributions to the Correspondence section are welcomed. 
They should be typewritten and double spaced.
Multiple Giant Fibroadenomas
To the editors.—Dr. Kuusk in this issue 
of the Journal (pages 133 and 134) reports 
an interesting and rare case of multiple 
successive fibroadenomas that developed 
in the left breast of a 14-year-old adoles­
cent. In her discussion, she rightly stresses 
that for patients with giant or multiple 
fibroadenomas, local excision is usually 
adequate and there is no recurrence of the 
excised tumours. This is what is usually 
seen in clinical practice.
In this particular case there were mul­
tiple successive fibroadenomas represent­
ing the ultimate expression of this dis­
order where virtually all breast tissue is 
transformed into massive yet benign 
fibroadenomas.
I would like to emphasize that the need 
for total mastectomy is not only because 
of the large size of the lesions or in order 
to remove all the lesions, but mostly 
because if any breast tissue is left behind, 
the condition will recur.
Luc Deschenes, md, frcsc
tion to remove the main core with 
attached side cores intact. Angiographic 
studies also showed that branches were 
not occluded by atheromatous debris and 
intimal flaps.1
In an attempt to verify this histologi­
cally, autopsy was performed on 45 
patients who had recently undergone 
coronary endarterectomy and bypass 
grafting. The study did confirm the 
absence of ostial occlusion by the “ snow­
plough” effect in most cases. However, 
we did encounter one interesting case in 
which the ostium of a major side branch 
of a recently endarterectomized right 
coronary artery was obstructed by a typi­
cal large residual intimal-medial flap (Fig. 
1). The contribution of the side branch 
occlusion to the patient’s early postoper­
ative death of acute myocardial infarction 
was, however, thought to be minimal in 
the presence of a thrombosed distal right 
coronary artery and graft.
Although early authors were correct in 
predicting the possible occurrence of 
occlusive intimal-medial flaps at the ostia
of major coronary artery side branches, 
the extremely low incidence, as shown in 
this autopsy study, demonstrates that it 
is not a major problem.
Roger W. Byard, mb, bs 
Department of Laboratory Medicine
Wilbert J. Keon, md, frcsc 
Director,
Heart Institute
Virginia M. Walley, md, frcpc 
Department of Laboratory Medicine
Ottawa Civic Hospital,
1053 Carling Ave.,
Ottawa, Ont.
K1Y 4E9
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Intimal Flaps in Manual Coronary 
Endarterectomy
To the editors.—Manual endarterectomy 
of the coronary system is a technique that 
is used to improve blood flow in diffusely 
atheromatous arteries that are to receive 
aortocoronary vein grafts. It also pro­
vides a better vessel wall for the graft- 
artery anastomosis.1
Initial reports were concerned that the 
removal of the atheromatous core from 
the main artery would result in shearing 
and occlusion of smaller side branches, 
much as a snow-plough blocks side streets 
while clearing main thoroughfares.2 Sub­
sequently, this was not found to be a 
problem, as it is possible by a combina­
tion of careful dissection and gentle trac-
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FIG. 1—Occlusion of ostium of side branch of right coronary artery by large intimal-medial 
flap (arrow). Circumferential recent mural thrombus is present in artery. Inset shows flap at 
higher magnification (Movat’s pentachrome stain, original magnification x 35, inset x 60).
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SURGEONS’ UPDATE
What's new in surgery is the subject of this column. The short items are designed to let readers know 
who's doing what and why. Surgeons are interested in what other surgeons are doing in 
research, education, practice and administration. Surgery is a vibrant specialty, and, as 
its practitioners, you must be the source as well as the readers of this column.
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Heart Research in Ottawa
Surgeons at the University of Ottawa’s 
Heart Institute recently performed the 
world’s first coronary endarterectomy 
using an excimer laser. The laser was 
developed by Lumonics Inc., an Ottawa- 
based laser manufacturer, with technical 
and financial assistance from the National 
Research Council of Canada. An 
ultraviolet laser beam, transmitted 
through a fiberoptic delivery system, cuts 
away plaque deposits that have accumu­
lated in the coronary arteries. An on-line 
helium-neon laser that does not change 
the properties of the excimer laser aids the 
surgeon in threading the fibre through the 
arteries and locating plaque.
An excimer laser is also being deve­
loped that could be used for angioplasty. 
An optical fibre contained in a catheter 
would be inserted into a major artery 
(such as the femoral artery) and threaded 
to the coronary arteries and then used to
Contributions to this column are welcome. 
Please send your material to: Miss Laurel 
Williamson, Canadian Journal o f Surgery, 
PO Box 8650, Ottawa, Ont. K1G 0G8.
transmit a pulse of ultraviolet energy that 
would destroy the plaque deposit. The 
pulses of ultraviolet energy would allow 
precision in cutting away plaque deposits 
and a cooling time to prevent heat 
damage to surrounding tissues.
Refinement of the laser’s use will be 
one of the areas of study at the new heart 
research centre at the University of 
Ottawa’s Heart Institute. Other areas will 
include further testing of the Jarvik-7 
artificial heart and development of more 
efficient power sources for it, develop­
ment of a portable electromechanical 
artificial heart and clinical trials of new 
cardiovascular drugs. Two-hundred and 
fifty researchers, technicians and support 
staff will be employed in the 48 research 
labs. Construction is expected to be com­
pleted by December 1988.
Research Centre in Hamilton
The creation of the Hamilton Civic 
H ospitals Research Centre was
announced recently. The Centre was 
developed jointly by the Hamilton Civic 
Hospitals, the Hamilton Regional Cancer 
Centre and the Faculty of Health Sciences 
at McMaster University and will initially 
be situated at Henderson General Hospi­
tal. Dr. J. Hirsh, Professor and Chair­
man of the Department of Medicine at 
McMaster will assume the position of 
Director of Research in July 1989. Dr. G. 
Browman, Associate Professor of Medi­
cine, will be the interim director.
Toronto’s Trauma Care 
Capacity Increased
St. Michael’s Hospital, which now 
treats approximately 150 trauma cases 
annually, will, over the next 2 to 3 years, 
be able to treat 300 to 350 trauma victims 
a year. This is the latest step in the 
development of Toronto’s integrated 
trauma care system, a system that the 
Metropolitan Toronto District Health 
Council advised Ontario’s Ministry of 
Health was required due to the size and 
complexity of the Toronto area.
Laurel Williamson
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Conference on Shock
Fontana, Wisconsin will be the site of the 
Shock Society’s 11th annual conference 
on shock, June 5-8, 1988. Symposia 
include such topics as “ Organ Blood 
Flow and Metabolism in Shock” and 
“ The Effects of Endotoxemia in Humans 
and in Experimental Septic Shock” . The 
keynote speaker will be John J. Spitzer 
of the Louisiana State University Medi­
cal Center and workshops entitled 
“ Animal Models That Simulate Circula­
tory Shock in Humans: Fact or Fan­
tasy?” and “ Use of Hypertonic Solutions
for Shock Resuscitation” are planned. 
For further information, contact: Dr. 
Sherwood M. Reichard, Shock Society, 
Medical College of Georgia, Augusta, 
GA 30912, USA.
Extended Programs in 
Medical Education
The University of California in San Fran­
cisco is sponsoring a postgraduate course 
in general surgery, Apr. 14-16, 1988. 
Further information can be obtained by 
writing: Extended Programs in Medical 
Education, University of California
School of Medicine, Room 569-U, San 
Francisco, California 94143 or calling: 
(415) 476-4251.
International Symposium
Paris is the location of a symposium on 
therapeutic progress in urological cancers 
scheduled for June 29-July 1, 1988. For 
details contact: Dr. Gerald P. Murphy, 
Professor of urology, School of Medi­
cine, State University of New York at 
Buffalo, 139 Parker Hall, Buffalo, NY 
14214; telephone: (716) 831-2338.
continued on page 104
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1987 Gallie Lecture. Quality Control in Surgical Research:
Importance to the Patient
One of the deficiencies in surgical 
scholarship is the rarity of timely, well- 
controlled research to evaluate new 
operative procedures. The invasive 
aspect of surgery makes randomized 
studies more difficult to initiate, and in 
studies with large numbers of participat­
ing surgeons, the impact of unsatisfac­
tory surgical expertise (craftsmanship) is 
a major variable. In an effort to improve 
surgical research, the use of quality con­
trol data for early assessment of the 
effectiveness of the operative procedure 
is strongly recommended. Early postoper­
ative studies of stimulated gastric acid 
secretion have led to improved surgical 
performance during trials of operations 
using vagotomy for control of peptic 
ulcer disease. Similar, early, quality con­
trol studies have been effective when 
investigating selective shunts for control 
of variceal bleeding; necessary data 
include shunt patency, portal perfusion 
of the liver and obliteration of major por- 
toazygous collaterals. Failure to incor­
porate objective tests for surgical quality 
control can lead to erroneous assess­
ment of operations. Carefully planned 
prospective studies of well-performed 
operations are urgently needed.
Une des carences de la science en chi- 
rurgie reside dans la rarete des projets de
* Whitehead Professor and Chairman, 
Department o f  Surgery, Emory University 
School o f  Medicine, Atlanta, Ga.
Presented at the 56th annual meeting o f the 
Royal College o f  Physicians and Surgeons 
o f  Canada, Winnipeg, Man., Sept. 13,
1987
Accepted fo r  publication Nov. 26, 1987
Reprint requests to: Dr. W. Dean Warren, 
Department o f  Surgery, Emory Univer­
sity School o f  Medicine, 1364 Clifton 
Rd. NE, Atlanta, GA 30322,
USA
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recherche bien controles et opportuns 
visant a evaluer les nouvelles techniques 
operatoires. Le cote sanglant de la chi- 
rurgie rend plus difficile la mise en route 
d'etudes randomisees et, dans les etudes 
necessitant la participation d'un grand 
nombre de chirurgiens, I'influence d'une 
expertise chirurgicale deficiente constitue 
une variable majeure. Si Ton veut amelio- 
rer la recherche en chirurgie, il est forte- 
ment recommande d'utiliser des donnees 
de controle de la qualite afin d'effectuer 
une evaluation precoce de I'efficacite de 
la technique operatoire. Des etudes post- 
operatoires precoces de stimulation gas- 
trique ont permis d’ameliorer I'execution 
de I'acte chirurgical lors d’essais de tech­
niques ayant recours a la vagotomie pour 
traiter I'ulcere gastro duodenal. De meme 
des etudes precoces de controle de la 
qualite ont ete efficaces lors de recher- 
ches sur le choix des derivations desti- 
nees a soulager les hemorragies vari- 
queuses; les donnees requises portent 
sur la permeabilite des derivations, sur la 
perfusion porte du foie et sur I'oblitera- 
tion des principales collaterals porte- 
azygos. Le defaut d'inclure des tests 
objectifs de controle de la qualite de 
I'acte chirugical peut entraTner une eva­
luation erronee des interventions chirurgi- 
cales. Des etudes prospectives soigneu- 
sement planifiees d'actes chirurgicaux 
bien faits sont requises de toute 
urgence.
One of my concerns for the generic field 
of surgery is the rarity of prompt, 
accurate assessment of new operations 
designed to extend or improve the qual­
ity of life in our patients. There is cer­
tainly no dearth of testimonials for new 
procedures, often reporting a low opera­
tive mortality and early improvement in 
symptoms, comparing them to other 
therapeutic modalities. However, most of 
these papers present retrospective, uncon­
trolled and incompletely reported data 
from a group of selected patients.
In nonsurgical fields, recognition of the 
need for intensified clinical science has 
been extensively documented. The crucial 
role of the controlled prospective ran­
domized trial has received general accep­
tance, and any current debate centres 
around ethical considerations and metho­
dology for implementing such studies. 
The New England Journal o f  Medicine 
has played a major role in stimulating 
interest in clinical trials, and there are now 
several textbooks devoted wholly or in 
part to this general field. There are, 
however, few references to surgical trials 
and the complex factors that are unique 
to surgery. An illustration of the paucity 
of such data is found in Fundamentals o f 
Clinical Trials.1 There is but one indexed 
reference to surgery and that is on a sin­
gle page. It relates to difficulties in obtain­
ing good data in relation to the efficacy 
of coronary bypass surgery, one of the 
most frequently performed operations in 
the United States. This glaring defect in 
the fundamental structure of surgical 
science needs to be examined. As I have 
considered these problems, three primary 
difficulties have seemed to me most evi­
dent: (a) disinterest of the surgeons, (b) 
ethical questions specific for surgery and 
(c) methodologic problems unique to 
surgery.
I shall not consider the first two points 
in detail today. There is little doubt that 
threatened loss of income is a major fac­
tor in inhibiting such studies. Cardiac sur­
geons whose personal income is generated 
largely from coronary bypass procedures 
are rarely enthusiastic about randomiza­
tion with a nonsurgical therapeutic inter­
vention. The period of randomization 
itself often results in reduced surgical 
volume, and the ultimate analysis of data 
could indicate the need for a permanent 
realignment of the role of surgery in the 
care of patients with coronary artery dis­
ease. It should come as no surprise that
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most such trials will come from health 
care systems in which surgical income is 
unrelated to surgical volume or patient 
entry into the system is through nonsur- 
gical physician participants. An exception 
to this rule is the recent exemplary effort 
initiated and designed primarily in 
Canada.2 Although the subject of heated 
debate,3 this example should be of great 
value in stimulating further work in all 
surgical disciplines. Several papers in the 
Mar. 27, 1987 issue of the New England 
Journal o f  Medicine address this issue.
The major ethical concern that tends 
to inhibit investigations in which a surgi­
cal procedure is randomly allocated is 
rooted in the inability to “ correct” for 
an inferior outcome. Drug trials are 
usually readily managed with the placebo, 
double blinding and crossover techniques. 
In most instances, all patients in such 
studies can look forward to receiving the 
superior product once the results are 
clear. Such is usually not the case with 
surgical procedures, for obvious reasons. 
Virtually all carefully considered analyses 
of these issues have concluded that ran­
dom surgical trials are not only ethical, 
but sorely needed.
The focus of this paper will be on the 
third impediment to excellent surgical 
trials, methodologic factors unique to the 
surgical disciplines that inhibit optimal 
design.
Basic Scientific Methodology 
Not Applicable in Surgery
There are several factors inherent in the 
surgical discipline that prevent the utili­
zation of some of the classic tools of clin­
ical investigations.
Placebo
Use of the placebo is well documented 
in the clinical investigation of pharmaceu­
ticals and a “ response” rate of about 
20% to 25% is often quoted. The use of 
a sham operation would be its equivalent 
in surgical trials. A few such studies have 
been done in the past but are neither prac­
tical nor defensible for complicated, risky 
surgical procedures.
Blinding
Here again a sound fundamental tech­
nique to lessen the impact of bias is sim­
ply not feasible for most surgical studies. 
When certain aspects of “ quality of life” 
are important end-points (e.g., severity of 
dyspepsia), an independent observer can 
be helpful. However, most surgical inter­
ventions require specific knowledge of the 
procedure by the patient and physicians 
involved in postoperative care. Patient 
safety as well as appropriate therapy for 
symptoms and potential complications 
rule out effective use of blinding.
Randomization o f  the First Patient
The premise behind this concept is to 
avoid the difficulty with which true scien­
tific studies are initiated once seemingly 
spectacular results are achieved with early 
uncontrolled interventions.4 This is a 
much debated issue in all fields of clini­
cal study but in surgery is not really moot. 
One must first learn how to do the oper­
ation (laboratory animals are not the 
same) and, second, determine if the 
desired physiologic goals are achieved 
(e.g., a marked reduction in stimulated 
gastric acid secretion following vagot­
omy). The point at which to institute con­
trolled trials of new surgical procedures 
versus older, standard ones, continues to 
be a valid question. The technical require­
ments of most new operative procedures 
must be elucidated by experience and any 
physiological changes sought by the new 
procedure confirmed by objective test­
ing whenever possible. If early studies 
show that the operation fails to produce 
the desired physiologic result, the opera­
tion needs to be redesigned or abandoned, 
not randomized. One frequently cited 
example of an excellent and rapid analy­
sis of a new procedure was that of gas­
tric freezing for duodenal ulcer disease. 
Appropriate studies confirmed dimin­
ished gastric acid secretion in the period 
immediately after freezing. Controlled 
trials demonstrated failure to achieve 
long-term control of the ulcer diathesis 
and complications that rendered the 
procedure useless if not harmful. Gastric 
freezing for duodenal ulcer was quickly 
abandoned.
Unique Requirements for 
Definitive Surgical Trials
Surgical Expertise:
Surgical Quality Control
A specific problem in the design and 
evaluation of surgical trials is the varia­
ble of surgical expertise (skills, craftsman­
ship) possessed by individual participat­
ing surgeons. This issue has clouded 
interpretation of surgical studies for a 
long time,5 but has been elucidated more 
clearly by the excellent work of Johnston 
and colleagues,6'7 Adami and colleagues8 
and van der Linden.9 The basic question 
concerns the validity of surgical trials 
in which operative procedures are 
improperly performed or do not achieve 
reasonable standards. An excellent and 
pioneering effort in this regard has been 
the careful analysis of surgical perfor­
mance in trials of vagotomy for duodenal 
ulcer disease.6-8'10 In these patients 
objective data can be obtained that make 
feasible the early assessment of the effec­
tiveness of the operation. Using insulin- 
stimulated gastric acid secretion as an 
indicator of the completeness of vagot­
omy, several studies have addressed the 
question of the importance of expertise 
(craftsmanship) in surgical controlled 
trials. The data provide convincing evi­
dence that (a) substandard surgical per­
formance is an important variable affect­
ing the results of a trial, (b) failure to 
achieve the surgical goals of the study 
grows as the number of surgeons included 
in the study increases, (c) training and 
increased experience in a specific tech­
nique improves operative performance 
and (d) the knowledge that early testing 
can identify an inadequate operation 
improves the performance of the surgeon 
and the quality of the study. From my 
own experience, as well as study of the 
efforts of others, I believe these observa­
tions are correct and important in both 
planning and evaluation of surgical trials. 
The term “ surgical quality control” con­
veys the essence of this Gallie Lecture. 
The importance of such efforts to 
upgrade surgical science, when doing clin­
ical trials, has become more apparent in 
recent years.
When to Randomize:
Selection o f  Participating Surgeons
There has been a good deal of debate 
on this subject in reference to all clinical 
trials, but I believe it is a much more cru­
cial issue for operative (including radio- 
logic and endoscopic interventions) than 
nonoperative trials. As noted in studies 
cited earlier,6' 10 the attainment of the 
physiologic goal of an operation is more 
certain when the surgeons are carefully 
selected from those with real expertise in 
the particular field of surgery and for the 
specific operation being tested. Those 
who oppose this approach cite the “ res­
trictive” nature of the study and empha­
size its lack of wide applicability or exter­
nal validity. I believe the logical first step 
in the evaluation of a new procedure is 
to determine if there are significant 
improvements in therapy when the new 
operation is tested by “ experts” . If nega­
tive findings are forthcoming (no 
improvement or even harmful effects, 
even with a high-quality control score), 
there is obviously no need for wide appli­
cation and a useless or dangerous 
approach can be terminated. On the other 
hand, if the new operation provides 
superior results, its use should be 
expanded with additional controlled trials 
at different sites, with different patients 
and different surgeons. This approach is 
in agreement with that espoused by 
Bunker and associates.11 The opposite 
approach (trials with large numbers of 
surgeons in many different hospitals) has 
a confounding effect if no quality con­
trol is instituted and the results are poor 
or equivocal. Some randomized trials of 
the selective-shunt concept to control 
variceal bleeding illustrate this point.
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There are three primary goals inherent 
in the selective distal splenorenal shunt 
(SDSRS) design. The first is to prevent 
variceal bleeding by decompression of the 
varices in the gastroesophageal area. This 
requires a patent shunt. The second fun­
damental goal of the procedure is to 
preserve portal venous perfusion of the 
liver. The underlying hypothesis is that 
continued portal perfusion of the liver 
ameliorates the incidence and severity of 
hepatic encephalopathy when compared 
with operations that shunt all portal flow 
around the liver. Effectiveness in this 
regard requires (a) a patent portal vein 
with a pressure high enough to perfuse the 
liver and (b) obliteration of major col­
laterals (portal azygous disconnection); 
such collaterals divert portal flow away 
from the liver. The third desired effect is
FIG. 1—Emory University randomized trial 
of selective distal splenorenal shunt (S) versus 
mesocaval interposition shunt (NS). Note 
markedly increased incidence of encephalopa­
thy with patient nonselective shunt (p < 0.01). 
Of great interest is shape of selective-shunt 
curve, with steady increase for 2 years and then 
long-term stabilization. Published by permis­
sion from: M illikan WJ jr , W arren WD, 
H enderson JM, et al: Ann Surg 1985; 201: 
712-722, with minor modifications.
FIG. 2—Toronto randomized trial of distal 
splenorenal shunt (solid line) versus nonselec­
tive end-to-side portacaval shunt (dashes). 
Again, significant protection is seen with selec­
tive shunt and both curves are almost identi­
cal to those in Fig. 1. In addition, Toronto 
group presented data showing encephalopathy 
was less severe and quality of life higher in dis­
tal splenorenal shunt group. Published by per­
mission from: Lancer B, T aylor BR, Mack­
enzie DR, et al: Gastroenterology 1985; 88: 
424-429, with minor modifications.
to maintain high intestinal venous pres­
sure, which has been shown to ameliorate 
encephalopathy further. This goal also 
requires closure of the major collateral 
veins.
There are, then, definitive early qual­
ity control tests for selective shunt surgery 
that include at least angiographic assess­
ment of shunt patency, portal perfusion 
of the liver and obliteration of the portal- 
azygous collateral. Other important end­
points include operative mortality, he­
patic encephalopathy, rebleeding, ascites, 
long-term survival and quality of life.
Two rigorous random trials testing this 
hypothesis were carried out early, one at 
Emory University12 and one at the 
University of Toronto.13 A group of 
three surgeons in each city carried out the 
surgery, and the quality of the surgery 
was high. Figures 1 and 2 show the results 
of these two studies in assessing the rela­
tive risk of encephalopathy between the 
SDSRS and the total shunts. The similar­
ity in the findings is striking. There was 
a steadily progressive impact of encephal­
opathy in the total shunt patients in each 
study; there was a clear protective effect 
in the SDSRS patients with a markedly 
lower rate of encephalopathy. Note the 
early rise followed by a pronounced flat­
tening of the curve in the SDSRS groups. 
This was present in each study and appar­
FIG. 3—Survival curve from Emory study 
at median of 10 years. Published by permis­
sion from: M illikan W J j r , Warren W D, 
H enderson JM , et al: Ann Surg 1985; 201: 
712-722, with minor modifications.
FIG. 4—Toronto survival curve. Note cross­
ing of survival curves in each study around 5 
to 6 years. Solid line = selective distal 
splenorenal shunt, dashes = portacaval shunt. 
Published by permission from: Lancer B, 
T aylor BR, Mackenzie DR, et al: Gastroen­
terology 1985; 88: 424-429, with minor modifi­
cations.
ently relates to an important physiologic 
feature of even a well-performed SDSRS; 
in patients destined to lose portal perfu­
sion, this usually occurs within the first 
postoperative year and frequently after 
only a few months.
In contrast, a third trial, carried out in 
six hospitals with 12 surgeons participat­
ing, reached the opposite conclusion, that 
no protection was provided against 
encephalopathy by the selective shunt.14 
With such a large number of surgeons 
attempting to study a new and complex 
operation, good surgical quality control 
should have been an integral part of the 
study but was not. In that study, 
■documentation of shunt patency, portal 
venous perfusion of the liver and col­
lateral venous pathway occlusion was not 
regularly obtained. Great emphasis was 
given to a low operative mortality as the 
validator of surgical quality, an errone­
ous concept. I agree with Rutstein15 and 
others16 in believing the most lamentable 
human studies are those in which ran­
domization is employed but the design of 
the study makes the results uninterpreta­
ble. A “ negative study” (no difference in 
outcome between groups in a high-quality 
trial) is a legitimate scientific achieve­
ment!
Randomization o f  New or Complex 
Procedures
An additional role of surgical quality 
control includes a more accurate assess­
ment of a new, more complex procedure 
versus a standard technique. Again, the 
Toronto study13 has been an excellent 
example of how to approach this type of 
problem. In Toronto, the end-to-side por­
tacaval shunt had long been the standard 
approach for management of bleeding 
varices when the controlled surgical trial 
of the distal splenorenal shunt (DSRS) 
versus portacaval shunt was initiated. The 
first remarkable achievement of the 
Toronto group was the performance of 
all 40 portacaval shunts without any oper­
ative deaths. In contrast, in the first 20 
DSRS procedures there were five deaths, 
a significantly higher operative death rate. 
In the next 18 patients, however, there 
were no deaths in the DSRS group, 
emphasizing the principle that even excel­
lent surgeons go through a learning phase 
with new and complicated operations. Of 
equal importance, and deserving special 
note, the potential impact o f this 
phenomenon on the results and interpre­
tation of the study was discussed fully. 
In the analysis by the authors, it was 
pointed out that three of the early deaths 
were due to learning-phase technical 
problems; there were no operative deaths 
in the last 31 patients randomized to 
DSRS. Figures 3 and 4 show the survival 
data of our two studies.
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A different approach was taken at the 
University of Rome, when a trial of por­
tacaval shunt versus a modified Sugiura 
procedure was institu ted .17 Long 
renowned in the portacaval shunting 
field, the Rome group had limited 
experience with nonshunting procedures. 
The results in the nonshunt group were 
so poor that the study was quickly termi­
nated. In the discussion of this paper, it 
was clear that the authors believed an 
important problem was the superior sur­
gical expertise they had in the shunt arm 
of the study compared with the new non­
shunt technique. The importance of 
experience in a specific operation even for 
highly trained and skilled surgeons has 
been emphasized by van der Linden.9
Failure o f  Therapy -  Crossover
The question of crossover designs is 
prominent in the current literature and is 
a vital component of many clinical trials. 
In surgery, the crossover technique is 
usually not a planned step in the investi­
gation; it is an option for use when 
needed for patient safety. Often this is not 
possible in surgery versus surgery trials, 
but a potential impact is inherent in trials 
such as sclerotherapy versus shunt sur­
gery. There are now good data showing 
that sclerotherapy is superior to simple 
medical therapy (without sclerosis) for the 
management of the acute variceal hemor­
rhage. A continuing question of great 
clinical importance is the effectiveness of 
sclerotherapy in long-term control of 
variceal bleeding when compared with 
operative or other nonoperative tech­
niques. To illustrate the use of a crossover 
design — a method that requires deter­
mination of failure of therapy and an 
option offering another technique of 
management — I will briefly present and 
comment on some recent trials.
First is the Kings College trial18 of 
sclerotherapy versus usual medical man­
agement, which demonstrated the clear 
superiority of the sclerotherapy technique, 
with improved survival and greatly 
reduced rates of death from rebleeding. 
However, death from rebleeding con­
tinued to be an important factor in each 
group, with 25 in the control group and 
5 in the sclerotherapy group dying as a 
direct consequence of bleeding. In this 
trial there was no option for shunt sur­
gery, which was thought to be of little or 
no value.
The second study is that of Rikkers and 
associates,19 initially in Utah and now in 
Nebraska, comparing the efficacy of 
sclerotherapy versus shunt surgery for the 
control of variceal bleeding. Rikkers, an 
excellent surgeon, performed the opera­
tions himself and achieved a good surgi­
cal quality control rating. Survival in the 
failed sclerotherapy group, however, was 
not substantially enhanced by surgical
crossover. Ten of the 30 patients ran­
domized to the sclerotherapy group failed 
that therapy, but only 2 were managed 
successfully by surgical intervention. This 
appeared to be due, at least in part, to 
severity of the liver disease, long distances 
from a medical centre (patients entered 
into the study could reside as far away as 
500 miles) and the critically ill nature of 
the patient when again seen by the sur­
geon. This was a valid study with good 
surgical quality control. It raises the ques­
tion of the appropriateness of sclerother­
apy when urgent return to the medical 
centre, if needed, is not possible.
A third study is from Emory Univer­
sity. Sclerotherapy (plus surgery when 
needed) was randomized versus sur­
gery.20 Those patients randomized to 
sclerotherapy had a clearly superior sur­
vival (Fig. 5). The major difference in our 
results is summarized in Table I. Twelve 
patients failed sclerotherapy and 11 were 
crossed over (operated upon for bleed­
ing); all 11 survived the operation and left 
the hospital and 7 are still alive. Among 
the important findings of our controlled 
trial, not anticipated before the study, are 
improved hepatic function in the 
sclerotherapy group, safe return to the 
medical centre and an operative death rate 
no higher in sclerotherapy failure than in 
patients originally randomized to surgery. 
These important clinical events con­
tributed to the superior survival in the 
sclerotherapy group.
Some recently published data from the 
Barcelona sclerotherapy versus shunt
FIG. 5—Emory University sclerotherapy 
(EVS) versus distal splenorenal shunt (DSRS) 
study. Survival is clearly enhanced in the EVS 
patients (p <  0.01). Eleven patients crossed 
over to surgery and 8 were still surviving 
(arrows, Table I). Reproduced by permission 
from: Warren WD, Henderson JM, Mil­
likan WJ, et al: Ann Surg 1986; 203: 
454-462, with minor modifications.
Table l-Emory Randomized Sclerotherapy Group
Result
No. of patients 
(n=37)
%
Rebleeding 21 57
Rebleeding to failure 
of therapy
12 32
Death without surgery 1 3
Crossover to surgery 11 29
study21 highlight a different point related 
to the crossover principle. This study 
experienced numerous exclusions from 
the trial after randomization that were 
primarily in the surgical group. The 
authors concluded, from analysis of the 
exclusion data, that sclerotherapy was a 
simpler technique and must have much 
wider applicability. Therefore, in the 
absence of unequivocal superiority of the 
shunt, it seemed reasonable to start with 
sclerotherapy. From analysis of all these 
trials, one could conclude that an excel­
lent regimen for management of cirrhotic 
variceal bleeding is sclerotherapy when 
backed by accessible, and expert, surgery.
In concluding, I would like to consider 
some important factors for analysis of all 
clinical trials.22 First is the reliability of 
the data. Is there a personal and institu­
tional record of accurate publication of 
data from well-designed and controlled 
studies? Second, is the time period long 
enough to experience most of the impor­
tant events secondary to the intervention? 
Third, are all the patients entered into the 
study accounted for? Significant numbers 
of patients lost to follow-up or refusing 
treatment after randomization cast doubt 
on the basic strength of the investigation. 
Fourth, are there enough patients in each 
arm of the study to allow identification 
of real differences? One analysis of this 
question (power) used 10 patients in each 
study group as minimal, a surprisingly 
small num ber.16 Finally, population 
differences account for many of the 
apparent contradictions in data between 
high-quality trials. An illustration of this 
point is seen in the greatly increased sur­
vival of the nonalcoholic in the Atlanta 
study, while this was not found in 
Toronto. The small number of nonalco­
holics in the trials could be important, but 
in our evaluation of controlled surgical 
trials, the pertinence of the patient popu­
lation is always carefully considered.
In the final analysis, there are few sur­
gical studies that meet all the desirable 
goals of randomized trials. However, 
increasing awareness of the vital nature 
of such data should hasten this evolution.
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Symposium on Major Pelvic Trauma
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1. Injuries to the Urethra and Urinary Bladder Associated
With Fractures of the Pelvis
The posterior urethra or urinary bladder 
may be injured in patients who sustain 
fractures of the bony pelvis.
It is important to assess the urethra 
radiologically by retrograde urethrogra­
phy before introducing a urethral 
catheter to avoid missing a urethral 
injury or causing further damage. The 
author's approach to the immediate 
management of urethral injury is supra­
pubic cystostomy. The urethra may be 
repaired later after other injuries have 
healed. With this approach the incidence 
of permanent impotence and inconti-
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nence will be low and the stricture cure 
rate high.
If the urethra has not been injured, a 
catheter is introduced and cystography 
performed to rule out bladder injuries. If 
the bladder is ruptured, the area is 
explored, the perivesical space drained 
and urinary drainage is provided by either 
a suprapubic cystostomy or a urethral 
catheter.
Une blessure de I'uretre posterieur ou de 
la vessie peur survenir chez les patients 
qui subissent une fracture du bassin.
II est done important de faire I'examen 
radiologique de I'ur&tre par uretrographie 
retrograde avant d'y introduire une sonde 
uretrale, et ceci afin d'eviter de manquer 
une lesion uretrale ou de causer des 
dommages supplementaires. L'auteur 
aborde le traitement immediat des 
lesions uretrales par une cystostomie 
suprapubienne. L'uretre peut etre repare 
plus tard, apres la gu£rison des autres 
blessures. De cette facon, I'incidence de 
I'impuissance et de I'incontinence perma- 
nentes est faible et le taux de guerison 
des retrgeissements est eleve.
Si I'uretre n'a pas ete touchy, un 
catheter est introduit et une cystographie 
est effectuee afin d'eliminer la possibility
de lesions vesicales. S'il y a rupture de 
la vessie, on explore cette region, 
I'espace perivesical est draine et on 
assure le drainage urinaire, soit par 
cystostomie suprapubienne, soit par 
cathetyrisme uretral.
Approximately 5% of patients who sus­
tain fractures of the pelvis will have 
associated injuries to the bladder, and a 
similar percentage will have injuries to the 
posterior urethra.
In this paper we outline our diagnostic 
and therapeutic approaches to the 
management of these injuries.
Injuries to the Posterior Urethra
Posterior urethral injury is one o f the 
most serious and challenging problems a 
urologist is required to manage. Initial 
mismanagement can incapacitate the 
patient for life. The potential complica­
tions include severe strictures, repeated 
lower urinary tract infections, recurrent 
pyelonephritis, lithiasis, periurethral 
abscesses and fistulas, urinary inconti­
nence and sexual impotence. Some 
patients may suffer renal failure if the 
problem is not corrected.
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It is important to suspect this injury in 
all patients with pelvic fracture. It occurs
FIG. 1—Retrograde urethrogram showing 
loss of urethral continuity.
FIG. 2—Combined cystogram and retro­
grade urethrogram demonstrates complete 
transection of posterior urethra.
FIG. 3—Combined cystogram and retro­
grade urethrogram demonstrating length of gap 
between severed urethral ends.
more frequently when the anterior por­
tion of the pelvic ring is involved. There 
is often blood at the external urinary ure­
thral meatus, but this is not a constant 
finding. The bladder may be distended if 
the patient has not voided for a few 
hours. The patient is usually unable to 
void and should be discouraged from try­
ing to do so. It is important to rule out 
injuries to the rectum and the possibility 
of bony spicules projecting into its lumen. 
The classic boggy mass described on rec­
tal examination and the marked upward 
displacement of the bladder and prostate 
cannot always be relied upon as an indi­
cation of urethral transection. It is pos­
sible for the urethra to be markedly 
stretched without disrupting. A retro­
grade urethrogram is the final and most 
important step in confirming the diagno­
sis. The most suitable contrast is 
intravenous urographic medium as it is 
not uncommon for the fluid to enter dis­
rupted vascular channels. Figure 1
FIG. 4—Use of male sounds shows actual gap between severed ends of urethra. Although 
ends are in close contact there is slight malalignment. Reconstruction in this case is easy through 
short midline perineal incision.
FIG. 5—I Jrethroscope passed through suprapubic cystostomy opening to demonstrate exact 
length of gap between severed urethral ends. Combined cystogram and retrograde urethrogram 
indicates artificially long gap extending from bladder neck to proximal bulbar urethra. In fact, 
gap is short, and although there is some malalignment, anastomosis is not difficult.
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demonstrates complete transection of the 
posterior urethra with contrast medium 
entering a vascular channel. The retro­
grade urethrogram shows the urethral 
injury but does not determine whether 
there is complete or incomplete transec­
tion of the lumen. Generally, however, 
some contrast medium will pass into the 
urinary bladder when the transection is 
incomplete.
There are several alternatives in the 
management of this injury. Because most 
of these patients have sustained multiple 
injuries, attention to higher priority sys­
tems must be considered initially. The 
urethral injury may be handled by 
primary anastomosis of the severed
FIG. 6—Edges of proximal and distal ure­
thra have been trimmed and spatulated.
FIG. 7—End-to-end anastomosis.
FIG. 8—Completed anastomosis.
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ends,1 primary realignment over a Foley 
urethral catheter with traction to the 
catheter to maintain the severed urethra 
in continuity until healing occurs2 or the 
severed ends may be held in contact by 
the use of perineal sutures placed through 
the prostate and tied over gauze in the 
perineum.3 We have tried all the above 
techniques and were not entirely satisfied 
with the results. In a high percentage of 
the patients, strictures developed and 
some patients were incontinent and impo­
tent. For these reasons, in 1965, we 
changed our therapeutic approach.
Current Management
Once the diagnosis is confirmed by 
retrograde urethrography, a suprapubic 
cystostomy tube is placed in the dome of 
the urinary bladder. Three months later, 
elective urethral reconstruction is done for 
complete transections. If the injury has 
involved only part of the urethral circum­
ference, the patient will usually void spon­
taneously within 3 weeks and further 
reconstructive surgery may not be neces­
sary, but in some patients who have stric­
tures an internal urethrotomy may be 
required.
A suprapubic cystostomy at the time of 
injury has the advantages of being easy 
to perform and being a technique well 
known to all urologists. The short oper­
ating time required is important in the 
patient with multiple injuries who may 
require the services of several other 
specialists. By avoiding manipulation of 
the urethra it is possible to avoid the 
danger of converting a partial rupture 
into a complete one. Since the area is not 
explored and infection is avoided, the 
hematoma is usually absorbed with 
minimal scarring, permitting urethral
Table 1-Results With Johanssen Technique4
(119 Patients)
Result No. (%)
Complete rupture 105 (88)
Partial rupture 14 (12)
Healed without stricture 8
Successful internal urethrotomy 5
Urethral reconstruction 1
Continent without stricture 113 (95)
Stress incontinence 6 (5)
Reoperation for stricture 7 (6)
Impotence 10 (8)
Table I I -  Results With Single-Stage Perineal 
Spatulated End-to-End Anastomosis 
(26 Patients)*
Result No. (%)
Stricture cure 23 188)
Incontinence 0 (0)
Impotence 3 (11 .5 )
* All were complete disruptions; 3 patients in 
whom procedure failed were cured by internal 
urethrotomy.
reconstruction to be performed without 
much difficulty. This approach also 
results in a low incidence of permanent 
impotence and urinary incontinence. In 
addition, the external sphincter mechan­
ism is not destroyed or bypassed.
Patients who have sustained a complete 
transection of the posterior urethra are 
generally suitable for urethral reconstruc­
tion 3 to 4 months after injury. In some 
cases this may be delayed because of other 
injuries. When the patient is readmitted 
for urethral reconstruction, combined 
cystography and retrograde urethrogra­
phy is done (Fig. 2). The bladder is filled 
to capacity with urographic contrast 
medium through the suprapubic cys­
tostomy tube which is then clamped. With 
the patient in the oblique position, con­
trast medium is injected into the urethra 
through the external meatus. During the 
procedure the patient is instructed to bear 
down in an attempt to void. This enables 
some patients to open their bladder neck 
and reveal the exact length of the gap 
between the severed urethral ends (Fig. 3). 
Many patients, however, cannot open the 
bladder neck to demonstrate the prostatic 
urethra. In such cases, the length of the 
gap between the severed urethral ends can 
be determined by passing a male sound 
(Fig. 4) or urethroscope (Fig. 5) through 
the suprapubic cystostomy and gently 
guiding it through the bladder neck down 
the prostatic urethra until it meets the 
point of obstruction. Another sound is 
passed proximally along the urethra until 
it meets the obstruction. A composite film 
(Fig. 4) will demonstrate the gap between 
the severed ends.
The urethroscope permits visualization 
of the bladder neck and is the procedure 
of choice if any difficulty is encountered 
in introducing the male sound into the 
prostatic urethra.
Figures 6 to 8 demonstrate the tech­
nique of end-to-end spatulated anastomo­
sis. The edges of the proximal and distal 
urethra are trimmed and spatulated on 
opposite sides, approximately 180° apart. 
The anastomosis is accomplished (Fig. 7) 
using 4-0 Dexon suture. An indwelling 
urethral catheter is left in position for 
approximately 2 weeks.
From 1965 to 1983 we performed a 
two-stage scrotal flap urethral reconstruc­
tion using mostly the technique of 
Johanssen.4 In a few cases the Turner- 
Warwick method5 was used.
Table I shows the results using the 
Johanssen technique of suprapubic 
cystostomy4 followed approximately 3 
months later by a two-stage urethral 
reconstruction. This technique was used 
in 119 consecutive cases. Of these, 105 
were complete and 14 were partial ure­
thral transections. After the two-stage 
urethral reconstruction, 95% of the 
patients were continent and cured of their
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strictures. Six patients complained of 
stress incontinence. Because of restrictur- 
ing, seven required repeat first-stage ure­
thral flap reconstruction, which must 
always be done before a second stage if 
there is any narrowing. Of these 119 
patients, 109 were sexually potent. The 
follow-up ranged from 3 to 21 years.
Since 1983 we have managed all 
patients with complete urethral transec­
tion by a one-stage perineal end-to-end 
spatulated anastomosis. Other techniques 
described for the management of this 
injury are the transpubic reconstruction 
using a one-stage anastomosis6 or some­
times a combined transpubic and perineal 
one-stage repair.7 The latter two proce­
dures are generally unnecessary and have 
the potential to increase the complication 
rate.
Table II shows the results using a one- 
stage perineal spatulated end-to-end 
anastomosis. They are similar to those 
using the two-stage scrotal flap technique. 
The one-stage method is technically less 
demanding and requires one less opera­
tion. We believe, therefore, it is the proce­
dure of choice for reconstruction of com­
plete urethral transection associated with 
pelvic fractures.
Bladder Injuries
Contusion is an unimportant, non­
penetrating injury of the bladder not 
requiring treatment. Intraperitoneal rup­
ture (Fig. 9) usually follows a blow to the 
lower abdomen when the bladder is dis­
tended. The peritoneal surface, not being 
supported by bony or muscular struc­
tures, is the weakest part, so these inju­
ries occur in the posterior wall or fundus.
Intraperitoneal rupture may also occur 
with fracture of the bony pelvis, as in 
18% of the 181 pelvic fractures with blad­
der rupture studied by Prather and 
Kaiser.8 In their series it was impossible 
to determine whether the pelvic injury was 
responsible for the bladder rupture. Prob­
ably the trauma produced two indepen­
dent effects — distension of the bladder, 
producing intraperitoneal rupture, and a 
crushing of the bony pelvis. Extraperi- 
toneal rupture (Fig. 10) is usually seen in 
association with fracture of the bony 
pelvis. The urine escapes into the perives­
ical tissues but not into the peritoneal 
cavity.
FIG. 10—This cystogram shows extra- 
peritoneal rupture of bladder with contrast 
medium in perivesical tissues. Smooth outline 
of urinary bladder is obscured by escape of 
contrast.
In the study of Prather and Kaiser,8 
embracing 1798 patients with fractured 
pelvis, 181 patients (10%) had associated 
rupture of the bladder, 141 (82%) being 
extraperitoneal, twice the rate of our 
experience.
Bladder injury is unusual with isolated 
fractures of the sacrum, coccyx, ileum or 
acetabulum. It is seen more frequently 
with fractures below the pelvic brim, par­
ticularly the pubic rami and symphysis, 
although sometimes severe distortion of 
these bones may not cause injury to the 
bladder.
Most extraperitoneal injuries to the 
bladder occur on the anterolateral wall, 
close to the vesical neck, and urine 
extravasates to the prevesical space.
Combined intra- and extraperitoneal 
rupture is relatively rare but may be seen 
in patients with pelvic fractures. The diag­
nosis is confirmed by a retrograde cysto­
gram if the intravenous urogram is incon­
clusive. With intraperitoneal rupture of 
the bladder, dye accumulates in the 
dependent portions of the peritoneal 
cavity and in the paracolic gutters. With 
extraperitoneal rupture, the opaque 
medium should be evident in the pre- and 
perivesical spaces (Fig. 11). The injury is 
serious and treatment should be prompt 
after the required attention, where nec- 
cesary, for shock, hemorrhage and higher 
priority systems. The surgery is relatively 
straightforward. At laparotomy, bladder 
drainage is more important than precise 
suturing of a laceration, but tears should 
be closed if possible. Urine should be 
aspirated, blood clots evacuated and 
involved areas liberally drained. The 
prognosis is excellent if the injury is 
treated without delay.
FIG. 9—Cystogram shows intraperitoneal 
rupture of urinary bladder. Contrast medium 
is easily seen in right and left paracolic gutters.
FIG. 11—This cystogram shows combined 
intra- and extraperitoneal rupture of urinary 
bladder. Contrast medium extravasates into 
perivesical space and peritoneal -avity.
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2. Hemorrhage and Pelvic Fractures
Hemorrhage is the major cause of death 
in pelvic fractures. In closed pelvic 
fractures the bleeding is usually self­
limited. In the small number of patients 
with continuing hemorrhage there may 
be disruption of a major iliac vessel, 
which will require immediate exploration 
and repair. In a few patients continuing 
hemorrhage is due to disruption of a 
branch of the hypogastric artery, which 
may be identified by angiography and 
controlled by embolization. A manage­
ment protocol is suggested for these 
patients.
L'hemorragie est la principale cause de 
deces dans les cas de fracture pelvienne. 
Le saignement est habituellement con- 
tenu lors des fractures pelviennes fer- 
mees. Chez un petit nombre de patients 
chez qui l'hemorragie persiste, il peut y 
avoir rupture d'un vaisseau iliaque 
majeur exigeant une exploration et une 
reparation immediates. Chez certains 
patients, l'hemorragie est due a la rup­
ture d'un tronc de I'artere hypogastrique. 
On peut en faire I'identification par 
angiographie et on peut juguler I'hemor- 
ragie par embolisation. On propose un 
protocole de traitement pour ces 
patients.
The importance of hemorrhage associated 
with pelvic fractures as a major cause of 
death has been emphasized by Rothen- 
berger and colleagues,1 who reported a 
12% death rate in 604 patients. Of the 72 
who died, pelvic fractures were the 
primary cause in 26, and 18 of these 
patients died of exsanguination from their 
pelvic injury shortly after hospital admis-
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sion. Eight patients had disrupted major 
iliac vessels, usually the iliac veins. With 
open pelvic fracture there is a greater 
propensity for bleeding because there is 
no tamponade effect from a closed 
retroperitoneal space.
In recognizing the seriousness of 
hemorrhage in pelvic fractures one must 
consider methods of control. Most 
patients with an undisturbed retro­
peritoneal hematoma will have spontane­
ous control of bleeding. External com­
pression with the military antishock 
trousers (MAST) as reported by Flint and 
colleagues2 may contribute to this con­
trol. This remains controversial, and seri­
ous complications with the MAST have 
been identified. The patient who con­
tinues to bleed after initial resuscitation 
and the exclusion of other possible causes
Fig. lb
FIG. 1—(a) Selective angiogram of left inter­
nal iliac artery demonstrates contrast extrava­
sation (arrow), (b) Angiogram after success­
ful embolization of internal pudendal artery 
(arrow).
poses a major problem in management. 
Ligation of the hypogastric arteries 
enjoyed a period of popularity, but its 
ineffectiveness was reported by Patterson 
and Morton3 in 1973.
More recent reports4-6 have demon­
strated the effectiveness of angiography 
and catheter embolization for arterial 
bleeding. The problem of timing of the 
angiographic assessment remains con­
troversial. Some aggressive investigators 
such as Panetta and colleagues5 sug­
gested that all unstable patients with a 
negative peritoneal lavage and who 
require more than four units of blood in 
24 hours should be subjected to pelvic 
angiography with a view to embolization.
The trauma unit at the Health Sciences 
Centre in Winnipeg recommends angiog­
raphy after 12 units of blood or continued 
transfusion requirement after 18 hours 
(Burns CM: Personal communication, 
1986). We have had experience with 
embolization in four patients and success­
fully controlled the bleeding in three. An 
example of arterial bleeding from the 
internal pudendal artery with control by 
embolization is shown in Fig. 1.
Occasionally, especially in open frac­
tures, packing may be necessary to con­
trol venous bleeding, but the packing 
should be removed as early as possible to 
reduce the likelihood of pelvic sepsis. 
External or internal fixation may reduce 
persistent venous bleeding from the frac­
ture sites.
The rare case of major vessel injury 
usually presents as exsanguinating hemor­
rhage necessitating early laparotomy 
without angiography. Repair of the iliac 
arteries or veins may be life-saving.
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Any institution receiving trauma 
patients with pelvic fractures should have 
a treatment protocol in place. The follow­
ing is recommended for management of 
hemorrhage associated with pelvic frac­
tures (Fig. 2).
A patient with multiple injuries will ini­
tially require general resuscitation. If the 
patient remains stable after resuscitation, 
the pelvic fractures can be treated as 
required for orthopedic stabilization.
If, however, the patient remains unsta­
ble after the initial volume replacement, 
supraumbilical peritoneal lavage should 
be performed. If the lavage contains 
blood, celiotomy will be necessary and 
appropriate treatment will be apparent. 
The retroperitoneal hematoma should not
be disturbed unless it is pulsatile or there 
is obvious disruption of major vessels 
which require repair. If there is continued 
blood loss after all other mechanical 
bleeding has been appropriately managed, 
angiography should be carried out. When 
an arterial branch of the hypogastric 
artery is identified as the bleeding site, dis­
tal embolization with autologous clot or 
Gelfoam should be performed. Usually, 
this will control the bleeding. Only occa­
sionally will bleeding continue, in which 
case continued transfusions and replace­
ment of clotting agents will be necessary. 
External fixators or internal bony fixation 
may be necessary to control bleeding. 
Rarely will direct vessel ligation or pack­
ing for venous bleeding be required.
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3. Infectious Problems in Pelvic Trauma
Pelvic injury provides a challenge to the 
trauma surgeon. Acute awareness of the 
possibility of associated hollow-viscus 
damage must be maintained to identify 
these injuries and steps must be taken to 
correct them. This article reviews the 
current thinking concerning infectious 
problems in pelvic trauma. With the 
development of new and more-powerful 
antibiotics, plus immunomodulators that 
may correct the suppression of host 
defences seen after pelvic trauma, there 
may be an improvement in the number 
and severity of septic complications that 
occur following such injuries.
Les blessures pelviennes represented un 
defi pour la chirurgie des traumatismes. II 
faut savoir garder un sens aigu du risque 
de retrouver des dommages associes aux 
organes creux, si I'on veut reconnaftre 
ces blessures et les traiter correctement. 
Cet article fait le point de la situation sur 
les problemes infectieux relie aux trau­
matismes pelviens. Avec I'arrivee de
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nouveaux antibiotiques plus puissants, 
d'immunomodulateurs capables de corri- 
ger la suppression des defenses immuni- 
taires consecutive £ un traumatisme pel- 
vien, il y a possibility d'une amelioration 
du nombre et de la gravite des complica­
tions infectieuses qui accompagnent ces 
blessures.
Infectious complications of major pelvic 
trauma relate to the type of trauma. Blunt 
or “ crushing” pelvic trauma results from 
motor vehicle accidents or falls from great 
heights, and penetrating trauma from 
sharp instruments or missiles. Combina­
tions of the two types can occur and this 
form of pelvic trauma is associated with 
the highest morbidity and mortality.
The infectious sequelae of major pel­
vic trauma are of two types — superfi­
cial soft tissue and deep tissue. Superfi­
cial infections, such as those of skin, 
subcutaneous tissues, muscle and bone 
(with open pelvic fractures) are usually 
caused by exogenous pathogens. Deep tis­
sue infections are usually due to endo­
genous pathogens, secondary to rupture 
of the bowel or the infected urinary tract. 
Pelvic trauma may lead to breakdown of 
environmental defence barriers such as 
the skin and bowel mucosa. The trau­
matic event also causes suppression of 
both nonspecific and specific host- 
defence mechanisms.1 If, in addition, 
bacterial contamination of the wounds 
occurs, the stage is set for infectious com­
plications. Crushing pelvic trauma with 
major disruption of the pelvic ring can 
lead to severe retroperitoneal hemorrhage 
and a high death rate in the period 
immediately after trauma. If the patient
survives, the blood loss further com­
promises host defences,2 again augment­
ing the chance of infection.
The development of soft-tissue infec­
tion caused by exogenous organisms in 
major pelvic trauma depends on the 
degree of skin breakdown and bone 
exposure and also on the location of the 
accident which can dictate the degree of 
bacterial contamination. For example, an 
open pelvic fracture sustained when the 
patient is crushed by a tractor at a farm 
carries a higher risk of infection than a 
fracture sustained in a cleaner environ­
ment. Sound surgical principles of trau­
matic wound care must be applied to 
reduce the chance of infection. Foreign 
bodies, particularly bits of clothing, 
should be removed. Dead skin should be 
excised but not extensively as there may 
be a need to cover exposed deeper tissues. 
Dead muscle must be debrided until fresh 
contractile bundles are encountered. Bone 
is left alone unless there are small frag­
ments in the wound that have lost their 
blood supply. The following couplets can 
be useful to the young surgeon who may 
treat such wounds.
Of the edge of the skin 
take a piece very thin
The tighter the fascia 
the more you should slash’er
Of muscle much more 
till you see fresh gore
And bundles contract 
at the least impact
Leave intact the bone 
except bits quite alone
— Sir James Learmonth.
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Tetanus toxoid should be administered 
to these patients. If there has been no 
previous history of tetanus immunization, 
human tetanus immune globulin (500 to 
1500 units) may be given in addition. 
Antibiotics against Clostridium tetani do 
not prevent the infection; local initial 
wound care is more beneficial. A booster 
dose of tetanus toxoid vaccine must be 
given. The development of the disease 
itself does not provide immunization. The 
neurotoxin is very powerful and the 
amount required to cause the disease is 
not enough to stimulate the host immune 
system to synthesize antitetanus anti­
bodies.
Antibiotics given prophylactically for 
superficial wounds that do not involve 
bone are of no benefit unless a dirty 
wound is present, in which case the issue 
is not prophylaxis but treatment. The 
work of Miles and colleagues,3 elabo­
rated later by Polk and Lopez-Mayor,4 
has shown that prophylactic antibiotics 
are effective in reducing wound infections 
if given during “ the golden period” (i.e., 
adequate tissue levels of antibiotic must 
exist before the infectious challenge). 
Thus, in pelvic trauma the prophylactic 
use of antibiotics is impractical. The 
issues of routine antibiotic use in open 
pelvic fractures, the mode of administra­
tion (systemic versus topical), the type of 
antibiotic and the dosage have not been 
resolved.
With open and dirty pelvic fractures the 
concern is to prevent osteomyelitis and its 
subsequent morbidity and mortality. 
Rothenberger and colleagues5 reported a 
series of 604 patients with pelvic fractures, 
22 (4%) of whom had open fractures. The 
death rate for those with open fractures 
was 50% compared with 10.5% for 
closed fractures. The higher rate was due 
to increased hemorrhage immediately 
after trauma or to later infection. Perry6 
also found that 31 (4%) of 738 patients 
with pelvic trauma had open pelvic frac­
tures, and of these, 13 (42%) died as a 
result of hemorrhage or late sepsis. A cul­
ture taken from the wound at the time of 
initial assessment is most likely to yield 
the organisms that will subsequently 
infect the wound,7 usually a penicillin- 
resistant Staphylococcus aureus. Antibi­
otic use in open, dirty fractures is ther­
apeutic. The antibiotic should be bacteri­
cidal and should provide broad-spectrum 
coverage against both gram-positive and 
gram-negative bacteria. It should be capa­
ble of producing suitable antibiotic con­
centrations in the blood, the extracellu­
lar fluids and the joint fluids. It should 
be given immediately after the initial 
assessment of the patient. The antibiotic 
should be administered for 2 to 14 days 
after trauma, depending on the clinical 
situation and the surgeon’s preference. 
Cefazolin, a first-generation cephalospo­
rin, or cefoxitin, a second-generation 
broad-specti um cephalosporin with bet­
ter gram-negative and anaerobic bacterial 
coverage, would be good choices.
Viscus injuries with blunt pelvic frac­
tures are rare. Awareness will prevent 
some of the serious infectious sequelae of 
endogenous bacterial contamination and 
subsequent abscess formation, which can 
lead to fatal disseminated sepsis. 
Penetrating injuries of the pelvis fre­
quently involve pelvic organs such as the 
bladder, urethra, vagina or rectum, the 
last being the most lethal. Three thousand 
years ago the Chinese used impalement 
as an effective method of execution. Since 
the latter part of World War II, the 
accepted management of major rectal 
wounds has been fecal diversion by a 
completely defunctioning colostomy, 
closure of the rectal wound when possi­
ble, dependant drainage of the retrorec­
tal space, irrigation of all feces from the 
rectum, and systemic administration of 
antibiotics. The improved results with 
irrigation removal of retained stool in the 
rectum were proven in the Vietnam con­
flict.8 Associated urethral injuries have 
usually been repaired primarily. More 
recently, Cass9 suggested that the 
management of posterior urethral injuries 
is changing from primary realignment of 
the rupture to suprapubic cystostomy 
alone, followed later by surgery for the 
resulting stricture. The main move in 
preventing infectious consequences is the 
provision for drainage of urine from the 
bladder. Though the urinary tract may be 
sterile initially, especially in men, 
undrained urine collections contribute to 
infectious complications.
The majority of related papers in the 
medical literature state that “ systemic 
antibiotics” should be given to patients 
with penetrating or blunt pelvic injuries 
that involve penetration into a pelvic 
viscus. The type of antibiotic, the route 
and especially the duration of administra­
tion are as controversial as with open pel­
vic fractures that do not involve a pelvic 
organ. The type of antibiotic to be 
administered directly after injury, in order 
to reduce infectious complications, is 
based on empiric therapy and should pro­
vide adequate coverage against a broad 
spectrum of organisms. Penetration of 
the rectum will allow contamination with 
bowel flora, most notably gram-negative 
anaerobes such as Bacteroides fragilis and 
other Bacteroides sp, aerobes such as 
Escherichia coli and other Enterobacteria- 
ceae, as well as gram-positive organisms. 
In a woman with involvement of the 
vagina, Clostridium sp, Bacteroides 
bivius, Bacteroides disiens, Chlamydia 
trachomatis and Neisseria gonorrhoeae 
must also be covered. Cefoxitin, 2 g 
intravenously every 6 hours for 5 days 
after injury, provides coverage against
most of these organisms and has proven 
effective in preventing these infections in 
patients sustaining penetrating injuries of 
the colon and rectum. This regimen pro­
vides equal efficacy when compared with 
the gold standard for broad-spectrum 
coverage (i.e., an aminoglycoside plus 
clindamycin).10 No randomized study of 
prophylactic antibiotics in patients with 
isolated pelvic trauma has been reported 
in the literature. A recent study by Del­
linger and colleagues11 has provided evi­
dence that a shorter course of antibiotics 
after penetrating colorectal injuries might 
suffice. They randomized 116 patients 
with confirmed penetrating injuries of the 
colon or small bowel to receive either 12 
hours or 5 days of antibiotics. Age, sex, 
weapon, severity of injury and other risk 
factors were evenly distributed between 
groups. Infection developed in 28 (24%) 
of the patients and it was trauma-related 
in 21 (18%); 3 of the patients died. There 
were no significant differences between 
groups in any category of outcome. For 
patients with penetrating intestinal or 
colonic injury, a 12-hour course of antibi­
otics was found to be as effective as a 
5-day course and had the advantage of 
lower cost and, theoretically, fewer side 
effects.
If subsequent pelvic or systemic infec­
tions occur, definitive treatment is based 
on culture and sensitivities of the isolated 
pathogens. Until such results are availa­
ble, treatment Of life-threatening sepsis 
from pelvic injuries is based on empiric 
therapy. The most common organisms
Table I—Common Organisms in 
Established Pelvic Infection
Aerobes 
Gram positive 
Enterococcus sp 
Staphylococcus aureus 
Staphylococcus epidermidis 
Gram negative 
Acinetobacter sp 
Escherichia coli 
Enterobacter sp 
Klebsiella oxytoca 
Klebsiella pneumoniae 
Klebsiella sp 
Lactobacillus sp 
Pseudomonas aeruginosa 
Pseudomonas fluorescens 
Pseudomonas maltophila 
Pseudomonas sp 
Proteus mirabilis 
Serratia sp 
Anaerobes
Bacteroides bivius 
Bacteroides disiens 
Bacteroides fragilis 
Bacteroides sp 
Clostridium  sp 
Corynebacterium  sp 
Eusobacterium  sp 
M icrococcus sp 
Peptostreptococcus sp 
Others
Candida albicans
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found in established infections of pelvic 
origin are set forth in Table I.
Single-organism bacteremias occur in 
approximately 64% of cases, two or more 
organisms in 33% and three or more 
organisms in 11% of patients. The gold 
standard of empiric broad-spectrum 
antibiotic coverage is an aminoglycoside 
such as tobramycin for the gram-negative 
organisms such as Enterobacteriaceae and 
clindamycin for the anaerobes and some 
staphylococci. New third-generation 
cephalosporins can be used in place of the 
aminoglycoside, especially in cases of 
renal failure. Cephoperazone, ceftazidime 
or cefotaxime plus clindamycin or 
metronidazole for Bacteroides sp can also 
be used. Most of these regimens are now 
undergoing efficacy trials against 
aminoglycoside-clindamycin combina­
tions. None of the above regimens covers 
Enterococcus. Since the role of 
enterococci as pathogens is not clear, they 
should be covered if found in the blood 
or as the only organism grown from pus 
of an abscess cavity. A new antibiotic of 
the carbapenam  class, imipenam- 
cilastatin (Primaxin) has recently received 
approval for use in the United States. 
Trials are on-going in Canada and
approval for use is pending. This antibi­
otic alone provides excellent coverage 
against all of the organisms listed in Table 
I, including Enterococcus, except for 
Pseudomonas sp such as Pseudomonas 
maltophila and Pseudomonas cepaciae. 
Until culture findings and sensitivities are 
available it may prove useful for empiric 
broad-spectrum coverage in a patient in 
whom the septic focus is the pelvis.
In summary, pelvic injury provides a 
challenge to the trauma surgeon. Acute 
awareness of the possibility of associated 
hollow viscus damage must be maintained 
to identify these injuries and take steps 
to correct them. With the development of 
new and more powerful antibiotics, plus 
immunomodulators that may correct the 
suppressed host defences seen after pel­
vic trauma, we may see improvement in 
the septic complications that occur fol­
lowing such injuries.
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Presidential Address, 1987: 
the Future of General Surgery in Canada
Manpower studies carried out by the 
Canadian Association of General Sur­
geons revealed a need for approximately 
70 new general surgeons to enter prac­
tice each year to replace those who will 
discontinue practice for various reasons. 
The Royal College of Physicians and Sur­
geons of Canada certifies about 70 
general surgeons each year; however, 
two-thirds of these pursue further 
specialty training, leaving only 20 to 25 
to continue in general surgery. Training 
programs in Canada are of variable 
length and content. Less than half the 
trainees have substantial research 
experience. Programs designed to train 
the comprehensive community general 
surgeon are lacking in Canadian medical 
schools and reductions in residency 
training posts and other governmental 
constraints may worsen the anticipated 
shortage of general surgeons.
Strong leadership is needed to bring 
together organized medicine, the surgical 
specialties, universities and government 
to address the training and manpower 
requirements for general surgeons in 
Canada.
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veaux chirurgiens generaux devraient 
joindre la pratique chaque annee pour 
remplacer ceux qui quittent pour diver- 
ses raisons. Le College royal des mede- 
cins et chirurgiens du Canada agree 
environ 70 chirurgiens generaux 
annuellement; toutefois les deux-tiers 
poursuivent leur formation en specialite, 
de sorte que seulement 20 a 25 conti- 
nuent en chirurgie generate. Les pro­
grammes de formation au Canada sont 
de teneur et de duree variables. Moins 
de la moitie des stagiaires possedent une 
experience de recherche appreciable. Les 
facultes de medecine manquent de pro­
grammes destines a former des chirur­
giens generaux complets; les coupures 
de postes de residents, ainsi que les 
autres contraintes gouvernementales 
sont susceptibles d'aggraver la penurie 
anticipee de chirurgiens generaux. Une 
direction forte devra etre exercee afin de 
rallier medecine organisee, specialites 
chirurgicales. universites et gouverne- 
ments afin de repondre aux besoins de 
formation et d'effectifs de la chirurgie 
generate au Canada.
I received a telephone call from a senior 
general surgeon in Toronto 5 years ago; 
he had positions available for two sur­
geons (one senior and one recent gradu­
ate) and asked if we had any candidates 
for these jobs. I mentioned that the 
University of Toronto graduated six 
young men from their residency training 
program the year before and all were suc­
cessful in obtaining a fellowship in 
general surgery. His response was that 
each one was pursuing specialty training 
and not continuing in general surgery.
This conversation heightened my con­
cern about the future of general surgery 
and stimulated my interest in surgical 
manpower. Immediately, I encountered 
the problem of the definition of general 
surgery, an exercise that has also 
interested the Canadian Association of 
General Surgeons (CAGS), the American 
Board of Surgery, the American Surgical 
Association and, through its accreditation
program, the Royal College of Physicians 
and Surgeons of Canada (Royal College).
On behalf of the CAGS, Dr. Ted 
Mullens was asked to propose a defini­
tion of general surgery that would reflect 
the position of the association. He 
reviewed the various definitions previ­
ously prepared by other organizations and 
sent a questionnaire to program directors, 
chairmen of departments of surgery and 
community surgeons in Canada. He 
presented his report to the Education 
Committee on Feb. 19, 1983, and the fol­
lowing definition was adopted.
General Surgery is that field of surgical skill 
that includes surgery of the Head and Neck, 
the Alimentary Tract, the Chest, the Breast, 
the Endocrine system exclusive of the pituitary, 
the Trunk, soft tissues and limbs, and vessels 
exclusive of the Heart. It includes the manage­
ment and direction of the care of multiple inju­
ries. In some circumstances it includes the spe­
cial designations of the general thoracic 
surgeon, vascular surgeon or paediatric sur­
geon, to indicate special training and compe­
tence in a restricted field.
Surgical Manpower
The Canadian Association of General 
Surgeons has been active in manpower 
studies. The Federal-Provincial Advisory 
Com m ittee of Health Manpower 
report,1 published in 1985, predicted an 
annual outflow from the general surgical 
pool of 88 general surgeons each year 
between 1981 and 1990 and 96 general 
surgeons each year between 1991 and 
2000. The committee used the Southam 
medical data base which was the best 
available at the time but which had many 
shortcomings. In 1986, under the direc­
tion of Dr. Frank Turner, the CAGS, 
with the Royal College and the Canadian 
Medical Association (CMA), carried out 
a validation of the Physician Resource 
Data Bank. This data bank provided a list 
of 2683 “ general surgeons” . The chief of 
surgery or director of every hospital in the 
country was contacted by members of 
Dr. Turner’s committee with respect to 
the surgical staff, and 1517 (56.5%) of the
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2683 were confirmed to be practising, 
fulltime general surgeons. An additional 
204 surgeons were identified, giving a 
total for Canada of 1721. It is estimated 
that 20% of these will retire during the 
next 5 years, requiring an inflow of 344 
new general surgeons (70/yr) to replace 
them, but that only 38 general surgeons 
(Canadian graduates) would enter prac­
tice, leaving a net deficit of 154 by 1991. 
The problem is further compounded by 
the fact that 20% of Canadian residents 
in a number of surgery programs are 
women and for various reasons their 
productivity in the field compared with 
men is rated to be only 70%. Changes in 
life-style and attitudes also have an 
unpredictable impact on manpower.
Development of the Surgical 
Specialties in Canada
To understand changing trends in man­
power, I thought it wise to look at the his­
tory of the surgical specialties in Canada.
The Royal College of Physicians and 
Surgeons of Canada was incorporated by 
an act of parliament and received royal 
assent on June 14, 1929. Its charter was 
to encourage and assess postgraduate 
training and to grant suitable diplomas.
The first examinations consisted of a
T a b le  1 - R e s id e n t s  G ra n te d  F e llo w s h ip  
in  G e n e ra l S u r g e r y , 1 9 8 5  a n d  1 9 8 6
R e s id e n ts 1 9 8 5 ,  n o . (% ) 1 9 8 6 ,  n o . (% )
M a le
F e m a le
5 8  (8 9 )  
7  (1 1 )
5 3  (7 8 )  
1 5  (2 2 )
T o t a l 6 5  ( 1 0 0 ) 6 8  ( 1 0 0 )
primary, similar for medical or surgical 
candidates, which was a basic science 
written examination and an oral exami­
nation. In surgery a final examination 
covered all of the field as was then 
known. Although certificates of special 
competence were approved in ophthal­
mology, otolaryngology and urology in 
1937, fellowships were awarded only in 
general surgery and general medicine until 
1947. The first 15 years of Canadian 
Royal College activities, therefore, were 
dominated by internists and general sur­
geons. Dr. Patch, a urologist from Mon­
treal, suggested in 1940 that a modified 
form of fellowship be considered for 
those in special branches of the profes­
sion. The Committee on Educational 
Standards made this recommendation in 
1944, thus introducing recognition of the 
specialties in medicine and surgery. Nine 
surgical specialties were issuing certifi­
cates of competence by the early 1950s. 
Cardiovascular and thoracic surgery was 
added during the 1960s and pediatric sur­
gery in 1976. The flood gates for sub­
specialization (fragmentation in the opin­
ion of some) opened at the beginning of 
the present decade. A certificate of vas­
cular surgery was approved in 1980 and 
awarded in 1983. There is agitation in the 
surgical community for certification in 
colorectal surgery, surgical oncology, 
intensive care, head and neck surgery, 
transplantation and biliary pancreatic 
surgery.
In its wisdom the Royal College has put 
the issuing of new subspecialty certificates 
of competence on hold and is examining 
a program of accreditation without cer­
tification. In fact, Dr. Ronald V. Christie 
suggested to the Royal College Council 
in 1965 that the College did not want the 
central core of general surgery and inter­
nal medicine to be “ nibbled away until 
there is nothing left” . This position is 
strongly supported by the CAGS.
The American Board of Surgery 
recently issued a policy statement relat­
ing to this suggestion. In July 1985, at a 
meeting in Denver, the following state­
ment regarding specialization and frag­
mentation was developed.
The American Board of Surgery recognizes 
that with the evolution and advancement in 
medicine, specialization within the art and 
science of surgery will occur. The Board makes 
a distinction between specialization, which 
occurs under the continuing aegis o f general 
surgery and articulates with the whole, and 
fragmentation, which is a separation and dis­
articulation from the surgical corpus. The 
Board makes this distinction to emphasize the 
importance of preserving the primary compo­
nents of surgery and yet recognizes the contri­
butions of specialization in the overall objec­
tive of quality care and training. The Board 
believes that this is best achieved by adding 
qualifications to the surgery certificate and not 
by creating separate certificates or boards.
With this background, in 1986 I sent 
a detailed questionnaire to the directors 
of general surgical training programs in 
the 16 Canadian medical schools. Not 
only did all complete the questionnaire, 
but most added editorial comment either 
in the form of a letter or notes appended 
to the questionnaire itself. The question­
naire showed that 65 residents received 
their fellowships in general surgery in 
1985 and 68 in 1986. Of those in the 1986 
cohort 20% were women (Table I). I was 
not surprised to learn that two-thirds (45 
[66%] in 1986, 44 [68%] in 1985) of those 
receiving their general surgical fellowships 
planned further certification, which 
means that only one-third (21 [32% ] in 
1985 and 23 [34%] in 1986) intend to con­
tinue with general surgery.
Table II sets forth the career goals of 
the 133 Canadian general surgeons receiv­
ing fellowships during 1985 and 1986.
The certificates granted to successful 
candidates by the Royal College in all 
specialties appear in Table III. I have 
listed the surgical specialties in numeri­
cal order. There is a slight variance 
between the results of my survey and that 
of the Royal College, possibly because 
Royal College figures include non- 
Canadian graduates.
If we substitute for the number of cer­
tificates granted in general surgery in 1985 
and 1986 (69 and 73), the number of resi­
dents (fellows) planning to continue to 
specialize in general surgery (21 and 23), 
we find that the number is similar to those 
entering urology, plastic surgery, vascu­
lar surgery and otolaryngology.
T a b le  I I - - C a r e e r  G o a ls  ( 1 9 8 5 - 8 6  C o h o r t)
A r e a s  o f  in te r e s t N o . %
G e n e ra l s u rg e ry 4 4 3 3
C a r d io v a s c u la r /th o r a c ic  s u rg e ry 2 5 1 9
V a s c u la r  s u rg e ry 1 2 9
T h o r a c ic  s u rg e ry 1 0 7
O n c o lo g y 1 0 7
C o lo r e c ta l s u rg e ry 9 7
In te n s iv e  c a re 6 5
P e d ia t r ic  s u rg e ry 5 4
T r a n s p la n ta t io n 4 3
P la s t ic  s u rg e ry 3 2
L iv e r /b il ia r y  s u rg e ry 3 2
H e a d  a n d  n e c k  s u rg e ry 2 2
T a b le  I l l - C e r t i f i c a t e s  G ra n te d  b y  R o y a l C o lle g e  in  1 9 8 5  a n d  1 9 8 6
S p e c ia l ty 1 9 8 5 1 9 8 6
G e n e ra l s u rg e ry 6 9 7 3
O b s te t r ic s  a n d  g y n e c o lo g y 6 6 5 9
O r th o p e d ic  s u rg e ry 4 4 5 0
O p h th a lm o lo g y 4 3 3 4
P la s t ic  s u rg e ry 2 2 2 2
U ro lo g y 2 0 1 6
V a s c u la r  s u rg e ry 1 7 11
O to la ry n g o lo g y 1 7 2 4
C a r d io v a s c u la r /th o r a c ic  s u rg e ry 1 4 11
N e u ro s u rg e ry 8 11
T h o r a c ic  s u rg e ry 4 2
P e d ia tr ic  s u rg e ry 2 0
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Training Programs in General Surgery
Training programs in general surgery 
vary both in structure and content across 
the country (Table IV).
Five programs offer 5 years of general 
surgical training after internship and the 
others offer 4 surgical years after either 
a straight, rotating or comprehensive 
internship. All program directors felt that 
5 years of surgical training after intern­
ship is desirable and I believe this will be 
recommended — however, problems of 
funding will inevitably arise.
Research Experience in 
Training Programs
Fraser Gurd has written a stimulating 
and challenging essay entitled “ Scholar­
ship and science, and the Royal Col­
lege” .2 The Council of the Royal College 
has decided to increase its commitment 
to involve trainees in biomedical research 
and to place more emphasis on science in 
training programs. This approach is to be 
highly commended, since in this age of 
rapidly advancing technology we must 
graduate true professionals who have the 
intellectual tools to seek new knowledge 
and incorporate it into their professional 
activities.
Current resident research experience in 
our 16 programs indicates that in 1985 
and 1986, only half our general surgical 
trainees had research exposure (Table V).
The Future of General Surgery 
in Canada
We will soon enter our third decade of 
universal health care in this country. 
There has been a slowly progressive and 
inevitable increase in government control 
of our training programs and in the way
Table IV—Training Programs in 
General Surgery in Canada*
Comprehensive (6) Rotating (5)
R1 R1
R2 R2
R3 R3
R4 R4
R5
Rotating (4) Straight (1)
R1 R2
R2 R3
R3 R4
R4 R5
'Numbers in brackets indicate no. of medical 
schools.
Table V—Residents' Exposure to
Research Experience
Exposure 1985, no. (%) 1986, no. (%)
1 yr 26 (401 28 (41)
6 mo 4 (6) 5 (7)
None 35 (54) 35 (51)
we practise. Most provinces have reduced 
the number of residency posts available, 
some quite severely. The amount of 
research money available from the Med­
ical Research Council of Canada has been 
eroded to the point where only 10% of 
the applications for new research grants 
were funded last year. University hospi­
tals in some provinces are grossly under­
funded and a formula recognizing that 
these tertiary care teaching institutions are 
important health care resources, requir­
ing a premium of their budgets, is not 
universal. In Quebec, the government has 
attempted to control the distribution of 
health care professionals by reducing the 
income of young surgeons in urban areas 
while augmenting it in rural areas. Limit­
ing billing has been used in British 
Columbia to control the numbers of phy­
sicians practising in a given area. Health­
care planners have determined the opti­
mum number of practitioners for institu­
tions and have thus limited the positions 
available. They unfairly blame physicians 
for the high cost of health care and would 
further limit our ability to provide state- 
of-the-art care to patients. Hospital 
deficits are being met by the closure of 
hospital beds while administrative staff 
and bureaucracy seem to expand. In Que­
bec, 20% of beds in some acute-care 
hospitals must be occupied by chronic- 
care patients. Our numerous medical 
associations seem disorganized, frag­
mented and complex, and react to rather 
than participate in the planning of events 
that have an impact upon us all. Data on 
surgical manpower lack guidelines and 
there is no specific body charged with 
overall planning and development.
Although for the profession the picture 
seems gloomy, surgeons do have an 
opportunity to influence change and to 
some degree control their destiny — if 
aggressive leadership is shown. The 
general surgeon must survive because his 
strength is his comprehensive training and 
approach to patient care. It is clear that 
further subspecialization will occur but it 
must do so within general surgery, so that 
those who obtain additional training in 
specific areas will remain general surgeons 
in concept and in outlook. Residency 
training program committees, under 
suitable directors, should design our pro­
grams for the educational needs of the 
candidates. These committees should 
recognize that it is more advantageous to 
preserve surgery in general than to des­
troy it with increasing fragmentation. If 
the foundation and pillars of surgical 
training in general are weakened, the tem­
ple will collapse. The following three 
training programs might be offered by a 
large university department:
• Two core years of surgery in 
general, to include urology, obstetrics and 
gynecology, otolaryngology, and possibly 
orthopedics and neurosurgery.
• Two core years of surgery in
general, 1 year of research and 2 more 
years of general surgery, to include cardi­
ovascular and thoracic surgery, plastic 
surgery, vascular surgery, thoracic sur­
gery, colorectal surgery, pediatric surgery, 
oncology, head and neck surgery, inten­
sive care procedures and academic general 
surgery.
• Two core years of surgery in
general, 1 year of research, 2 years general 
surgery and 1 comprehensive year for 
community general surgery.
The specialty should select residents 
before they enter training, and the pro­
gram should be designed and tailored to 
the needs of the trainee for his future 
specialty. The academic general surgeon 
would require 2 additional years of 
research at the end of his surgical train­
ing. The community surgeon, if he knew 
by the final year where he intended to 
practise, could tailor his training during 
that year to meet the surgical problems 
he would likely encounter there.
In the future, I think, a network of 
hospitals and health care facilities should 
be developed, with a major tertiary care 
centre (a university teaching hospital) at 
the core of the organization. Residents 
going out to practise in a community 
would establish and maintain contact with 
the university hospital for consultation, 
transfer of tertiary care patients and con­
tinuing medical education. They would be 
encouraged to return to the university 
hospital to acquire skills they lacked or 
to upgrade existing skills. If they wished, 
they could participate in the care of their 
patients with complex problems at the 
health care centre. In some cases, the ter­
tiary care staff might spend periods of 
time at the outlying hospitals.
I think there are exciting challenges for 
general surgery in the future. Sub'speciali- 
zation is a good thing for patient care, for 
teaching and for stimulating research. 
Our challenge is to stop fragmentation 
while encouraging specialization. Most of 
all we must have an organizational struc­
ture that allows us to examine these 
problems, to react to them, to anticipate 
future needs and to show leadership.
In my view and my experience, the 
CAGS from its inception has reduced 
fragmentation while encouraging speciali­
zation and continues to grow in influence 
and strength. We should actively cooper­
ate with the Canadian universities, the 
Royal College and governments in this 
regard. I thank you for the honour of 
being your president. I thoroughly 
enjoyed my tenure.
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Prevention of Intra-abdominal Abscesses 
With Fibrinolytic Agents
Fibrin deposition during secondary perito­
nitis predisposes to abscess formation by 
protecting bacteria from host-defence 
mechanisms. To test the hypothesis that 
local fibrinolytic therapy can prevent the 
formation of intra-abdominal abscess, 
daily injections of the fibrinolytic 
enzymes trypsin and tissue plasminogen 
activator (t-PA) were administered 
intraperitoneally to Wistar rats inoculated 
intraperitoneally with infected fibrin 
clots. After 5 days, trypsin (1 mg/ml) 
had significantly Ip <  0.001) reduced 
abscess formation in animals inoculated 
with monomicrobial Bacteroides fragilis 
clots (2 0 %  versus 8 7 % ) or mixed 
Escherichia coii-B. fragilis clots (11%  
versus 9 1 % ). Bacteroides fragilis 
abscesses were also completely 
prevented with t-PA (0.25 mg/mi). The 
number of B. fragilis organisms present 
in residual abscesses in the trypsin- 
treated group was significantly (p < 
0.05) lower than in the control group 
(8.2 ± 0.2, n = 7 versus 5.7 ± 1.4, n 
= 4, log CFU/g abscess). In-vitro studies 
demonstrated that trypsin had no bac­
tericidal effect on B. fragilis. suggesting 
enhanced clearance of bacteria. From 
these studies it appears that controlled 
fibrinolysis at operation may be a useful 
adjunct to surgery and systemic antibi­
otics in preventing abscess formation 
postoperatively.
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Durant une peritonite secondaire, le 
depot de fibrine cree un terrain favorable 
a la formation d'abces en protegeant les 
bacteries contre les defenses immunitai- 
res de I'hote. Dans le but de verifier 
I’hypothese voulant qu'un traitement 
fibrinolytique localise puisse prevenir la 
formation d'abces intra-abdominaux, des 
injections quotidiennes d'enzymes fibri- 
nolytiques, trypsine et activateur du plas- 
minogene tissulaire (t-PA) ont ete admi- 
nistrees par voie intraperitoneale a des 
rats Wistar a qui on avait inocule dans le 
peritoine des caillots de fibrine infectes. 
Apres 5 jours, la trypsine (1 mg/mL) 
avait reduit significativement (p < 0.001) 
la formation d'abces provoques par des 
caillots monomicrobiens de Bacteroides 
fragilis (20%  contre 8 7 % ) ou des caillots 
mixtes de Escherichia coii-B. fragilis 
(1 1 %  contre 91 % ). Les abces a B. 
fragilis ont aussi ete completement 
prevenus par le t-PA (0.25 mg/mL). Dans 
le groupe traite a la trypsine, le nombre 
de B. fragilis present dans les abces resi- 
duels etait significativement (p < 0.05) 
inferieur a celui du groupe temoin (8.2 ± 0.2, 
n = 7 contre 5.7 ± 1.4, n = 4, log VCF/g 
d'abces). Des etudes in vitro demontrent 
que la trypsine ne possede aucun effet 
antibacterien contre B. fragilis, ce qui 
indique une augmentation de I'extraction 
des bacteries. Ces etudes indiquent 
qu'une fibrinolyse controlee durant I'ope- 
ration peut etre, avec les antibiotiques 
systemiques, un appoint therapeutiques 
utile a la chirurgie pour prevenir la forma­
tion postoperatoire d'abces.
The deposition o f fibrin after bacterial 
soiling o f the peritoneal cavity is an 
important defence mechanism, as it 
entraps bacteria, thereby preventing sep­
ticemia and death.1'2 As a consequence 
o f this containment, however, the protec­
tion from host defences afforded by the 
fibrin mesh predisposes to abscess forma­
tion.2-3 Clinically, postoperative intra­
abdominal abscesses frequently represent 
a source o f continued sepsis that may ulti­
mately lead to multisystem failure and 
death. In combination with modern sur­
gical techniques and antibiotics given
intravenously, an agent capable o f 
preventing residual abscess formation 
could potentially improve the morbidity 
and mortality associated with peritonitis. 
The purpose o f the present study was to 
determine whether intraperitoneal 
fibrinolysis, accomplished with fibrino­
lytic enzymes, could prevent intra­
abdominal abscesses from forming in a 
clinically relevant infection model.
Materials and Methods
Growth and Culture o f  Microorganisms
A  clinical isolate o f Escherichia coli has 
been used repeatedly for experiments by 
one o f us (O .R .).3'4 It is maintained at 
-7 0 °C  in brain-heart infusion broth 
(B H I; Difco Laboratories, Detroit, Mich.) 
in 10% glycerol. Daily preparations o f E. 
coli were made by inoculating 30 ml o f 
BHI with a loop sample from a stock 
plate. A fter incubation at 37°C for 18 
hours in a shaker bath, the bacteria were 
washed three times by centrifugation at 
1600 g for 10 minutes and resuspended 
in sterile isotonic saline. Approximate 
numbers o f bacteria were estimated by 
densitometry and exact enumerations 
were established by viable colony count­
ing on nutrient agar plates (Difco Labora­
tories). Bacteroides fragilis V P I9032 was 
provided by Dr. Tracy Wilkins, Virginia 
Polytechnic Institute, Blacksburg, Va. 
Stock cultures o f this bacterial strain were 
maintained at -7 0 °C  in thioglycolate 
broth (BBL Microbiology Systems, Cock- 
eysville, Md.). Frozen cultures were 
thawed and 0.5-ml aliquots were inocu­
lated into tubes containing 30 ml o f 
minimal growth media as described previ­
ously.5 The tubes were incubated for 18 
to 20 hours at 35°C in an anaerobic 
chamber (Forma Scientific, Marietta, 
Ohio), which maintained an atmosphere 
o f 85% nitrogen, 10% hydrogen and 5% 
carbon dioxide.
For inoculation into fibrin clot, the 
B. fragilis culture was removed from the 
anaerobic chamber, pelletted by centrifu­
gation (1600 g for 10 minutes) and 
resuspended in prereduced Hank’ s 
balanced salt solution (HBSS; Gibco,
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Grand Island, NY), supplemented with 
0.05 mg/dl cysteine hydrochloride (Sigma 
Chemical Company, St. Louis, Mo.). To 
quantitate viable bacteria, resuspended 
B. fragilis were surface-plated on sup­
plemented BHI agar and counted after 48 
hours of incubation at 35°C.
Incorporation o f  Bacteria 
into Fibrin Clots
Human fibrinogen (Sigma Chemical 
Company) was dissolved in calcium-free 
Dulbecco’s phosphate-buffered saline 
(PBS; Irvine Scientific, Irvine, Calif.) and 
pore-limit dialyzed with 10 000 MW 
cutoff overnight to remove sodium 
citrate. The fibrinogen was sterilized by 
ultraviolet irradiation and the concentra­
tion adjusted to 100 mg/dl with PBS. 
Thrombin (Parke-Davis, Morris Plains, 
NJ) was suspended in distilled water to 
a concentration of 30 IU/ml. In the 
anaerobic chamber, 1.4 ml of fibrinogen 
was added to the 75 x 12 mm polysty­
rene tube. Either B. fragilis (2 x 109 
CFU) alone or a mixture of B. fragilis (2 
x 108 CFU) and E. coli (2 x 106 CFU) 
were added to the fibrinogen solution. A 
0.2-ml aliquot of thrombin was then 
added to each tube to clot the mixture. 
The final volume of the fibrin clot was 
2 ml.
FIG. 1—Effect of trypsin on abscess forma­
tion induced by clots infected with Bacteroi- 
des fragilis. Starting at surgery, animals were 
injected intraperitoneally each day with 
phosphate-buffered saline or trypsin at various 
concentrations. On day 5, animals were killed 
and peritoneal cavity was inspected for abscess 
formation. T-I -  combined injection of 
trypsin inhibitor (1 mg/ml) plus trypsin (1 
mg/ml) *p <  0.001 versus control.
Fibrin Clot Rat Peritonitis Model
Male Wistar rats, weighing 200 to 250 
g each, were inoculated intraperitoneally 
(ip) with infected clots as described previ­
ously.6 Beginning at surgery, daily 5-ml 
injections of PBS, trypsin in PBS (Sigma 
Chemical Company, 0.25 to 1.0 mg/ml) 
or 4 ml injections of tissue plasminogen 
activator (t-PA, 0.25 mg/ml) were 
administered ip. The t-PA was kindly 
provided by Dr. Michael Shepherd, 
Genentech Inc., San Francisco, Calif. 
Animals were weighed daily and deaths 
monitored.
Quantitation o f  Viable Bacteria 
in Abscesses
On day 5, rats were killed by carbon 
dioxide asphyxiation. The peritoneal 
cavity was inspected for the presence of 
abscesses, characterized in this model by 
the presence of a single walled-off collec­
tion of purulent material. The abscess was 
aseptically excised, weighed and carefully 
minced into a tube (containing prereduced 
HBSS and sterile glass beads) held under 
a VPI anaerobe apparatus.7 The tube 
was stoppered, vortexed and transferred 
to the anaerobic chamber. The tube con­
tents were serially diluted in prereduced 
HBSS and surface-plated in duplicate on 
supplemented BHI agar and nutrient 
agar. The supplemented BHI agar plates 
were incubated anaerobically at 35°C for 
48 hours and the nutrient agar plates were 
incubated aerobically at 37°C for 24 
hours. The number of viable bacteria 
(CFU) were quantitated and these num­
bers were transformed to log 10 values.
Statistics
Mortality and abscess formation data 
were evaluated by a Fisher’s exact test. 
Data comparing abscess weights and via­
ble bacterial numbers in abscesses were 
analysed using a one-way analysis of var­
iance.
Results
In-Vitro Fibrinolysis o f  Sterile 
Fibrin Clots by Trypsin
Sterile fibrin clots were incubated in
various concentrations of trypsin at 37°C 
to determine the time required for the clot 
to dissolve. At 1.0 mg/ml, the clot dis­
solved within 10 minutes and at 0.5 
mg/ml, by 30 minutes. Lower concentra­
tions (0.25 mg/ml) failed to dissolve the 
clot over the 30-minute examination 
period. These studies formed the basis for 
the trypsin concentrations used in vivo.
Effect o f  Fibrinolysis on Abscess 
Formation Induced by Bacteroides 
fragilis-Th/ectec? Clots (Fig. 1)
Intraperitoneal inoculation with fibrin 
clots containing B. fragilis (2 x 109 
CFU/clot) resulted in abscess formation 
in 87% of animals (n = 15) when injected 
simultaneously with PBS. Trypsin signifi­
cantly (p <  0.001) decreased the incidence 
of abscess formation at a concentration 
of 1 mg/ml (n = 20) and was progres­
sively less effective as the concentration 
was reduced. To support the concept that 
trypsin was acting through its proteolytic 
effect, trypsin inhibitor (Sigma Chemical 
Company, 1 mg/ml) was injected with the 
trypsin. Trypsin inhibitor completely 
reversed the ability of trypsin to prevent 
abscesses (n = 4).
Another potential mechanism by which 
trypsin might exert its effect was through 
a direct microbicidal effect. In fact, via­
ble bacteria (log CFU/g abscess) in 
B. fragilis abscesses were 8.2 ± 0.2 (n = 
7, mean ± SEM) in the PBS group and 
5.7 ± 1.4 (n = 4) in the trypsin (1 mg/ml) 
group (p <  0.05). In-vitro studies demon­
strated no direct microbicidal effect of 
trypsin on B. fragilis or E. coli, suggest­
ing that enhanced bacterial clearance was 
responsible for reduced abscesses and 
bacterial numbers.
Tissue plasminogen activator, which 
acts by converting the zymogen plasmino­
gen to the fibrinolytic enzyme plasmin, 
completely prevented abscess formation 
at the single concentration tested (0.25 
mg/ml). In B. fragilis-induced abscesses, 
no deaths occurred.
Effect o f  Trypsin on Mortality
and Abscess Formation Induced
by a Mixed Bacterial Inoculum (Table I)
Trypsin significantly (p < 0.01) 
reduced abscess formation at concentra­
tions of 1.0 mg/ml and 0.5 mg/ml but not 
at 0.25 mg/ml. Although the death rate 
was slightly higher in the trypsin groups, 
the difference was not significant. Tryp­
sin alone (1 mg/ml) had no gross adverse 
effect on the animals.
Discussion
Peritonitis and its complications are 
associated with a high death rate, partic­
ularly among the elderly (range from 60% 
to 80%),8 in whom management should
Table 1-Effect of Trypsin on Death Rate and Abscess Formation 
Induced by a Mixed Escherichia coli-Bacteroides fra g ilis  Inoculum
Treatment3
Deaths, no.1 
total no. (%)
Abscess formation 
in survivors, 
no./total no. (%)
Phosphate-buffered saline (PBS) 
Trypsin, mg/ml
1/12 (8.3) 10/11 (91)
1.0 3/12 (25) 1/9 (11)b
0.5 2/12 (16) 1/10 (10)b
0.25 0/4 (0) 3/4 (75)
“Animals were injected intraperitoneally with 5 ml of the indicated solution beginning at surgery, then
daily for 5 days.
bp <  0.01 versus PBS control.
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include adequate fluid resuscitation, 
administration of broad-spectrum antibi­
otics and appropriate surgical therapy. 
The goals of surgery are to control the 
source of the bacterial spillage and to pre­
vent septic complications postoperatively. 
With present techniques, patients usually 
survive the first week after surgery for 
peritonitis. Death is invariably associated 
with infection leading to multisystem 
organ failure and progressive deteriora­
tion despite aggressive therapy.
Therapy aimed specifically at prevent­
ing late postoperative infection might pre­
vent the development of multisystem 
organ failure and subsequent death. One 
approach has been to reduce fibrin depo­
sition associated with peritonitis. Fibrin 
deposition occurs during the early inflam­
matory stage of peritonitis when the 
fibrinogen-rich exudate in the peritoneal 
cavity is converted to fibrin by tissue 
thromboplastin activity.8 Fibrin acts to 
wall off and contain bacteria, thereby 
forming a nidus for residual infection. 
The purpose of our study was to deter­
mine the effect of local fibrinolytic ther­
apy on abscess formation using a well- 
defined intra-abdominal infection model. 
The hypothesis that fibrinolysis might 
prevent infection is well founded and 
based on experimental studies of infec­
tions at other sites. Thrombolysis was 
used successfully by Durack9 to prevent 
endocarditis in a rabbit model. Rode- 
heaver and colleagues10 used fibrinolytic 
agents to reduce the number of wound 
infections induced by infected plasma 
clots in guinea-pig skin incisions.
Both trypsin and t-PA reduced the fre­
quency of abscesses in animals infected 
with monomicrobial B. fragilis clots. 
Similarly, trypsin prevented abscesses 
induced by E. coli-B. fragilis clots. 
Several lines of evidence support the con­
cept that abscesses were prevented 
through fibrinolysis. First, the concentra­
tion of enzyme required to prevent 
abscesses correlated well with those 
needed for in-vitro clot lysis. Second, 
trypsin inhibitor reversed the ability of 
trypsin to prevent abscesses. Finally, tryp­
sin demonstrated no direct microbicidal 
activity, thereby making it unlikely that 
its effect was due to an antimicrobial 
property. These data suggest that reduced 
bacterial numbers in residual abscesses in 
the trypsin group were due to enhanced 
clearance of bacteria (probably due to 
partial fibrinolysis) rather than to a 
microbicidal effect. One further possible 
mechanism was that trypsin may have 
stimulated cellular host defences, result­
ing in enhanced bacterial clearance. Low 
concentrations of trypsin have been 
shown to enhance superoxide production 
by macrophages.11 In contrast, our 
previous studies3 have shown that tryp­
sin slightly impaired the neutrophil
respiratory burst in response to particu­
late stimuli.
Based on the presumed bacterial trap­
ping function of fibrin in the defence of 
the peritoneal cavity, fibrinolysis would 
be expected to result in bacteremia and 
increased mortality, which would be 
unlikely in monomicrobial B. fragilis 
clots, since high inocula of B. fragilis, 
even if administered systemically, are 
rarely lethal.12 With mixed E. coli-B. 
fragilis clots, the death rate was only 
slightly increased. It is not clear whether 
failure to demonstrate an increased death 
rate was owing to the fact that a sublethal 
inoculum of E. coli was initially present 
in the clot or that fibrinolysis resulted in 
a slow release of bacteria into the circu­
lation that the host defences were able to 
handle.
Previous studies13'16 examining those 
agents that may prevent intra-abdominal 
abscesses have focused on the prevention 
of fibrin deposition using anticoagulants. 
Experimental studies in several animal 
models have demonstrated that heparin 
and low-molecular-weight dextran can 
prevent abscess formation. In those 
studies, anticoagulants were usually 
administered when peritonitis was 
initiated (i.e., before fibrin deposition). 
The present model more closely mimics 
the clinical setting in that fibrin is present 
when the infection is initiated, just as 
infected fibrinous exudates are found 
in patients with diffuse peritonitis. 
Anticoagulants may be less effective in 
these circumstances. Indeed, heparin did 
not prevent abscess formation when 
tested in the rat fibrin clot model.17 The 
use of fibrinolytic agents may represent 
an enzymatic means of “ radical 
peritoneal debridement” , which has been 
advocated as a method of preventing 
postoperative sepsis.18
The present study reports initial 
experience with the use of t-PA to pre­
vent intra-abdominal abscesses. Several 
of its properties make it an attractive 
fibrinolytic agent for use in the peritoneal 
cavity.19 Its high molecular weight and 
affinity for fibrin tend to confine its 
activity to the peritoneal cavity, thereby 
enhancing its potency and reducing side 
effects. In addition, plasmin, formed by 
the action of t-PA on plasminogen, is 
rapidly inactivated by circulating antiplas- 
mins should it escape into the systemic cir­
culation. Further studies are presently in 
progress examining the potential use of 
t-PA in intra-abdominal sepsis.
We thank Miss Christina Wareham for 
preparing the manuscript.
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Percutaneous Endoscopic Gastrostomy 
by the “Pull” and “Introducer” Methods
After 28 patients, studied prospectively, 
underwent percutaneous endoscopic gas­
trostomy (PEG) by the Ponsky "pull" 
technique, another 28 patients under­
went PEG by the Russell "introducer" 
method. These two groups were com­
pared retrospectively with 28 patients 
who had previously undergone Stamm 
gastrostomy as an independent operation 
performed by the same group of sur­
geons. All procedures were done within 
a 5-year period. The major indication for 
gastrostomy was the inability to swallow 
due to neurologic diseases; a similar 
number of patients in each group also 
had pharyngeal blockage, cachexia, 
respiratory failure and inhalation burns. 
Percutaneous endoscopic gastrostomy 
could be done most appropriately under 
local anesthesia, the "introducer" 
method requiring less time than the 
"pull”  method, which in turn required 
less time than the Stamm gastrostomy. 
Feeding was generally instituted success­
fully 24 hours after PEG compared with 
3 days after Stamm gastrostomy. 
"Introducer" PEG was not associated 
with peristomal infection, and the 
authors postulate that the peristomal 
infections in the "pull" PEG group were 
due to oropharyngeal bacteria brought 
through the abdominal wall by that tech­
nique.
Apres qu'un premier groupe de 28 
patients eut subi, dans une etude pros-
From the *Department o f Surgery and 
t Department of Nutritional Sciences, 
University o f  Toronto and St. Joseph’s 
Health Centre, Toronto, Ont.
Presented at the 10th annual meeting o f  the 
Canadian Association o f  General Surgeons, 
held in conjunction with the 56th annual 
meeting o f  the Royal College o f  Physicians 
and Surgeons o f Canada, Winnipeg, Man., 
Sept. 13, 1987
Accepted fo r  publication Nov. 26, 1987
Reprint requests to: Dr. M. Deitel, St. 
Joseph’s Health Centre Research Founda­
tion, 30 The Queensway, Toronto, Ont. 
M6R IBS
pective, une gastrostomie endoscopique 
percutanee (GEP) par la technique de 
"traction" de Ponsky, 28 autres patients 
furent soumis a une GEP par la techni­
que "d'introduction" de Russell. Ces 
deux groupes furent ensuite compares a 
28 autres patients qui avaient subi aupa- 
ravant une gastrostomie de Stamm aux 
mains du meme groupe de chirurgiens. 
Toutes les interventions ont ete prati- 
quees a I'interieur d'un intervalle de 5 
ans. La principale indication de gastros­
tomie etait I'incapacite d'avaler consecu­
tive a un probleme neurologique; dans 
chaque groupe, un nombre similaire de 
patients souffrait de blocage pharynge, 
de cachexie, d'insuffisance respiratoire 
ou de brulure par inhalation. La GEP peut 
etre pratiquee de facon adequate sous 
anesthesie locale, la technique par 
"introduction" exigeant moins de temps 
que la methode de "traction" qui, en 
retour, peut etre faite plus rapidement 
que la gastrostomie de Stamm. L'alimen- 
tation a generalement pu etre reprise 24 
heures apres une GEP, comparativement 
3 jours pour la gastrostomie de Stamm. 
La GEP par "introduction" n'a pas ete 
reliee a des infections du stoma et les 
autres emettent I'hypothese que les 
infections de ce type dans les GEP de 
"traction" sont dues a des bacteries de 
I'oropharynx qui sont ramenees a travers 
la paroi abdominale par cette technique.
In 1980, Ponsky’s group1 described a 
percutaneous method of passing a suture 
into the stomach. The suture was pulled 
out through the mouth using a gastro- 
scope and tied to a tube which was then 
pulled back through the stomach and 
abdominal wall. Subsequently, Preshaw2 
described a method of insufflating the 
stomach and introducing a Stamey cys­
toscopy catheter percutaneously as a gas­
trostomy tube; this technique did not have 
endoscopic control. In 1984, Russell and 
colleagues3 reported a percutaneous gas­
trostomy made by pushing an introducer 
contained in a pacemaker lead peel-away 
sheath over a guidewire into the stomach. 
We have compared percutaneous 
endoscopic gastrostomy (PEG) by the
Ponsky “ pull” and Russell “ introducer” 
techniques and the standard operative 
Stamm gastrostomy.
Patients and Methods
Starting in 1983, patients who under­
went the “ pull” PEG were studied 
prospectively using a data collection 
form. After 28 such gastrostomies we 
became aware of the “ introducer” or 
push technique, one that we had used for 
10 years to insert long-term hyperalimen­
tation catheters and pacemaker elec­
trodes; accordingly, the next 28 patients 
underwent PEG by the “ introducer” 
technique. For further comparison, we 
reviewed 28 patients who had previously 
undergone Stamm gastrostomies, per­
formed by the same group of surgeons.
All gastrostomies in this study were 
performed within a 5-year period. Proce­
dures were performed in a surgical 
endoscopy room, part of the operating- 
room complex in which anesthesia was 
usually available. Patients received 
meperidine and atropine before the proce­
dure and oropharyngeal lidocaine when 
local anesthesia was used.
Techniques
The “Pull” Techinque
After an initial esophagogastroduo- 
denoscopy, the stomach is insufflated 
with air and the skin cleansed and 
anesthetized at the site of puncture. With 
the room lights dimmed, the endoscope 
light is visualized, located high in the left 
upper quadrant, and a no. 16 Medicut 
(Sherwood Medical Industries, St. Louis, 
Mo.) is passed into the stomach. A heavy 
silk or Mersilene suture, rendered some­
what rigid with collodion, is inserted 
through the Medicut, snared and with­
drawn in turn through the gastroscope. 
Another suture, guided through a second 
no. 16 Medicut, is threaded on a needle, 
passed through the end of a no. 16F 
mushroom catheter and brought back 
through this Medicut; traction on the 
suture impacts the end of the catheter into 
the wide end of the Medicut.1 Into the
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side of a segment of the connecting end 
of the catheter, previously cut off, a small 
hole is made and the piece is threaded 
down the shaft against the mushroom to 
act as a flange. The entire assembly with 
the tapered end of the Medicut leading is 
pulled through the stomach and abdomi­
nal wall. Gastroscopy verifies that the 
flange is against the anterior gastric wall, 
apposing gastric serosa to parietal 
peritoneum without excess tension. A 
second flange is then passed over the pro­
truding shaft of the gastrostomy tube and 
sutured in place against the abdominal 
wall. The tube is placed on gravity 
drainage for 24 hours.
The “Introducer” Technique
A 7-cm-long no. 18 needle is introduced 
through the abdominal wall into the 
stomach at the site where the endoscope 
light is visualized in the left upper quad­
rant and where the endoscopist can see 
an indentation on the stomach made by 
the surgeon’s finger. Air is aspirated for 
confirmation, the syringe removed, and 
a J-tipped guidewire introduced using a 
straightener.3 A no. 16F introducer in a 
peel-away sheath is then pushed over the 
guidewire into the stomach, and when 
definitely visualized by the endoscopist, 
the introducer with the contained guide- 
wire is removed. A no. 14F lubricated 
Foley catheter is then inserted, the bal­
loon inflated and the sheath peeled away. 
The balloon is verified endoscopically to 
be pulled against the anterior gastric wall 
and is then sutured to the skin.
Stamm Gastrostomy
The classic operation or a modifica­
tion of it4 is performed. A no. 18F to 
22F Foley catheter is used.
Postoperative Care
All patients received a cephalosporin 
intravenously 30 minutes before the 
procedure and two further doses at 
6-hour intervals thereafter. Patients 
already on antibiotics continued on the 
medication.
An orange plastic occlusive tape was
placed securely over a gauze square to 
prevent the gastrostomy tube being pulled 
out. This dressing was removed and the 
wound inspected every 2 days or any time 
the patient had fever or leukocytosis. 
Ranitidine was added to the intravenous 
fluids postoperatively to decrease volume 
and increase pH of gastric contents while 
adhesion of the stomach to parietal 
peritoneum began.
Tube feeding was started 3 days after 
the Stamm operation and 24 hours after 
the PEG procedures. Initially a non­
stimulating elemental diet (Vivonex TEN, 
Flexical HN) was given, progressing to a 
non-digested liquid diet (IsoSource, Iso- 
cal or Osmolyte) after 5 to 7 days. After 
2 weeks, patients to be on a gastrostomy 
for many years were started on a liquid 
diet with fibre (Enrich), and ultimately 
progressed to a blenderized diet. Tubes 
were not changed before 2 weeks 
postoperatively or after longer periods in 
depleted, diabetic patients or those on 
steroids. In the PEG patients, a larger 
lubricated Foley catheter could later be 
inserted at weekly intervals until a no. 18F 
size was reached.
Results (Table I)
The major indications for gastrostomy 
were neurologic problems including 
stroke, dementia, brain trauma, anoxic 
encephalopathy, Parkinson’s disease, 
amyotrophic lateral sclerosis and Hun­
tington’s disease. It was also used in 
patients with pharyngeal or esophageal 
blockage due to malignant or benign 
disease, including those who had under­
gone radiotherapy for hypopharyngeal 
tumours. Indeed, one patient with a large 
hypopharyngeal tumour underwent dila­
tation, thus enabling a “ pull” PEG to be 
accomplished. Other indications were 
weakness due to cancer, failure to thrive 
in the elderly, chronic respiratory failure 
and inhalation burns.
The PEG methods were more easily 
accomplished under local anesthesia than 
the Stamm operation. Patients with 
uncontrollable movements such as Hun­
tington’s chorea or who were unable to 
cooperate required general anesthesia.
The duration of the procedures, taken
from operative records, was less with 
PEG than the Stamm operation and least 
with the “ introducer” technique (Table 
I). Wound infections in the Stamm group 
were within the subcutaneous tissues of 
the abdominal incision, while those in the 
“pull” group were peritubal. It is interest­
ing that no peritubal infections occurred 
with the “ introducer” method.
There was one death in the recovery 
room after a Stamm gastrostomy. It may 
have been related to the magnitude of the 
procedure in this patient; no autopsy was 
carried out. Other deaths within 30 days 
were due to the underlying disease.
Abdominal distension occurred 
immediately after PEG in 20% of cases, 
disappearing clinically within 18 hours 
and indicating pneumoperitoneum that 
had no sequelae. We were impressed by 
the absence of pain after the PEG proce­
dures, but three patients had problems 
with gastroesophageal reflux despite ele­
vation of the head of the bed and admin­
istration of metoclopramide, so the feed­
ing was changed to a jejunostomy. Two 
of these had had “ pull” procedures in 
which the tip of the mushroom catheter 
had been cut off (as was our practice). In 
such cases a no. 9.6F polyurethane feed­
ing tube with a suture tied about the 
weighted tip was passed through the gas­
trostomy tube into the stomach. Through 
a gastroscope the suture was grasped and 
the weighted tip delivered to the second 
part of duodenum. In the stomach suffi­
cient slack was left in the tube to enable 
progression to jejunum.5-6 In the third 
patient, who had had the “ introducer” 
PEG and episodes of aspiration, the 
Foley catheter could have been changed 
to a mushroom with a polyurethane tube 
passed through its side.7 However, the 
tract in this patient was well developed, 
so a polyurethane feeding tube was passed 
alongside the Foley catheter and success­
fully negotiated endoscopically beyond 
the pylorus.8
Discussion
Nasoenteral feeding has advanced 
remarkably during the past 15 years, with 
the development of fine nonirritating 
tubes and improved diets. However, tubes 
that traverse the gastroesophageal junc­
tion can result in aspiration of stomach 
contents. They may plug, dislodge, 
require tape on the face and are not 
accepted for feeding at some nursing 
homes. Many debilitated patients with 
severe dysphagia can regain their ability 
to swallow and eat orally, if their nutri­
tion can be maintained over a prolonged 
period.
The use of gastrostomies, although 
requiring meticulous technique, attention 
and maintenance, has increased over the 
past few years. Gastrostomies should not 
be used to feed patients whose disease is
T a b le  1— C o m p a r is o n  o f  th e  T w o  M e th o d s  o f  P e r c u ta n e o u s  E n d o s c o p ic  
G a s t r o s t o m y  (P E G ) a n d  S ta m m  G a s t r o s to m y
S ta m m , " P u l l"  P E G , " In t r o d u c e r "
n  =  2 8 n -  2 8 P E G , n  =  2 8
M e a n  a g e  ±  S D , y r 6 8  ±  1 2 6 9  ±  1 4 7 3  ±  1 5
In d ic a t io n
N e u ro lo g ic  d is e a s e s 1 5 1 6 1 4
P h a ry n g e a l b lo c k a g e 3 4 6
C a c h e x ia , r e s p ir a to r y , b u rn 1 0 8 8
N o . u n d e r  lo c a l a n e s th e s ia 5 1 3 1 7
M e a n  t im e  fo r  p ro c e d u re  ± 5 5  ±  7  p <  0 .0 0 1 2 7  ±  8  p <  0 .0 0 1 1 6  ±  3
S D , m in
W o u n d  in fe c t io n 5 6 0
D e a th  w ith in  3 0  d 4 2 2
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rapidly progressive and who will shortly 
die. However, there are many patients 
who require nutritional maintenance, 
whose gut is functioning, who cannot or 
will not eat orally, and who no longer 
have available peripheral veins for 
intravenous infusion. In these patients, a 
feeding gastrostomy can be beneficial.
Percutaneous endoscopic gastrostomy 
is contraindicated in patients with ascites, 
because the procedure could lead to infec­
tion or leak because of a lack of sealing 
against the anterior abdominal wall. Rela­
tive contraindications are significant 
coagulopathy, esophageal varices and a 
nonfunctioning gut, and the procedure 
cannot be performed if the patient has 
complete esophageal obstruction or has 
previously undergone a total gastrectomy. 
Percutaneous endoscopic gastrostomy 
must be used with caution in patients who 
have had previous upper abdominal oper­
ations, the light must clearly be seen high 
in the left upper quadrant, with the tip 
of the gastroscope palpable through the 
abdominal wall. One of our patients with 
a previous Stamm gastrostomy had the 
tube removed after she regained her abil­
ity to eat; 1 year later she suffered a 
relapse and, with the stomach already 
adherent to anterior abdominal wall, 
PEG was done safely and easily. With a 
large hiatal hernia, the surgeon should 
confirm radiologically that it can be 
reduced into the abdomen before PEG 
is performed.9 With severe gastroeso­
phageal reflux, a means of inserting the 
tip of a tube endoscopically into the 
duodenum for jejunal feeding must be 
part of the PEG technique.10
The organisms in the “ pull” PEG 
peritubal infections were mainly 
Staphylococcus aureus and /3-hemolytic 
streptococci. These were associated with 
the other multiple gram-positive and 
gram-negative aerobic and anaerobic 
microorganisms that reside in the 
oropharynx and had been introduced into 
the subcutaneous tissues of these fre­
quently debilitated patients. The value of 
antibiotics given prophylactically in such 
patients has not yet been proven prospec­
tively, but we believe, in line with similar 
surgical situations, that antibiotics here 
are advantageous.11 Patients on H2 
blockers preoperatively, especially those 
who are diabetic, atherosclerotic, mal­
nourished or on steroids, warrant 
prophylactic antibiotic therapy.12 There 
are three reports of necrotizing fasciitis 
and myositis, which required extensive 
abdominal wall debridement, following 
the “ pull” PEG technique.13-15 The oral 
cavity in debilitated or semicomatose 
patients often contains thick crusting and 
debris. When antiseptic gargles are not 
possible preoperatively, the oral cavity 
should be prepared with a povidone- 
iodine-m oistened packing before 
introducing the gastroscope. Our data
suggest that peristomal infection is more 
frequent with the “ pull” than the 
“ introducer” method, likely because, 
with the “ pull” PEG, the tube with the 
flange is pulled through the oro- 
hypopharynx and the endoscope must be 
passed a second time.
Kits for the “ pull” PEG are available 
from a number of sources: Dumex, Scar­
borough, Ont. M1V 2V4; R. Laborie, 
Rexdale, Ont. M9W 6C8; Turdell (Glaser 
PEG), London, Ont. N5Z 3M5; Ameri­
can Endoscopy, Mentor, OH 44060; Tri- 
Med (E-Z PEG), Stanley, KS 66223; 
Davol, Cranston, RI 02920. A variation 
of the Ponsky “ pull” method is the 
Sacks-Vine kit (BeeJay, Oakville, Ont. 
L6L 5M1), in which a percutaneously 
inserted, long guidewire is retrieved from 
the stomach through the gastroscope and 
a polyethylene mushroom tube with a 
flange is pushed perorally over the guide- 
wire and through abdominal wall.
Subsequent to our study, a kit for the 
“ introducer” method has been marketed 
(Cook, Markham, Ont. L3R 3B1); this kit 
contained a Foley catheter found to have 
a defective balloon that frequently 
decompresses within 48 hours, leaving a 
free gastric hole causing peritonitis and 
infusion of diet into peritoneal cavity. 
The complication with this kit was 
widespread across North America. We 
had three such emergency occurrences 
recently, two patients were treated by sur­
gical gastrostomy and one by a repeat 
PEG, with a successful outcome. To over­
come the problem, Cook is now market­
ing a kit that permits introduction of a 
Malecot catheter through the peel-away 
sheath’ an outer tube is slid over the inner 
tube. However, we continue to have 
greatest ease of performance with the no. 
16F pacemaker lead introducer (Cook C- 
PLI-16-38) and a no. 14F Foley catheter, 
instead of a kit.
Percutaneous endoscopic gastrostomy 
can generally be performed on patients 
who are considered very high risks and 
is less costly than the Stamm gastrostomy. 
It appears that the “ introducer” PEG is 
simpler, faster and safer than the “ pull” 
PEG, but all three methods require 
meticulous technique and proper surveil­
lance. Percutaneous endoscopic gas­
trostomy requires two experienced wor­
kers — a skilled surgeon at the abdomen 
and a skilled endoscopist at the head.
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University of Toronto — 
Continuing Education
The Faculty of Medicine of the Univer­
sity of Toronto has scheduled two courses 
to be presented this spring. The first will 
take place May 19 and 20, 1988, at the 
Mount Sinai Hospital and is entitled 
“ Allografts in Orthopaedic Surgery — 
Banking and Clinical Applications” . On 
May 31 and June 1 at the same location, 
a course entitled “ Advances and Con­
troversies in Vascular Surgery” will be 
held. Further information on both of 
these courses can be obtained by writing: 
Continuing Medical Education, Faculty 
of Medicine, University of Toronto, Med­
ical Sciences Building, Toronto, Ont. 
M5S 1A8 or by calling: (416) 978-2718.
Multiorgan Transplantation 
Symposium
The first Canadian symposium on mul­
tiorgan transplantation will be held at 
University Hospital, London, Ont., Apr. 
28-29, 1988. Further information can be 
obtained by contacting: Continuing Med­
ical Education, Faculty of Medicine, The 
University of Western Ontario, London, 
Ont. N6A 5C1; telephone (519) 661-2074.
Congres annuel de (’Association 
des chirurgiens generaux
L’Association des chirurgiens generaux 
du Quebec tiendra son congres annuel, 21 
et 22 avril, 1988, a l’Hotel Le Quatre Sai-
continued on page 109
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Announcing a 
transform ation 
of parenteral antibiotic 
therapy
PMMAXIN
(imipenem and cilastatin sodium for injection)
iv « £ r+ f
A carbapenem, representing a totally new class of antibiotics 4  •
The broadest spectrum  
single-agent antibiotic
possessing bactericidal activity against a great 
majority of clinically significant pathogens
PRIMAXIN* offers the activity of
*  -
the penicillins against gram-positive aerobes -  
including coverage of Streptococcus faecalis
plus
the aminoglycosides and 3rd generation cephalosporins 
against gram-negative aerobes -  * ^
including coverage of Pseudomonas aeruginosa « *
plus
the antianaerobic agents -  h -
including coverage of Bacteroidesfragilis
** 1
«-■*
■i i
PRIMAXIN* is not active against Corynebacterium group JK, Fusobacterium varium, Mycobacterium spp., 
Chlamydia spp., Streptococcus faecium, Pseudomonas maltophilia, and some strains of: P cepacia,
P. pseudomallei, methicillin-resistant staphylococci, and Flavobacterium spp.
h  - t
u *
¥
*
Single-agent antibiotic for 
documented and empiric 
therapy in many impo 
infections'
including
□ infections usually treated with combination 
therapy
□ infections complicated by underlying 
disease
□ nosocomial infections
■
>. *
Imipenem and cilastatin sodium are present in a 1:1 ratio in PRIMAXIN* I.V. 
Imipenem is the sole antibacterial component. The role of cilastatin sodium is to 
prevent the inactivation of imipenem in the kidney and obtain antibacterial 
concentrations of imipenem in the urine.
tCaused by organisms susceptible to PRIMAXIN* I.V.
PRIMAXIN ,v
(im ipenem  and cilastatin  sodium  for injection)
Clinical efficacy in many 
im portant infections
EFFICACY IN INTRA-ABDOMINAL INFECTIONS1
91% cure or improvement
in  164 evaluable patients
1. Kager, L., Nord, C.E.: Imipenem/ 
cilastatin in the treatment of intra­
abdominal infections: A review of 
worldwide experience, Rev Infect Dis 
7 (Suppl 3): S518-S521, July-August 
1985.
EFFICACY IN LOWER RESPIRATORY TRACT 
INFECTIONS2
85% cure or improvement
in  2 0 4  evaluable
patients \
2. Acar, J.E: Therapy for lower j
respiratory tract infections with ,
imipenem/cilastatin: A review of
worldwide experience, Rev Infect Dis « • -*
7 (Suppl 3): S513-S517, July-August .
1985. *  '
+Caused by organisms susceptible to PRIMAXIN* I.V.
EFFICACY IN BACTERIAF SEPTICEMIA
90%  cure or 
improvement
in 135 evaluable 
patients
3. Eron, L.J.:
Imipenem / cilastatin 
therapy of bacteremia,
Am J Med 78 (Suppl 6A):
95-99, June 7, 1985.
V  -
4 -
patients
4. Sweet, R.L.: Imipenem/ 
cilastatin in the treatment 
of obstetric and gynecologic 
infections: A review of 
worldwide experience,
Rev Infect Dis 7 (Suppl 3): 
S522-S527, July-August 1985.
EFFICACY IN GYNECOLOGICAL
INFECTIONS4
97%  cure or 
improvement
in  72 evaluable
L.
PREV1AXIN* I.V. offers management 
advantages over combination therapy 
that includes an aminoglycoside
Generally w ell tolerated -  
safety profile 
sim ilar to cefazolin3
*-
□ 1723 patients, including the severely ill, have received therapy in clinical trials.
The incidence of the most common adverse experience (nausea) was no greater 
than 2%.
□ Avoids the potential nephrotoxicity or ototoxicity experienced with v 
aminoglycosides.
□ Avoids the potential hypoprothrombinemia and clinical bleeding experienced
with cephalosporins with MTT side chain. 4
H Avoids the potential disulfiram-like effect experienced with metronidazole and *
cephalosporins with MTT side chain.
Convenience of a single agent
The broadest spectrum single­
agent antibiotic representing 
a transformation of parenteral 
antibiotic therapy
5. Calandra G.B., Ricci F.M., Wang C., Brown K.R.: Safety and 
tolerance comparison of imipenem/cilastatin to cephalothin and 
cefazolin. J Antimicrob Chemother 12(suppl D): 125-131,1983.
+ Certain antibiotics which possess, as part of their molecular structure, the l-methyl-5-thiotetrazole (MTT) 
group have been associated with hypoprothrombinemia (and in some cases, clinical bleeding) and with 
a disulfiram-like effect.
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PRIMAXIN*
(imipenem and cilastatin sodium 
for injection)
Antibiotic
CNS adverse experiences such as myoclonic 
activity, confusional states, or seizures have 
been reported with PRIMAXIN* especially when 
recommended dosages based on renal function 
and body weight were exceeded. These exper­
iences have occurred most commonly in patients 
with CNS disorders (e.g., brain lesions or 
history of seizures) and/or who have compro­
mised renal function. However, there were rare 
reports in which there was no recognized or 
documented underlying CNS disorder. Close 
adherence to recommended dosage schedules 
is urged, especially in patients with known factors 
that predispose to seizures.
ACTION
Imipenem exerts a bactericidal action by inhibiting 
cell wall synthesis in aerobic and anaerobic gram­
positive and gram-negative bacteria.
PRIMAXIN* consists of tw o com ponents: 
(1) imipenem, a derivative of th ienam ycin, a 
carbapenem antibiotic; and (2) cilastatin sodium, a 
specific inhibitor of dehydropeptidase-l a renal 
enzyme which metabolizes and inactiva tes 
imipenem. Cilastatin blocks the metabolism of 
imipenem in the kidney, so that concomitant 
administration of imipenem and cilastatin allows 
antibacterial levels of imipenem to be attained in the 
urine.
Inhibition of cell-wall synthesis is achieved in gram­
negative bacteria by the binding of imipenem to 
penicillin binding proteins (PBPs). In the case of 
E sch e rich ia  c o li and se lec ted  s tra in s  of 
Pseudomonas aeruginosa, imipenem has been 
shown to have highest affinity for PBP-2, PBP-1a 
and PBP-1 b, with lower activity against PBP-3. The 
preferential binding of imipenem on PBP-2 and 
PBP-1 b leads to direct conversion of the individual 
cell to a spheroplast resulting in rapid lysis and cell 
death without filament formation. When imipenem 
is removed prior to complete killing of gram­
negative species, the remaining viable cells show a 
measurable lag, termed a "post-antibiotic effect" 
(PAE), prior to resumption of new growth.
INDICATIONS AND CLINICAL USE
PRIMAXIN* (imipenem and cilastatin sodium for 
injection) may be indicated in the treatment of 
serious infections when caused by sensitive strains 
of bacteria. Where considered necessary, therapy 
may be initiated on the basis of clinical judgment 
before results of sensitivity testings are available. 
Continuation of therapy should be reevaluated on 
the basis of bacteriological findings and of the 
patient’s clinical condition.
Imipenem is active in vitro against a wide range of 
gram-positive and gram-negative aerobic and 
anaerobic bacteria, including most strains which 
are beta-lactamase producing. Patients have 
responded while under treatment with PRIMAXIN* 
for single or mixed infections of the following body 
systems, when they were associated with a number 
of pathogenic species and strains of the genera 
listed:
1. Lower Respiratory Tract Infections
2. Urinary Tract Infections
3. Intra-Abdominal Infections
4. Gynecological Infections
5. Septicemia
6. Endocarditis caused by Staphylococcus 
aureus
1. Bone and Joint Infections 
8. Skin Structure Infections
Gram-positive Aerobes
•  Listeria monocytogenes
• Nocardia asteroides
• Staphylococcus (excluding many strains 
which are methicillin resistant)
•  Streptococcus (excluding S. faecium)
Gram-negative Aerobes
•  Acinetobacter
•  Citrobacter
• Enterobacter
• Escherichia coli
• Haemophilus influenzae
•  Haemophilus parainfluenzae
• Klebsiella
• Morganella morganii
•  Neisseria
• Proteus (indole positive and indole negative 
strains) 1
•  Providencia
•  Pseudomonas aeruginosa
• Serratia marcescens
Gram-positive Anaerobes
•  Clostridium (excluding C. difficile)
• Peptococcus
•  Peptostreptoccus
Gram-negative Anaerobes
•  Bacteroides fragilis
•  Bacteroides (non-fragilis)
CONTRAINDICATIONS
PRIMAXIN’  (imipenem and cilastatin sodium for 
injection) is contraindicated in patients who have 
shown hypersensitivity to either component of this 
product.
WARNINGS
PRIMAXIN* (imipenem and cilastatin sodium for 
in jec tion) SHOULD BE ADMINISTERED WITH 
CAUTION TO ANY PATIENT WHO HAS DEMONS­
TRATED SOME FORM OF ALLERGY, PARTICULARLY 
TO STRUCTURALLY-RELATED DRUGS. IF AN 
ALLERGIC REACTION TO PRIMAXIN* OCCURS, 
DISCONTINUE THE DRUG. SERIOUS HYPER­
SENSITIVITY REACTIONS MAY REQUIRE 
EPINEPHRINE AND OTHER EMERGENCY 
MEASURES.
Pseudomembranous colitis
Pseudomembranous colitis has been reported with 
the use of PRIMAXIN*. Therefore it is important to 
consider this diagnosis in patients who develop 
diarrhea during or after therapy. This colitis may 
range from mild to life threatening in severity.
Mild cases of pseudomembranous colitis may 
respond to drug discontinuance alone. In more 
severe  cases, m anagem en t may in c lu d e  
sigm oidoscopy, appropria te  bacte rio log ica l 
studies, fluid, electrolyte and protein supple­
mentation, and the use of a drug such as oral 
vancomycin, as indicated. Other causes of colitis 
should also be considered.
PRECAUTIONS
General
Prolonged use of PRIMAXIN* (imipenem and 
cilastatin sodium for in jection) may result in 
overgrowth of resistant organisms. Repeated 
evaluation of the patient’s condition is essential. If 
superinfection occurs during therapy, appropriate 
measures should be taken.
CNS adverse experiences such as myoclonic 
activity, confusional* states, or seizures have been 
reported with PRIMAXIN* especially when recom­
mended dosages based on renal function and body 
weight were exceeded. These experiences have 
occurred most commonly in patients with CNS 
disorders (e.g., brain lesions or history of seizures) 
and/or who have compromised renal function. 
However, there were rare reports in which there was 
no recognized or documented underlying CNS 
disorder. Close adherence to recommended dosage 
schedules is urged especially in patients with 
known factors that predispose to seizures (see 
DOSAGE AND A D M IN IS T R A T IO N ). A n t i­
convulsant therapy should be continued in patients 
with a known seizure disorder. If focal tremors, 
myoclonus, or seizures occur, patients should be 
evaluated neurologically and placed on anti­
convulsant therapy if not already instituted. If CNS 
symptoms continue, the dosage of PRIMAXIN* 
should be decreased or discontinued.
Use in Patients with Impaired Renal Function
Dosage in patients with impaired renal function is 
based on the severity of infection but the maximum 
daily dose varies with the degree of renal functional 
im pa irm ent (see DOSAGE AND A D M IN IS ­
TRATION - Dosage in Patients w ith  Renal 
Insufficiency).
Use in Pregnancy
The use of PRIMAXIN* in pregnant women has not 
been studied, therefore, PRIMAXIN* should be used 
during pregnancy only if clearly needed. Use of this 
drug in women of childbearing potential requires 
that the anticipated benefits be weighed against 
possible hazards.
Reproduction studies with bolus I.V. doses suggest 
an apparent intolerance to PRIMAXIN* (including 
emesis, inappetence, body weight loss, diarrhea
and death) at doses equivalent to the average 
human dose in pregnant rabbits and cynomolgus 
monkeys that is not seen in non-pregnant animals in 
these or other species. In other studies, PRIMAXIN* 
was well tolerated in equivalent or higher doses (up 
to 11 times the average human dose) in pregnant 
rats and mice (see REPRODUCTION STUDIES 
underTOXICOLOGY in the complete monograph).
Nursing Mothers
It is not known whether PRIMAXIN* is excreted in 
milk. If the use of PRIMAXIN* is deemed essential, 
the patient should stop nursing.
Pediatric Use
Efficacy and tolerability in infants under the age of 
3 months have not yet been established; therefore, 
PRIMAXIN* is not recommended in the pediatric 
age group below the age of 3 months.
Drug Interactions
Concomitant administration of PRIMAXIN* and 
probenecid results in only minimal increases in 
plasma levels of imipenem and plasma half-life. It is 
not recommended that probenecid be given with 
PRIMAXIN*.
PRIMAXIN* should not be mixed with or physically 
added to other antibiotics. PRIMAXIN* has been 
administered concomitantly with some antibiotics, 
such as aminoglycosides.
There is no evidence to suggest that association of 
PRIMAXIN* with any other beta-lactam antibiotics 
has any therapeutic advantage.
ADVERSE REACTIONS
PRIMAXIN* (imipenem and cilastatin sodium for 
injection) is generally well tolerated. The following 
adverse reactions were reported on 1,723 patients 
treated in clinical trials. Many of these patients were 
severely ill and had multiple background diseases 
and physiological impairments, making it d ifficu lt to 
determ ine causal re la tionsh ip of adverse ex­
periences to therapy with PRIMAXIN*.
Local Adverse Reactions
Adverse local clinical reactions that were reported 
as possibly, probably or definitely related to therapy 
with PRIMAXIN* were:
Incidence (%)
Phlebitis/thrombophlebitis 1.7
Infused vein pain 0.6
Vein induration 0.2
Infused vein infection 0.1
Systemic Adverse Reactions
Adverse clinical reactions that were reported as 
possib ly, p robab ly , o r d e fin ite ly  re la ted to 
PRIMAXIN* were:
Incidence (%)
Gastrointestinal
nausea 2.0
diarrhea 1.7
vomiting 1.6
tongue papillar hypertrophy 0.2
pseudomembranous colitis
(see WARNINGS) 0.1
hemorrhagic colitis <0.1
gastroenteritis <0.1
abdominal pain <0.1
glossitis <0.1
heartburn <0.1
pharyngeal pain <0.1
increased salivation <0.1
CNS
fever 0.4
dizziness 0.3
seizures 0.2
(see PRECAUTIONS)
somnolence 0.2
confusion 0.2
myoclonus 0.1
vertigo 0.1
headache 0.1
encephalopathy <0.1
paresthesia <0.1
Special Senses
transient hearing loss in 
patients with impaired hearing <0.1 
tinnitus <0.1
Respiratory TABLE 1 Dosage in Infants and Children
dyspnea 0.1
hyperventilation <0.1
thoracic spine pain <0.1
Cardiovascular
hypotension 0.4
palpitations 0.1
tachycardia <0.1
Renal
oliguria/anuria <0.1
polyuria <0.1
Skin
rash 0.9
pruritus 0.3
urticaria 0.2
skin texture changes 0.1
candidiasis 0.1
erythema multiforme <0.1
facial edema <0.1
flushing <0.1
cyanosis <0.1
hyperhidrosis <0.1
pruritus vulvae <0.1
Body as a whole
polyarthralgia <0.1
asthenia/weakness <0.1
Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug 
relationship, that were reported during clinical trials 
were:
Hepatic: Increased SGPT, SGOT, alkaline phospha­
tase, bilirubin and LDH.
Hemic: Increased eosinophils, positive Coombs 
test, decreased WBC and neutrophils, increased 
WBC, increased platelets, decreased platelets, 
decreased hemoglobin and hematocrit, increased 
monocytes, abnormal prothrombin time, increased 
lymphocytes, increased basophils.
Electrolytes: Decreased serum sodium, increased 
potassium, increased chloride.
Renal: Increased BUN, creatinine.
Urinalysis: Presence of urine protein, urine red 
blood cells, urine white blood cells, urine casts, 
urine bilirubin, and urine urobilinogen.
TREATMENT OF OVERDOSAGE
There are no data available on overdosage.
PRIMAXIN* (imipenem and cilastatin sodium for 
injection) is cleared by hemodialysis.
DOSAGE AND ADMINISTRATION
The dosage recommendations for PRIMAXIN* 
(imipenem and cilastatin sodium for injection) 
represent the quantity of imipenem to be ad­
ministered by I.V. infusion only. An equivalent 
amount of cilastatin is also present in the solution.
The dosage of PRIMAXIN* should be determined by 
the severity of the infection, renal function, body 
weight, the antibiotic susceptibility of the causative 
organism(s) and the condition of the patient. Doses 
cited are based on body weight of 70 kilos.
The median duration of treatment with PRIMAXIN* 
in clinical trials for infections of the various body 
systems ranged from 6 to 10 days except for 
endocarditis and bone and joint infections for which 
the median duration of treatment was 4 weeks.
Dosage in Adults
The recommended daily dose is 1 to 2 g adminis­
tered in equally divided doses every 6 to 8 hours 
(see Table 1).
Dosage in Elderly Patients
The recommended dosage of PRIMAXIN* in elderly 
patients with normal renal function is the same as 
given for adults above. Renal status of elderly 
patients may not be accurately portrayed by 
measurement of BUN or creatinine alone. Deter­
mination of creatinine clearance is suggested to 
provide guidance for dosing in such patients.
ADULT DOSAGE OF PRIMAXIN*
I.V. Administration
Severity 
of infection
Dose
(m g of im ipenem )
Dosage
Interval
Daily
Dose
Mild 250 mg 6 h 1.0 g
Moderate 500 mg 8 h 1.5 g
Severe (fully 
susceptible)
500 mg 6 h 2.0 g
Severe* infections
due to less
susceptible
organisms
or life threatening
conditions
1000 mg 
1000 mg
8 h 
6 h
3.0 g
4.0 g
* Primarily some strains of Ps. aeruginosa.
The recommended total daily dosage of PRIMAXIN* 
in children and infants 3 months of age and older is 
60 to 100 mg/kg of body weight divided into 4 equal 
doses given at six hour intervals. The higher 
dosages should be used for infants and young 
children. The total daily dosage should not exceed 
2 gram s. C lin ic a l data are in s u ffic ie n t to 
recommend an optimum dose for infants and 
children with impaired renal function.
Administration
CAUTION: CONTENTS OF VIALS NOT FOR 
DIRECT INFUSION.
Each reconstituted 250 mg or 500 mg dose should 
be given by intravenous infusion over twenty to 
th irty minutes. Each 1000 mg dose should be 
infused over 40 to 60 minutes. In patients who 
develop nausea during the infusion, the rate of 
infusion may be slowed.
RECONSTITUTION
The maximum daily dose should not exceed 4 g or 
50 mg/kg, which ever is less.
Contents of the 13 mL vials must be suspended and 
transferred to 100 mL of an appropriate infusion 
solution.
Dosage in Patients with Renal Insufficiency
P a tie n ts  w ith  c re a t in in e  c le a ra n c e s  o f 
<5 mL/min/1.73 m2 (<0.08 mL/s/1.73m2) should 
not receive PRIMAXIN* unless hemodialysis is 
instituted within 48 hours. Both imipenem and 
cilastatin are cleared from the circulation during 
he m odia lys is . The p a tie n t should receive 
PRIMAXIN* after hemodialysis and at 12 hour 
intervals timed from the end of that hemodialysis 
session. Dialysis patients, especially those with 
background CNS disease, should be carefully 
m o n ito re d ; fo r  p a tie n ts  on he m odia lys is , 
PRIMAXIN* is recommended only when the benefit 
outweighs the potential risk of seizures (see 
PRECAUTIONS). Currently, there are inadequate 
data to recommend the use of PRIMAXIN* in 
patients undergoing peritoneal dialysis.
TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN’ 
IN RELATION TO RENAL FUNCTION
RENAL
FUNCTION
CREATIN INE
CLEARAN CE
mL/min/1.73 m? 
(mL/s/1.73 m2)
DOSE
(9)
DOSAGE
INTERVAL
(h)
MAXIMUM
TOTAL
DAILY
DOSAGE
(9)
M ild
im p a irm e n t 3 1 - 7 0
( 0 .5 2 - 1 . 1 7 )
0.5 6 - 8 1 . 5 - 2
M o d e ra te
im p a irm e n t 2 1 - 3 0  
(0 .3 5  -  0 .5 0 )
0 .5 8 - 1 2 1 - 1 . 5
S e v e re *
im p a irm e n t 0 - 2 0  
(0  -  0 .3 3 )
0 .2 5  -  0 .5 12 0.5  - 1 . 0 * *
Patients w ith  c re a tin in e  clearance of 6 to 
20 mL/min/1.73 m2 (0.1 - 0.3 mL/s/1.73 m2) should 
be treated with 250 mg (or 3.5 mg/kg whichever is 
lower) every 12 hours for most pathogens. When 
the 500 mg dose is used in these patients, there may 
be an increased risk of seizures.
A suggested procedure is to transfer approximately 
10 mL from the 100 mL of the appropriate infusion 
solution to the vial (see list of diluents under 
COMPATIBILITY AND STABILITY). Shake well. 
Return the resulting 10 mL of suspension to the 
remaining 90 mL of the infusion solution.
Repeat, using 10 mL of the diluted suspension, to 
ensure complete transfer of the contents of the vial 
to the infusion solution.
CAUTION: CONTENTS OF VIALS NOT FOR 
DIRECT INFUSION.
COMPATIBILITY AND STABILITY
List of diluents
0.9% Sodium Chloride Injection 
5% or 10% Dextrose Injection 
5% Dextrose Injection with 0.02% sodium 
bicarbonate solution
5% Dextrose and 0.9% Sodium Chloride 
Injection
5% Dextrose Injection with 0.225% or 0.45% 
saline solution 
NORMOSOL-M in D5-W 
5% Dextrose Injection with 0.15% potassium 
chloride solution 
Mannitol 2.5%, 5% and 10%
Reconstituted solutions
Solutions of PRIMAXIN* range from colourless to 
yellow. Variations of colour within this range do not 
affect the potency of the product.
PRIMAXIN*, as supplied in vials and reconstituted 
as above maintains satisfactory potency for four 
hours at room temperature and for 24 hours under 
refrigeration (4°C). PRIMAXIN* has been found to 
be stable in 0.9% Sodium Chloride Injection for 
10 hours at room temperature and 48 hours under 
refrigeration.
DOSAGE FORMS
xx The highest dose is only recommended for 
infections due to less susceptible organisms 
primarily some strains of Ps. aeruginosa.
When only the serum creatinine level is available, 
the following formula (based on sex, weight, and 
age of the patient) may be used to convert this value 
into creatinine clearance (mL/min). The serum 
creatinine should represent a steady state of renal 
function.
Males: Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL) 
Females: 0.85 x above value.
AVAILABILITY
PRIMAXIN* is supplied as a sterile powder mixture 
in vials conta in ing imipenem anhydrous and 
cilastatin sodium as follows:
3514 Ca - 250 mg imipenem equivalent and 250 mg 
cilastatin equivalent in vials.
3516Ca - 500mgimipenemequivalentand500mg 
cilastatin equivalent in vials.
STORAGE
The dry powder should be stored at a temperature 
below 30° C.
When using the International System of units (SI), 
the estimated creatinine clearance (mL/s) in males 
can be calculated as follows:
(lean body weight, kg) x (140 - age, years) x 1.4736 
(72) x (serum creatinine concentration,/rmol/L)
and in females the estimated creatinine clearance 
(mL/s) is:
(lean body weight, kg)x (140-age, years) x 1.2526 
(72) x (serum creatinine concentration, pmol/L)
PRIMAXIN* is cleared by hemodialysis. After each 
dialysis session the dosage schedule should be 
restarted.
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Diagnosis and Managem ent of Adrenal Masses:
1987 Du Pont Lecture
Adrenal enlargements were found in 
slightly more than 100 patients of 
approximately 15 000 who underwent 
abdominal computed tomography. A firm 
diagnosis was made in 61 patients. Of 
these, 34 were screened because of sus­
pected metastases from nonadrenal 
tumours. Major causes of adrenal 
enlargement were metastases (20 
patients), nonfunctioning adenomas (15) 
and hormonally active masses (9). Fine- 
needle aspiration biopsy was a useful 
diagnostic aid in patients with 
metastases. Surgical treatment was 
undertaken in 17 patients (three 
pheochromocytomas, one Cushing's ade­
noma, three Conn's adenomas, four 
primary carcinomas, two metastatic car­
cinomas, three nodular hyperplasias sus­
pected to be part of the multiple endo­
crine adenopathy syndrome and one 
myelolipoma). Work-up of an adrenal 
mass includes a full history and physical 
examination, search for possible 
nonadrenal primary malignant lesions, 
testing for excess adrenal hormone 
secretion, computed tomography of the 
abdomen and fine-needle aspiration 
biopsy in selected patients.
Sur environ 15 000 patients qui ont subi 
une tomodensitometrie, plus de 100 ont
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presente une hypertrophie de la surre- 
nale. Un diagnostic ferme a ete pose 
chez 61 patients. Parmi ceux-ci, 34 ont 
ete investigues pour des metastases 
soupconnees de tumeurs non surrdnales. 
Les principales causes d'hypertrophie de 
la surrenale etaient les metastases (20 
patients), des adenomes non secretants 
(15) et des tumeurs hormonalement acti­
ves (9). Une ponction-biopsie a I'aiguille fine 
a servi a poser un diagnostic chez les 
patients porteurs de metastases. Une 
intervention chirurgicale a ete pratiquee 
chez 17 patients (trois pheochromocyto- 
mes, un adenome de Cushing, trois ade­
nomes de Conn, quatre carcinomes pri- 
mitifs, deux carcinomes metastatiques, 
trois hyperplasies nodulaires soupcon­
nees d'etre impliquees dans un syndrome 
d'adenopathie endocrinienne multiple et 
un myelolipome). L'6laboration du dia­
gnostic d'une masse surrenale comprend 
les antecedents et un examen physique 
complet, la recherche de lesions mali- 
gnes primitives d'origine possiblement 
non surrenale, la verification d'une 
hypersecretion surrenale, une tomodensi­
tometrie de I'abdomen et une ponction- 
biopsie a I'aiguille chez des patients 
choisis.
Adrenal masses used to be diagnosed only 
when they caused symptoms. At that 
stage, malignant tumours were often 
incurable, and horm one-secreting  
tumours had already caused substantial 
morbidity. With the introduction o f com­
puted tomography we can now visualize 
normal adrenal glands and thus detect 
and localize abnormal glands.1 In two 
series,2-3 computed tomography o f the 
upper abdomen revealed asymptomatic 
adrenal masses in 0.6% and 0.7% of  
cases, respectively. The importance of 
such masses and the question o f further 
evaluation and treatment have posed 
dilemmas for clinicians. In this report we 
describe our experience with 61 patients 
with adrenal masses, discovered inciden­
tally in most.
Patients and Diagnoses
Between 1983 and 1987, clinical, radi­
ologic, histopathologic or cytopathologic 
diagnoses o f adrenal masses were made 
in 61 out of approximately 15 000 patients 
who underwent abdominal computed to­
mography at the University o f Cincinnati 
Medical Center and Cincinnati Veterans 
Administration Medical Center. Thirty- 
four patients underwent computed 
tomography for suspected metastases 
from a variety c f  primary malignant 
tumours (Table I). Those in whom 
adrenal metastases were not confirmed by 
fine-needle aspiration biopsy, underwent 
repeat computed tomography over a 
period of several months. Metastatic dis­
ease was diagnosed if the mass increased 
in size in untreated patients or decreased 
substantially in size during chemotherapy.
Nonfunctional adenomas and adrenal 
hyperplasia were diagnosed by fine-needle
T a b le  1— In d ic a t io n s  f o r  C o m p u te d  T o m o g r a p h y
In d ic a t io n N o .  o f  p a t ie n t s
S u s p e c te d  m e t a s t a s e s  f r o m 3 4
th e  f o l lo w in g  p r im a ry  
t u m o u r s *
L u n g  c a n c e r 2 0
C o lo n ic  c a n c e r 3
O v a r ia n  c a n c e r 2
N o n -H o d g k in 's  ly m p h o m a 2
P r o s ta t ic  c a n c e r 2
A d u lt  W ilm s ' tu m o u r 1
L e io m y o s a r c o m a 1
P a n c r e a t ic  c a n c e r 1
P h a r y n g e a l c a n c e r 1
C e r v ic a l c a n c e r 1
U n k n o w n  s ite 1
H y p e r te n s io n 6
M u lt ip le  e n d o c r in e 3
a d e n o p a th y
U n e x p la in e d  w e i g h t  lo s s 2
A b d o m in a l t r a u m a 2
F u n g a l in f e c t io n s 2
( s y s te m ic ,  p u lm o n a ry )
M a s c u l in iz in g  a d r e n o g e n ita l 1
s y n d ro m e
M is c e lla n e o u s  a b d o m in a l 11
c o m p la in ts
* 1  p a t ie n t  h a d  2  p r im a r y  t u m o u r s .
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aspiration biopsy or serial computed 
tomography. The finding of only normal 
adrenal cells in the aspiration specimens 
was considered compatible with either 
diagnosis. Computed tomography was 
considered diagnostic if no change in size 
occurred on follow-up over a period of 
6 months to 2 years. Adenomas appeared 
as a focal dominant mass in otherwise 
normal glands. Hyperplasia was seen as 
smooth adreniform or diffuse multinodu­
lar adrenal enlargement without a focal 
mass.
Conn’s tumour was diagnosed by clin­
ical history, serum biochemical analysis 
and pathological examination of the sur­
gical specimen. Two patients underwent 
diagnostic preoperative venous sampling, 
which was technically unsuccessful in one 
patient found to have aberrant venous 
drainage at surgery.
Adrenal myelolipoma was diagnosed 
by its characteristic computed tomo­
graphic appearance, with areas of the 
tumour having a fat density of -  80 to 
-1 0 0  Hounsfield units (HU). The 
appearance of an initially high-density 
mass (60 to 80 HU), that decreased in 
both size and density over 1 to 3 months 
was diagnostic for hemorrhage.
In patients whose clinical picture war­
ranted further investigation, urinary 
excretion of 17-hydroxycorticosteroids 
and 17-ketosteroids was measured, in 
addition to plasma concentrations of cor­
tisol and aldosterone. Catecholamine 
production was evaluated by calculating 
the urinary excretion of vanillylmandelic 
acid, metanephrine and catecholamines, 
and the plasma concentrations of 
norepinephrine and epinephrine. Other 
diagnostic tests included angiography, 
inferior vena caval venography, ultra­
sonography and adrenal venous sam­
pling.
Histopathologic studies were per­
formed on surgically removed specimens 
(17) and autopsy material (1) and 
cytopathologic studies were performed on 
fine-needle aspiration biopsy specimens 
(28). The last test was used mainly in 
patients with suspected metastases to the 
adrenal glands.
Findings
The lesions encountered and their 
dimensions are listed in Table II. Of the 
61 patients 17 (28%) had bilateral lesions 
— 9 adrenal metastases, 4 nonfunction­
ing adenomas, 2 nodular hyperplasia, 1 
myelolipoma and 1 histoplasmosis.
Metastases
The primary malignant tumours that 
were metastatic to the adrenal glands 
were as shown in Table III. Nine patients 
had bilateral lesions. The left adrenal 
gland was enlarged in 15 and the right in
14 cases. The diagnosis was confirmed by 
fine-needle aspiration biopsy in 12, by 
repeat computed tomography in 6 and by 
operation in 2. A 74-year-old man with 
persistent right upper quadrant pain, 
nausea and vomiting underwent a radi­
cal right nephroadrenalectomy for sus­
pected primary carcinoma of the adrenal, 
which was found to be a metastatic 
adenosquamous carcinoma, presumably 
from the lung (Fig. 1). He refused radi­
otherapy and chemotherapy and was lost 
to follow-up. The second surgical patient 
had palliative resection of a metastatic 
lesion of the adrenal from colonic carci­
noma. Several months later widespread 
metastases developed.
Nonfunctioning Adenomas
Of the 15 patients with nonfunctioning 
adenomas, the lesions were bilateral in 4, 
the left gland only was involved in 7, the 
right gland only in 4. The diagnosis was 
confirmed by fine-needle aspiration 
biopsy alone in five patients, by computed 
tomography alone (1 to 2 years follow­
up) in three patients and by both proce­
dures in seven patients (Fig. 2). One 4-cm 
diameter lesion contained a hemorrhagic 
cyst which was confirmed by fine-needle 
aspiration biopsy.
Nodular Hyperplasia
Of the five patients with nodular hyper­
plasia, two had bilateral lesions. Three 
patients had suspected multiple endocrine 
adenopathy — gastrinoma and pituitary 
tumour in one, the second a pituitary 
tumour only and hypertension with a sug­
gestive clinical picture in the third. The 
diagnosis of nonfunctional nodular 
hyperplasia was made only after removal 
of the affected glands, and all patients 
made smooth recoveries. In the two 
remaining patients fine-needle aspiration 
biopsy confirmed the diagnosis.
Pheochromocytoma
Only two of four patients with 
pheochromocytoma were hypertensive. 
The lesions involved both glands equally. 
One normotensive patient, previously
treated for ovarian cancer, underwent a 
right adrenalectomy for a suspected 
metastatic lesion. She became unexpect­
edly hypotensive when the adrenal gland 
was removed; a pheochromocytoma was 
subsequently diagnosed. She made a 
smooth postoperative recovery. Of the 
two hypertensive patients treated surgi­
cally, one was lost to follow-up and the second was normotensive with normal 
vanillylmandelic acid levels in the urine 
1 year later. The diagnosis was made at 
autopsy in the fourth patient, an 87-year- 
old normotensive man who was found to 
have areas of calciiication on computed 
tomography (Fig. 3).
Myelolipoma
The appearance of a fat-containing 
tumour on computed tomography was 
considered diagnostic in three of the four 
patients (Fig. 4). The fourth patient had 
a 4-cm partially calcified soft-tissue dense 
mass and underwent a nondiagnostic fine- 
needle aspiration biopsy; the diagno­
sis was made after surgical removal. One 
patient had bilateral lesions.
Adrenal Carcinoma
Three of the four adrenal carcinomas 
were clinically nonfunctional, the fourth 
caused masculinization in a woman. At 
the time of operation one patient had liver 
and nodal metastases with tumour 
thrombus in the inferior vena cava. Oper­
ation included radical nephroadrenalec­
tomy, node dissection and removal of the 
thrombus. Another patient had splenic, 
renal and lymph-node invasion (Fig. 5), 
requiring radical removal of the involved 
structures. Three of the four patients sub-
T a b le  I I I — P r im a r y  T u m o u rs  
M e t a s t a t i c  to  th e  A d re n a l G la n d
T u m o u r N o . o f  tu m o u rs
L u n g  c a n c e r 11
C o lo n ic  c a n c e r 3
N o n -H o d g k in 's  ly m p h o m a 2
O v a r ia n  c a n c e r 1
P r o s ta t ic  c a n c e r 1
W ilm s ' tu m o u r 1
U n k n o w n 1
T a b le  I I — D ia g n o s is  a n d  S iz e  o f  A d re n a l M a s s e s  in 6 1  P a t ie n ts
N o . o f  p a t ie n ts
S iz e  o f  le s io n , 
R a n g e
c m
M e a n
M e ta s t a s e s  t o  a d re n a l g la n d 2 0 1 -  1 0 4 . 8
N o n fu n c t io n in g  a d e n o m a 1 5 1 -  4 2 .5
N o d u la r  h y p e rp la s ia 5 1 -  3 —
P h e o c h r o m o c y to m a 4 2 . 5  -  8 5
M y e lo lip o m a 4 1 -  1 0 —
P r im a r y  a d re n a l c a r c in o m a 4 4 . 5  -  1 2 8
C o n n 's  a d e n o m a 3 1 -  3 —
A d r e n a l h e m o r rh a g e 3 2 -
F u n g a l in fe c t io n 2 3 —
C u s h in g 's  a d e n o m a 1 2 —
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FIG. 1—Right adrenal mass caused by metastatic adenosquamous 
carcinoma presumably of bronchial origin (IVC = inferior vena cava).
FIG. 2—Computed tomography was performed for suspected pan­
creatic carcinoma in middle-aged woman. Note left adrenal mass, 3 cm 
in dimension, diagnosed as nonfunctioning adenoma since there were 
no hormonal abnormalities and no change in computed tomography 
after 1-year follow-up.
FIG. 3—Calcified 5-cm right adrenal pheochromocytoma in nor- 
motensive 87-year-old man. Diagnosis was confirmed at autopsy.
FIG. 4—Bilateral myelolipomas in woman with abdominal pain and 
abnormal liver function test results. Note fat-density right adrenal mass 
(10 cm) and fat-density left adrenal mass (4 cm).
FIG. 5—Carcinoma of left adrenal gland measuring 12 cm in 63-year- 
old woman with left upper quadrant pain, nausea, vomiting and severe 
weight loss. Managed by in-continuity excision of adrenal gland, kid­
ney, spleen and lymph nodes.
FIG. 6—Left adrenal mass in 18-year-old hypertensive man. Diag­
nosis of Conn’s adenoma was confirmed by venous sampling. Patient 
became normotensive after left adrenalectomy.
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sequently suffered widespread metastases 
and died 7 to 24 months postoperatively. 
The fourth who had a nonfunctioning 
4.5-cm adenocarcinoma was well, with a 
normal abdominal computed tomogram 
more than 16 months after operation.
Conn’s Adenoma
All three patients with Conn’s ade­
nomas (Fig. 6) presented with hyperten­
sion and hypokalemia. All were treated 
surgically, with remission of hypertension 
in two. The third required low dosage 
antihypertensive medication.
Adrenal Hemorrhage
Adrenal hemorrhage occurred in three 
patients; hemorrhage occurred after 
abdominal trauma in two and in a third 
patient with relapsing polychondritis who 
was on long-term corticosteroid therapy. 
The density and size changes on serial 
computed tomography were considered 
diagnostic.
Fungal Infections
Two patients had disseminated fungal 
infections, one by histoplasmosis and the 
other by blastomycosis. In the former, the 
adrenal gland enlargement was bilateral 
and in the second it was unilateral with 
some calcification. The diagnosis was 
confirmed by fine-needle aspiration 
biopsy in both.
Cushing’s Syndrome
This patient’s lesion in the left adrenal 
gland was managed by surgical excision. 
There was almost complete remission of 
the syndrome except for persistent mild 
hypertension.
Discussion
High-resolution computed tomography 
has made the investigation of adrenal 
lesions much safer, eliminating many 
invasive and potentially harmful diagnos­
tic procedures.4 But, by unearthing 
previously unsuspected adrenal masses, 
computed tomography creates diagnostic 
dilemmas and may fail to detect a lesion 
1 cm or less in size4 or an adrenal mass 
in children or thin adults who have little 
retroperitoneal fat to provide sufficient 
contrast.
W ith a radiologically diagnosed 
adrenal enlargement, the surgeon faces 
two questions — is it hormonally active? 
and is it malignant? To answer these ques­
tions a careful review of the history, phys­
ical and biochemical findings is necessary 
to determine whether the patient has 
Cushing’s syndrome, primary aldostero­
nism, pheochromocytoma or the adreno­
genital syndrome (with masculinization or 
feminization).
In patients with Cushing’s syndrome, 
the dexamethasone suppression and 
metyrapone tests will determine whether 
the underlying cause is in the pituitary 
gland or whether an adrenal adenoma or 
carcinoma is responsible.5 Great care 
must be taken in performing the various 
tests and interpreting the results because 
they are subject to dietary, pharmacologic 
and environmental influences.6 Pheo- 
chromocytomas especially are easily 
missed as the absence of hypertension 
does not exclude the diagnosis in a patient 
with an incidentally discovered adrenal 
mass.5 In two large series,7,8 20% and 
24% of pheochromocytomas, respectively, 
were discovered only at autopsy. 
However, 131I-meta-iodobenzylguandine 
(MIBG) scintigrams show promise in 
effectively localizing the tumours, espe­
cially multiple and malignant lesions.4 In 
addition, iodocholesterol scintigrams 
have accurately localized Conn’s ade­
nomas in the majority of cases studied.4 
Nonfunctional adrenal carcinomas may 
be less common than previously thought 
and when urinary 17-ketosteroid levels are 
measured in such patients, many are 
found to be producing excessive amounts 
of steroids.5 One of the four primary 
carcinomas in our series caused a viriliz­
ing syndrome.
More important than the hormonal 
investigation is the need to determine if 
the lesion is malignant. In our series, 33% 
of adrenal enlargements were metastatic 
and only 7% primary malignant lesions. 
The predominance of metastatic lesions 
has been reported by others.2,5 In 
patients with known cancers elsewhere in 
the body, not all adrenal masses are 
metastases, as shown by 15 of 34 patients 
in our series who had benign lesions con­
firmed by fine-needle aspiration biopsy, 
clinical follow-up and serial computed 
tomography. A similar finding has been 
reported by Belldegrun and colleagues2 
who found that 27% of their patients with 
known primary carcinomas had unrelated 
benign adrenal lesions.
In the absence of metastasis or a func­
tional mass one must distinguish between 
benign lesions and primary adrenal car­
cinomas. Copeland5 emphasized the rar­
ity of adrenocortical carcinoma (0.0006% 
to 0.00017% annual incidence in cancer 
registries) compared with relative fre­
quency of benign, clinically silent ade­
nomas (1.4% to 8.7% in several autopsy 
series). Most cortical adenomas are small 
and occur most frequently in the 
elderly.6 Some investigators recommend 
serial computed tomography for adrenal 
masses less than 5 cm in diameter that 
have a smooth contour and well-defined 
margins.9 Others have recommended 
removal of masses larger than 3 to 4 
cm,3 3.5 cm,2 or 6 cm.5 In our experience
most benign lesions were 4 cm or smaller 
in diameter while primary malignant 
tumours were 4.5 cm or larger. The mean 
size of adrenal carcinomas in three large 
series2,10,11 ranged from 10 to 14 cm and 
the smallest tumours from 4 to 1 cm. 
Therefore, when a lesion is larger than 4 
cm in diameter we advise surgical 
removal. For smaller lesions we recom­
mend serial computed tomography to 
demonstrate lack of growth. If the mass 
shows enlargement on follow-up, we 
advise operation. If the adrenal lesion is 
suspected to be a solitary metastasis in 
patients with remote cancers, operation 
is also indicated.
Fine-needle aspiration biopsy, a valu­
able tool in our study, has been shown to 
be diagnostic in 83% to 94% of cases in 
selected patients.12-14 We found fine- 
needle aspiration biopsy to be most 
accurate in differentiating metastatic dis­
ease from primary adrenal tumours, and 
it made possible the diagnosis of fungal 
infection of the gland in two patients. 
However, it fails as a method of differen­
tiating a primary carcinoma from an ade­
noma, adenoma from hyperplasia or 
hyperplasia from normal adrenal tissue. 
The key to its successful use is meticulous 
technique using 22-gauge needles and 
careful route planning. A “ quick-stain 
technique” reduces nondiagnostic biop­
sies to a minimum. The specimen is 
stained and viewed by the cytopathology 
technician in the computed tomography 
room. Multiple passes are made until a 
good-quality specimen is obtained. Using 
a 21- to 23-gauge needle, the incidence of 
serious hemorrhage, pneumothorax or 
infection is less than 2%.
With the suggested guidelines we 
believe that an accurate diagnosis can be 
made in most patients. Preoperative 
localization allows the surgeon to plan an 
approach that combines ease of operation 
with low morbidity, avoiding the anterior 
transperitoneal route in many cases. In 
one series15 using this anterior approach, 
18% of patients who underwent left 
adrenalectomy required an incidental 
splenectomy. We agree with the recom­
mendation of others4,15 that the anterior 
incision be used for patients with 
pheochromocytoma, since approximately 
10% have either extra-adrenal tumours or 
a malignant lesion not accessible through 
a retroperitoneal approach. We also use 
the approach for large tumours, but when 
extensive en-bloc excision is anticipated 
we prefer a thoracoabdominal incision. 
For most small lesions we use the 
posterior route, which gives good 
exposure, particularly of the right adrenal 
where the venous drainage frequently 
enters the posterior surface of the vena 
cava and is less accessible anteriorly.4 
For small bilateral lesions, posterior inci­
sions are used. Perioperative blood 
replacement and postoperative morbidity
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Open pelvic fractures are highly lethal lesions, with at least half of such pa­
tients dying even in the absence of other injuries. Breaks or joint disruptions 
at two different sites occur when a major compressive force is applied to the 
bony pelvic “ ring.” Fracture fragments may penetrate the colon or rectum, 
thereby further complicating management, but the most common cause of death 
after major pelvic fracture continues to be blood loss from small arteries and 
veins arising from the hypogastric circulation. Blood at the urethral meatus 
after pelvic fracture suggests disruption of the urethra or base of the bladder, 
and dictates urethrography prior to attempts at cathether insertion.
B
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are lower with the posterior approach and 
the hospital stay is substantially shorter 
after unilateral or bilateral adrenalectomy 
than with the anterior incision.15
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NOTICES
continued from page 104 
sons de Montreal. Pour renseignements, 
s’adresser au secretariat de l’Association: 
(514) 849-8887.
Workshop in Liver Surgery
A workshop in liver surgery is sched­
uled for Apr. 29, 1988 in Sacramento, 
Calif., sponsored by the UC Davis School 
of Medicine. Topics covered will include: 
current indications and techniques for 
hepatic resection and the role of the ultra­
sonic dissector in surgery. Information 
can be obtained from the UC Davis 
School of Medicine, 2701 Stockton Blvd., 
Sacramento, CA 95817; telephone: (916) 
453-5390.
Postgraduate Course 
in General Surgery
The Department of Surgery of the 
University of California School of Medi­
cine, San Francisco, is holding a course 
in general surgery which will offer general 
surgeons an intensive overview of 
problems encountered in daily practice. 
The course will be held Apr. 14-16, 1988. 
For registration information write to: 
Extended Programs in Medical Educa­
tion, Registration Office, Room 575-U, 
University of California, San Francisco, 
CA 94143-0766 or call (415) 476-5808.
Annual Surgery Course 
of University of Minnesota 
Medical School
The University of Minnesota’s Medi­
cal School will present its 52nd annual 
surgery course, entitled “ Progress in Gas­
trointestinal Surgery” , June 15-18, 1988. 
For further information contact the 
Office of Continuing Medical Education, 
University of Minnesota, Box 202, 
UMHC, 420 Delaware St. SE, Min­
neapolis, MN 55455; telephone (612) 
626-5525.
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Gastroplasty With Distal Gastric Bypass: 
a New and More Successful Weight Loss Operation 
for the Morbidly Obese
Because of the unacceptable late failure 
rates associated with other surgical 
procedures for morbid obesity, the 
author has performed a new operation — 
vertical banded gastroplasty with distal 
gastric bypass — on 70 patients. In 
seven of these the gastroplasty stoma 
had to be debanded. The mean lowest 
loss of excess weight was 88%  and the 
mean final loss of excess weight was 
83%  for the main group. The postopera­
tive complication rate was acceptable 
and no late metabolic complications have 
been seen.
This operation gives improved weight 
loss when compared with gastroplasty or 
gastric bypass alone and has none of the 
late complications associated with intes­
tinal bypass.
A cause du taux inacceptable d’echecs 
retardes relies aux techniques chirurgica- 
les courantes pour obesite pathologique, 
I'auteur a pratique chez 70 patients un 
nouveau type d'operation, une gastro- 
plastie a bandelettes verticales avec deri­
vation gastrique distale. Dans sept cas, 
les bandelettes du stoma de gastroplastie 
durent etre defaites. La perte minimale 
moyenne d'exces de poids a ete de 88%  
et la perte finale moyenne d'exces de 
poids a ete de 83% pour le groupe prin­
cipal. Le taux de complications postope- 
ratoires est acceptable et aucune compli­
cation metabolique tardive n'a ete 
enregistree.
Cette operation augmente la perte de 
poids par rapport it la gastroplastie ou a
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la derivation gastrique seule et ne cause 
aucune des complications tardives reliees 
a la derivation intestinale.
Although initially a successful weight-loss 
procedure in my hands, gastroplasty, 
whether horizontal, vertical or vertical 
banded, has been associated with an 
unacceptable late failure rate. Data com­
piled at the University of Alberta Hospi­
tal and supported in the literature1-4 
show that this failure rate has steadily 
increased through the years (Table I5’6). 
Weight loss failure is defined as inability 
of the patient to lose or maintain a loss 
of more than 40% of excess weight.
When the failure of gastroplasty 
became evident some years ago, I began 
considering possible alternatives. In my 
hands, intestinal bypass in patients fol­
lowed up for between 2.8 and 6.8 years 
is associated with only a 2.5% failure of 
weight loss but a 20% overall failure rate. 
Gastric bypass is renowned as a techni­
cally difficult procedure and although it 
maintains weight loss for longer than gas­
troplasty, it was reported in one series to 
be associated with a late failure rate of 
31.5%.7 The pancreaticobiliary bypass 
of Scopinaro,8,9 apparently a very suc­
cessful weight loss operation, is also tech­
nically demanding and has some of the 
malabsorption problems associated with 
intestinal bypass.10,11
In this paper I report a new type of 
weight loss operation that combines the 
small vertical pouch and reinforced stoma 
of gastroplasty with the additional, and 
perhaps undefined, benefits of gastric 
bypass. I have found it highly successful
and associated with few side effects, save 
those of gastric restriction.
Patients and Methods
Vertical banded gastroplasty with dis­
tal gastric bypass was performed on 70 
patients, followed up for between 1.6 and 
4 years. The mean preoperative weight 
was 127.2 kg (range from 88.2 to 210.9 
kg). The patients met previously estab­
lished criteria for selection and were 
assessed in the same way as candidates for 
intestinal bypass or gastroplasty. They 
were assessed postoperatively at 1 month, 
3 months, 6 months and every year there­
after.
Weight loss for each patient was 
recorded on the day of maximum loss 
(greatest excess weight loss [GEWL]) and 
on the final day of follow-up (final excess 
weight loss [FEWL]). These figures show 
how profound weight loss has been and 
provide an estimate of the stability of 
weight loss or any tendency to rapid 
regain of weight. Ideal weights were esti­
mated from Metropolitan Life Insurance 
Company tables; the mean ideal weight 
for the group was 60.6 kg (range from 
48.6 to 77.3 kg).
Operative Technique
A vertical banded gastroplasty is per­
formed using the old TA90 stapler 
(United States Surgical Corp., Stamford, 
Conn.) with seven staples removed from 
the lesser curvature end of the staple clip 
to form a stoma. The stoma is reinforced 
with a 6-cm segment of 6-cm Impragraft
T a b le 1— Failure  R a te  ( % )  o f  th e  V a r io u s  G a s t r o p la s t y  P r o c e d u re s
a t  th e  U n iv e r s it y  o f  A lb e rta
T y p e  o f  g a s t r o p la s t y 1 9 8 5 5 1 9 8 5 6 1 9 8 6 *
H o rizo n ta l 3 6 . 5 3 3 4 3
V e rt ic a l 1 6 . 6 3 3 4 3
V e rt ic a l b and ed 1 8 3 2 4 4
* M o s t  re ce n t d a ta  - u npu b lished .
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(Impra Inc., Phoenix, Ariz.),12 sutured 
through the lesser curvature end of the 
staple line with 1-0 Prolene. The stoma 
is not calibrated with an intraluminal bou­
gie or catheter.
The distal gastric bypass (Figs. 1 and 
2) is constructed by applying two staple 
lines with the new TA90 stapler, running 
from the lesser curvature below the gas­
troplasty stoma to the greater curvature 
at the lower pole of the spleen. A Dennis 
clamp is applied above the staple line on 
the greater curvature and an appropriate 
incision made between clamp and staple 
line to accomodate the jejunal anasto­
mosis.
The jejunum is picked up at a distance 
of between 40 and 60 cm from the liga­
ment of Treitz and divided between 
Dennis clamps. The mesentery is opened 
and vessels of the arcade are individually 
grasped, divided and ligated. An antecolic 
gastrojejunostomy is then performed over 
clamps after the aseptic technique of 
Wangensteen13 and Dennis,14 using inter­
rupted 4-0 black silk Lembert sutures. 
The rent in the mesentery is closed with 
interrupted 4-0 black silk sutures.
A Roux-en-Y enteroenterostomy is 
then constructed below the gastroen­
terostomy and the mesentery closed. The 
nasogastric tube can be passed into the 
jejunum but often is only passed through 
the gastroplasty stoma.
Postoperative care is as reported previ­
ously for gastroplasties.15
Results
Postoperatively seven patients (follow­
up 1.6 to 2.9 years) had the gastroplasty 
stoma debanded. One was debanded 5 
days after operation because of a leak at 
the staple line and six were debended later 
because of excessive gastric restriction. 
Weight losses for this group are treated 
separately.
FIG. 1—Gastroplasty with distal gastric 
bypass. Distal staple line is well above gastric 
antrum at level of lower pole of spleen.
Weight Loss
All 70 patients lost at least 40% of 
excess weight. Weight loss was rapid and 
profound; all, except the ones who were 
heaviest, lost maximum weight within the 
first 12 to 14 months. Initial weight loss 
in 14 patients was either equal to or below 
the ideal weight. Subsequently, they 
regained a little weight to be near or just 
above the ideal.
For the main group (63 patients fol­
lowed up 1.9 to 4 years) the mean GEWL 
was 88% and mean FEWL was 83%. A 
detailed presentation of each patient on 
the last day of follow-up is presented in 
chronologic weight-loss graphs (Fig. 3).
Patients who underwent debanding had 
a mean GEWL of 80% and a mean 
FEWL of 72%.
Postoperative Complications
There were no major wound infections. 
Superficial wound infections occurred in 
2% of patients. One patient had an ileal 
strangulation 1 year after operation. The 
obstruction was due to an adhesive band. 
She underwent resection of the involved 
gut with primary anastomosis and subse­
quently did well. Two patients had an 
upper gastrointestinal hemorrhage, one 
after 18 months the other after 20 
months. Both underwent truncal vagot­
omy with suture of a bleeding posterior 
wall anastomotic ulcer. Neither patient 
has had further difficulties. Two patients 
have had minor dyspepsia treated success­
fully with H2 receptor blockade. Staple-
FIG. 2—Barium outlines esophagus, gas­
troplasty pouch (A) and stoma (B), distal gas­
tric pouch (C) and gastrojejunostomy (D). 
Pouches are not completely filled but staple 
lines and gas shadows indicate their extent.
line eventration occurred in two patients 
within 18 months. The result in each case 
was two stomas, one of standard size and 
a second somewhat smaller. The GEWL 
was 88% for one patient and 122% for 
the second. The FEWL was 67% at 766 
days for the former and 100% on day 913 
for the latter.
In one patient a 1-mm dehiscence deve­
loped in the distal staple line allowing 
contrast agent to leak into the distal
DAYS POSTOPERATIVE
DAYS POSTOPERATIVE
FIG. 3—Chronologic weight-loss graphs. 
Each vertical line represents one patient on last 
day of follow-up. Top of line is weight at oper­
ation, bottom is lowest weight, horizontal 
dash is final weight. Circle at bottom 
is ideal weight related to height and age 
(Metropolitan Life Insurance Company tables).
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defunctioned stomach. This was disco­
vered on day 52. By day 549 the excess 
weight loss was 98%.
Complete follow-up of serum labora­
tory data in all patients did not reveal any 
noteworthy abnormality. Results of liver 
function tests were all normal at 3 months 
and for the remainder of the follow-up 
period. No patient had renal stones or 
electrolyte abnormalities. There was no 
anemia, other than in the two patients 
with upper gastrointestinal hemorrhage.
The only serious side effects were 
related to gastric restriction and intoler­
ance of red meat, which affected 78% of 
patients during the first year, but only 7% 
by the end of the second year.
Diarrhea is not associated with this 
operation. Constipation preoperatively 
was improved by operation.
Discussion
The aim of surgery for morbid obesity 
is profound and lasting weight loss. Intes­
tinal bypass fulfilled these criteria, but 
neither gastroplasty nor gastric bypass 
alone has totally succeeded, and I no 
longer perform gastroplasty alone. 
However, gastroplasty with distal gastric 
bypass has proved to be unique in that ini­
tial weight loss is even more profound 
than that achieved with intestinal bypass 
and is not associated with metabolic side 
effects.
A comparison of my results with those 
reported by Reinhold16 for gastric bypass 
alone using his simplified method of 
evaluation is shown in Table II. Gas­
troplasty with distal gastric bypass obvi­
ously outperforms gastric bypass, achiev­
ing a much more consistent weight loss 
over comparable follow-up periods. The 
difference may well be related to the last­
ing intake restriction imposed by the 
lesser curvature vertical gastroplasty and 
the banded stoma, a feature less easily 
achieved with gastric bypass alone.
The limited intake imposed by the gas­
troplasty component is usually well toler­
ated. When intractable intolerance 
occurred, debanding relieved vomiting 
and dysphagia while not fundamentally 
altering weight loss.
The addition of distal gastric bypass to 
gastroplasty has not, in my hands, 
increased the risk of surgery; there were 
no deaths attributable to the procedure 
and the complication rate was similar to 
that of gastroplasty alone. Operating 
time, however, increased by one half and 
a slightly longer abdominal incision is 
necessary. This has not resulted in an 
increased need for blood replacement or 
rate of wound infection.
The positioning of the gastroen­
terostomy stoma more distally has meant 
that lengthening the jejunal mesentery is 
unnecessary in order to accomplish an an- 
tecolic gastroenterostomy. Early in the 
series several patients had retrocolic gas­
trojejunostomies, but it was soon disco­
vered that this was unnecessary so long 
as the jejunal limb was made at least 40 
cm from the ligament of Treitz. This held 
true even in the heaviest patients operat­
ed on.
The frequency of acid peptic problems 
after gastric bypass alone has been low, 
undoubtedly because the small pouch is 
made so high on the stomach that little 
parietal cell mass is included. I initially 
expected that acid peptic problems might 
be more frequent after gastroplasty with 
distal gastric bypass. That this was not the 
case is probably because the proximal gas­
troplasty staple lines denervate a substan­
tial part of the fundus thereby protecting 
the gastroenterostomy. The follow-up is 
still relatively short and only further 
review will ascertain whether or not 
anastomotic ulcers will occur more fre­
quently.
Eventration of both proximal and dis­
tal staple lines occurred in this series. The 
incidence has been small and so far has 
had only minimal impact on weight loss. 
Undoubtedly the gastric bypass to some 
degree ameliorates the effects of proximal 
staple-line failure.
Gastroplasty with distal gastric bypass 
demands more operating time and is tech­
nically more difficult to perform than 
either procedure alone. However, the 
more profound and lasting weight loss 
compared with gastroplasty or gastric 
bypass alone and the lack of complica­
tions when compared with intestinal
Table II—Comparison of Results of Combined Gastroplasty With 
Gastric Bypass and Gastric Bypass Alone16 Using Reinhold's 
Classification
No. of patients
Final excess Reinhold Salmon
weight, %* Result (n = 29) In -  61) Reinhold Salmon
<  25 Excellent 10 45 34.5 73.8
26 -  50 Good 7 15 24.1 24.6
51 -  75 Fair 8 1 27.6 1.6
76 -  100 Poor 3 0 10.3 0
>  100 Failure 1 0 3.4 0
‘ Final excess weight - final weight -  ideal body weight x ^  
ideal body weight
bypass more than compensates for oper­
ative time and difficulty. Moreover, many 
patients who undergo gastroplasty or gas­
tric bypass require reoperation to produce 
further weight loss, in itself time- 
consuming, expensive and not without 
operative risk.
Summary and Conclusions
The results o f a new operation, verti­
cal banded gastroplasty with distal gas­
tric bypass, have been presented. Seventy 
patients underwent operation, 63 achiev­
ing a mean greatest excess weight loss of 
88% and a mean final excess weight loss 
of 83%. Early and late postoperative 
complications are of an acceptable level. 
No late metabolic complications have 
occurred.
The operation gives better weight loss 
than gastroplasty or gastric bypass alone 
and has none of the late complications 
associated with intestinal bypass.
I thank Miss M.O. McArdle who has been 
instrumental in achieving the extensive follow­
up necessary to compile the complete data 
presented in the manuscript and in preparing 
the illustrations. Without her efforts this 
presentation would have been impossible.
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lleogastrostomy for Morbid Obesity
Jejunoileal bypass procedures for morbid 
obesity have been associated with 
numerous side effects, due mainly to the 
blind-loop syndrome. To overcome this, 
the authors describe a new procedure, 
ileogastrostomy, that they have per­
formed in 50 patients. All had good 
weight loss and returned to work.
Patient satisfaction with the operation 
was high and self-esteem increased.
There were no deaths or severe compli­
cations. Stool frequency and foul-smell­
ing stools were still problems but 
improved with time.
Stomal ulceration occurred at 3 months 
in three patients but resolved within 
1 month when treated with H2 blocking 
agents and was not encountered later 
than 3 months in any patient.
L'operation de derivation jejuno-ileale 
pour obesite pathologique a ete ratta- 
chee a plusieurs effets indesirables dus 
principalement au syndrome de I'anse 
borgne. Afin de pallier a ce probleme, les 
auteurs decrivent une nouvelle interven­
tion, I'ileogastrostomie, qu'ils ont prati­
que chez 50 patients. Tous ont connu 
une bonne perte de poids et ont repris 
leur travail. Le degre de satisfaction des 
patients etait dleve et leur confiance en 
soi augmente. On n'a constate aucun 
deces ou complication grave. Les selles 
frequentes et la mauvaise odeur des sel­
les constituaient toujours un probleme, 
mais celui-ci s'ameliorait avec le temps.
Une ulceration du stoma est survenue 
apres 3 mois chez trois patients. Les 
ulceres ont cede en moins d'un mois d 
un traitement anti-H2. Aucun cas n'a ete 
observe passe cette periode de 3 mois.
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Many hundreds of thousands of patients 
in North America have undergone 
jejunoileal bypass for morbid obesity, 
defined as more than 45 kg above the 
ideal body weight. Jejunoileal bypass 
procedures have varied from the Scott1 
operation, which leaves a short length of 
jejunum and ileum, to the Salmon2 
procedure, which leaves a longer length 
of small intestine in continuity, to the 
Payne3 operation which leaves a short 
length of ileum and a longer length of 
jejunum. In the Scott1 and Salmon2 
procedures, the blind loop of small bowel 
is implanted into the colon at a site of the 
surgeon’s preference and with the 
Payne3 operation, the blind loop is left 
in continuity with the distal ileum.
These operations may cause serious 
postoperative problems that include elec­
trolyte deficiencies, ranging from 
hypokalemia and dehydration to more 
subtle and long-lasting changes, resulting 
in hyperoxaluria and renal stones. Distur­
bance of liver enzymes and function may 
lead to liver failure, the patient being at 
greatest risk during the first postopera­
tive year.
Other notable complications, related to 
disturbance of the immune system, result 
in rashes and arthralgia. Malabsorption 
of food and bile salts can cause steator­
rhea, diarrhea and passage of offensive 
flatus. There are also many rare, recur­
ring side effects that have been well 
covered in the literature.
The cause of all these complications 
and side effects has in large part been 
ascribed to the blind loop syndrome, a 
well-known entity in gastroenterology.4’5 
Temporary reversal of these complica­
tions has been reported — the adminis­
tration of antibiotics has “ sterilized” the 
blind segment and freed it from the 
colonizing bacteria said to cause the 
problems.
Despite this, no one has proposed 
implanting the blind loop into a more 
sterile setting to avoid this syndrome. 
Implantation into the colon would result 
in colonization of the blind loop due to 
the higher colonic pressure and associated 
large numbers of bacteria and other 
organisms. This could also apply,
although to a lesser extent, to bowel in 
continuity with distal ileum.
There are at least two solutions to the 
problem. One is a permanent ileostomy 
of the blind loop. This procedure has the 
disadvantage of requiring a pouch on the 
anterior abdominal wall into which drains 
between 20 ml and 1 L/d of succus enteri- 
cus. Although the procedure has been 
done in extreme circumstances, it is obvi­
ously not desirable from the patient’s 
point of view. The alternative is implan­
tation of the ileum into the stomach.
Merendino and Thomas6 successfully 
substituted a small bowel implant for the 
distal esophagus with no subsequent 
ulceration. The analogy between this and 
ileogastrostomy has merit. Colonization 
would be less likely, due to natural 
peristalsis of the bypass loop combined 
with the relatively sterile stomach with its 
low pH.
Surgical Technique
An end-to-end jejunoileal bypass is 
constructed, the proximal jejunum meas­
uring 25 cm and the distal ileum 50 cm 
(Fig. 1). The proximal end of the residual 
blind loop is closed in one layer, the dis­
tal end is brought up in front of the colon 
and anastomosed high up in the parietal­
cell-mass area of the anterior part of the 
stomach. A small portion of the stomach 
is excised to facilitate the one-layer
FIG. 1—Operative model for ileogas­
trostomy.
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anastomosis (Fig. 1). There is no attempt 
to close the potential gap in the mesen­
tery of the small bowel.
Patients and Method
We studied the results of the first 51 
morbidly obese patients who underwent 
ileogastrostomy. One patient, a native 
Indian, vomited repeatedly when she 
returned home and did not eat. Because 
of the problem of long-term manage­
ment, bowel continuity was restored leav­
ing 50 patients to be studied.
All ileogastrostomies were performed 
by the same surgeon (R.H.G.). The study 
was considered complete when the 50 
patients enrolled had been followed up 
for a minimum of 1 year. The longest fol­
low up was 2.5 years.
Patient height and weight, operative 
complications, detailed blood work and 
a record of antidiarrheal medication, if 
any, were recorded preoperatively, at 
monthly intervals postoperatively to 1 
year and at 6-week intervals thereafter. 
(It was assumed that there were no elec­
trolyte disturbances, no nausea and no 
need for antidiarrheal medication before 
surgery.) In addition, all patients under­
went upper gastrointestinal endoscopy 3 
months postoperatively, which was 
repeated if there was any suggestion of 
ulcer. A questionnaire was completed by 
all patients and their personal physicians.
Weight was taken to be preoperative 
weight divided by ideal weight multiplied 
by 100, thus representing the percentage 
of the ideal weight.
Potassium deficiency was considered
present when the serum value was less 
than 3.6 mmol/L.
Mildly abnormal liver function was 
indicated by a serum asparta te  
aminotransferase value of 25 to 35 U /L  
(normal 7 to 24 U/L), serum alkaline 
phosphatase of 121 to 150 U/L (normal 
40 to 120 U/L), serum bilirubin 21 to 25 
ixmol/L (normal 5 to 20 /unol/L) and 
serum lactate dehydrogenase value of 120 
to 150 U /L (normal 45 to 120 U/L). 
Moderately abnormal liver function was 
defined by a serum aspartate aminotrans­
ferase value of 35 to 70 U/L, a serum 
alkaline phosphatase level of 151 to 175 
U /L , serum bilirubin 21 to 25 /tmol/L 
and serum lactate dehydrogenase of 175 
U /L . Severely abnormal liver function 
was considered present when levels of 
liver enzymes were higher than those in 
the moderate group or the serum bilirubin 
was greater than 25 /xmol/L. An abnor­
mal level of serum protein was that below 
60 g/L (normal 60 to 80 g/L) and of 
serum albumin below 35 g/L (normal 35 
to 48 g/L).
Renal function was considered abnor­
mal when the serum creatinine level was 
greater than 120 yimol/L (normal 40 to 
120 /imol/L) or the serum urea nitrogen 
level was 8.1 to 9.8 mmol/L urea (nor­
mal 2.5 to 8.0 mmol/L urea).
Iron and folate deficiencies were 
recorded when the values were below the 
lower limits of normal for the laborato­
ries in which they were tested.
Stomal ulcer was present when there 
was a deficiency of mucosa with a white 
base at or near the ileogastrostomy on 
endoscopy.
Patient satisfaction was graded on a 
scale of 1 (bad) to 10 (excellent).
Statistical analysis used missing data 
constraints when some patients were una­
ble to answer the questionnaire com­
pletely or when a patient was missed at 
follow-up.
Statistical results were adjusted so that 
non-respondents appeared similar to 
respondents. Missing data was substituted 
with means and proportions to respon­
dent data.
A 5% level was taken as significant 
using the x2 test.
Results
There were no deaths, and no patients 
were lost to follow-up. Some, because of 
distance, economic or other reasons, 
missed one or more test appointments, 
giving rise to a 20% missing data rate for 
the time-interval tests; 49 patients were 
followed up for 3 months or longer, 48 
for 6 months or longer, 48 for 9 months 
or longer, 46 for 12 months or longer, 43 
for 18 months or longer and 22 for 24 
months or longer. The mean follow-up 
was therefore 18 months.
Forty-five percent of the total weight 
loss occurred in the first 3 months 
postoperatively (Fig. 2), with a gradual 
reduction of the rate of fall over the next 
9 months (18%, 13% and 8%) and 
beyond. At 24 months the patients were 
125% of ideal weight (range from 100% 
to 172%) and all had lost more than 60% 
of excess weight.
Mean patient satisfaction was 9.9 
(range from 7 to 10). Their assessment of
Table 1— Electrolyte Disturbances
Postop months Yes, % No, %
3 15.9 84.0
6 7.1 92.8
12 9.0 90.9
18 0.0 100.0
24 0.0 100.0
Mean 6.4 93.5
Variance 0.3 0.3
X 2 -  1.573 less than 9.488, DF 
significant differences.
= 4. No
Table 11-Results in Patients After Ileogastrostomy
Postop time, mo
Findings Preop 3 18 24 p value
Nausea, % NS
Severe - 9.8 — 0
Mild
Bloating, %
— 4.9 — 0
<  0.05
Regularly 2.2 14.3 r —
Occasionally — 19 32 —
<  0.05Loose bowel - 69.7 - 10
movements, %
Bowel movements, no./d <  0.05
Mean 1.26 6.9 — 2.9
Range
Foul-smelling stools, %
0.3 -  4 3 - 2 0 0.5 -  9
<  0.05
Regularly 0 7.3 8.4 —
Occasionally 0 24.4 37.5 —
Need for — 40 - 3.2 <  0.05
antidiarrheal 
agent, %
NSStomal ulcer, % - 6.2 — 0
Disturbances of liver <  0.05
function, %
Mild 10.9 35.9 13.6 —
Moderate — 12.8 0 —
Potassium 8.3 46.2 14.3 — NS
deficiency, % 
Serum protein 2.3 21 4.3 — NS
abnormality, %
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self-esteem was higher for 96.8% of 
patien ts and unchanged for the 
remainder; 82.6% were working and 
93.7% were able to do more work than 
before the operation.
Complications within the first 3 months 
included wound infection (6.6%), respira­
tory complications (2.2%), nausea 
(11.1%) and electrolyte disturbances 
(15.9%), which resolved completely 
within 18 months (Table I).
Table II shows other results. The 
postoperative increase in the number of 
patients with loose bowel movements had 
decreased by 24 months as had the daily 
number of movements. There was no 
incontinence.
Although only 3.2% of patients were 
taking antidiarrheal medication after 24 
months, 9.7% were still taking the medi­
cation occasionally.
The number of patients with foul­
smelling stools increased markedly after 
operation and did not improve with time. 
Bloating was also a problem postopera- 
tively, and although the number of 
patients who regularly had bloating 
decreased with time, 32% still had occa­
sional bloating at 18 months. There were 
no cases with severe disturbances of liver 
function.
Potassium deficiency was present in 
8.3% of patients preoperatively, increas­
ing to 46.2% at 3 months postoperatively 
and decreasing to 14.3% by 18 months.
Possible stomal ulcer was sought 
endoscopically and found in 6.2% at 3 
months, the number gradually falling to 
zero at 6, 12 and 24 months. The ulcer 
was always smaller than 3 mm in dimen­
sion, occurring at the anastomosis of 
ileum and stomach. These patients had 
dyspepsia and used acetylsalicylic acid. A 
drop in the hemoglobin level, not neces­
sitating transfusion, occurred in one 
patient. On review of preoperative films 
another was discovered to have an ulcer 
of the second part of the duodenum with 
stenosis. The stomal ulcers resolved 
within 4 weeks of the start of H2 blocker 
therapy.
There were no significant differences in 
renal function, iron and folate deficiency, 
and the frequency of skin lesions or of 
joint pains.
Comments
Morbid obesity affects many people in 
North America, causing loss of income 
and self-esteem, and higher morbidity and 
mortality than in people of normal 
weight. It has many of the characteristics 
of a disease and often cannot be remedied 
by medical means.
Jejunoileal bypass was a satisfactory 
procedure in terms of maintained weight 
loss, but was associated with a high inci­
dence of serious complications, some 
fatal.
By a procedure that avoids the develop­
ment of a blind loop syndrome we can 
eliminate the most serious complications 
and reduce the severity of the less serious 
ones to an acceptable level.
The weight loss is as good as the most 
successful jejunoileal bypass operations. 
Patient satisfaction, increase in self­
esteem and ability to work are much bet­
ter than we have found with other proce­
dures.
Electrolyte disturbances, particularly 
potassium deficiency as encountered in 
other bypass surgery, are less frequent 
and of a lesser degree. A probable expla­
nation is that the succus entericus drains 
into the stomach where it can be more 
readily absorbed than when the blind loop 
is inserted into or close to the colon.
The absence of severe liver and renal 
disease, and the avoidance of arthritic and 
skin complications may be ascribed to the 
insertion of the blind loop into a more 
sterile setting.
The residual mild to moderate distur­
bance of liver function parallels the 
weight loss and may well reflect an 
associated temporary alteration of 
metabolism. Iron and folate absorption 
were satisfactory.
The increased number, decreased con­
sistency and foul odour of stools, which 
may be due to lactose intolerance, largely 
resolve with time. These problems are, 
however, not fully resolved by the surgery 
and it may be that the arbitrary lengths 
of bowel in continuity need clarification. 
Increasing the length of ileum may be 
beneficial.
Stomal ulceration is a specific compli­
cation of this operation and the one we 
most feared. It occurred in only three 
patients, on each occasion within the first 
3 months, and was treated successfully by 
H2 blockers prescribed for 1 month. The 
operation does not appear to produce a 
strong ulcer diathesis.
We believe that there may be a place 
for ileogastrostomy in patients with com­
plications of other bypass surgery due to 
the blind-loop syndrome.
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ANTIBIOTIC
ACTION
In vitro studies demonstrate that the bacteri­
cidal action of cefoxitin, a cephamycin derived 
from cephamycin C, results from the inhibition 
of bacterial cell wall synthesis. Evidence 
suggests that the methoxy group in the 
7a position is responsible for the resistance of 
cefoxitin to degradation by bacterial beta- 
lactamases.
INDICATIONS AND CLINICAL USES 
TREATMENT
The treatment of the following infections when 
due to susceptible organisms:
1 - In tra-abdom ina l in fections such as
peritonitis and intra-abdominal abscess
2 - G yn e co log ica l in fe c tio n s  such as
endometritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and 
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t infections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies 
should be performed to determine the sus­
ceptibility of the causative organism(s) to 
MEFOXIN*. Therapy may be started while 
awaiting the results of these tests, however, 
modification of the treatment may be required 
once these results become available. 
O rganism s pa rticu la rly  appropria te fo r 
therapy with MEFOXIN" are:
Gram positive
Staphylococci, penicillinase producing and 
non-producing
Streptococci excluding enterococci 
Gram negative (beta-lactamase producing 
and non-producing strains)
E. coli
Klebsiella species (including K. pneumoniae) 
Proteus, indole positive and negative 
Haemophilus influenzae 
Providencia species 
Anaerobes 
Bacteroides fragilis
MEFOXIN* may also be appropriate for the 
treatment of infections involving susceptible 
strains of both aerobic and anaerobic bacteria.
Clinical experience has demonstrated that 
MEFOXIN’  can be administered to patients 
who are also rece iv ing  c a rb e n ic illin , 
gentamicin, tobramycin, or amikacin (see 
PRECAUTIONS and ADMINISTRATION).
Intravenous Administration
The intravenous route is preferable for 
patients with bacteremia, bacterial septicemia, 
or other severe or life-threatening infections, 
or for patients who may be poor risks because 
of lowered resistance resulting from such 
d e b ilita tin g  conditions as m alnutrition, 
trauma, surgery, diabetes, heart failure, or 
malignancy, particularly if shock is present or 
impending.
PROPHYLACTIC USE
MEFOXIN* may be administered periopera- 
tively (preoperatively, intraoperatively and 
postoperatively) to patients undergoing 
vaginal or abdominal hysterectomy and ab­
dominal surgery when there is a significant 
risk of postoperative infection or where the 
occurrence of postoperative infection is 
considered to be especially serious.
In patients undergoing cesarean section, intra­
operative (after clamping the umbilical cord) 
and postoperative use of MEFOXIN* may 
reduce the incidence of surgery related post­
operative infections.
Effective prophylactic use depends on the 
time of administration. MEFOXIN* usually 
should be given one-half to one hour before
the operation. Prophylactic administration 
should usually be stopped within 12 hours. It 
has been generally reported that continuing 
adm inistration of any antib io tic beyond 
24 hours fo llow ing surgery increases the 
possibility of adverse reactions but, in the 
majority of surgical procedures, does not 
reduce the incidence of subsequent infection. 
If signs of postsurgical infection should 
appear, specimens for culture should be 
obtained for identification of the causative 
organism(s) so that appropriate therapy may 
be instituted.
CONTRAINDICATIONS
MEFOXIN* is contraindicated in persons who 
have shown hypersensitivity to cefoxitin or to 
the cephalosporin group of antibiotics.
WARNINGS
Before therapy with MEFOXIN* is instituted, 
careful inquiry should be made to determine 
whether the patient has had previous hyper­
sensitivity reactions to MEFOXIN*, cephalo­
sporins, penicillins orother drugs. MEFOXIN* 
should be given with caution to penicillin- 
sensitive patients.
There is some clinical and laboratory evidence 
of pa rtia l c ro ss -a lle rg en ic ity  between 
cephamycins and the other beta-lactam anti­
b io tics, pen ic illins and cephalosporins. 
Severe reactions (including anaphylaxis) have 
been reported  w ith  most beta-lactam  
antibiotics.
Pseudomembranous colitis has been reported 
with virtually all antibiotics. This colitis can 
range from mild to life threatening in severity. 
Antibiotics should therefore be prescribed 
with caution in individuals with a history of 
gastrointestinal disease, particularly colitis. It 
is important to considers diagnosis of pseudo­
membranous colitis in patients who develop 
diarrhea in association with antibiotic use. 
While studies indicate that a toxin produced 
by Clostridium dillicile  is one primary cause of 
antibiotic-associated colitis, other causes 
should also be considered.
Any patient who has demonstrated some form 
of allergy, particularly to drugs, should receive 
antibiotics including MEFOXIN* with caution. 
If an allergic reaction to MEFOXIN* occurs, 
administration of the drug should be discon­
tinued. Serious hypersensitivity reactions may 
require treatment with epinephrine and other 
emergency measures.
PRECAUTIONS
The total daily dosage should be reduced 
when MEFOXIN* is administered to patients 
with transient or persistent reduction of 
urinary output due to renal insufficiency (see 
DOSAGE AND ADMINISTRATION) because 
high and prolonged serum antibiotic con­
centrations can occur from usual doses.
In patients treated with MEFOXIN* a false­
positive reaction to glucose in the urine may 
occur with Benedict's or Fehling's solutions 
but not with the use of specific glucose 
oxidase methods.
Using the Jaffe Method, falsely high creatinine 
values in serum may occur if serum concen­
trations of cefoxitin exceed 100 pg/mL. Serum 
samples from patients treated with MEFOXIN* 
should not be analyzed for creatinine if with­
drawn within two hours of drug administration.
Increased nephrotoxicity has been reported 
fo llow ing concomitant administration of 
cephalosporins and aminoglycoside antibiotics. 
The safety of MEFOXIN* in the treatment of 
infections during pregnancy has not been 
e s ta b lish ed . If the a d m in is tra tio n  of 
MEFOXIN* to pregnant patients is considered 
necessary, its use requires that the anticipated 
benefits be weighed against possible hazards 
to the fetus. Reproductive and teratogenic 
studies have been performed in mice and rats 
and have revealed no evidence of impaired 
fertility or harm to the fetus due to MEFOXIN*.
Cefoxitin has been observed in the milk of 
nursing mothers receiving the drug. 
Prolonged use of MEFOXIN* may result in the 
overgrowth of non-susceptible organisms. 
Repeated evaluation of the patient’s condition 
is essential and if superinfection occurs 
during therapy, appropriate measures should 
be taken. Should an organism become 
resistant during antibiotic therapy, another 
antibiotic should be substituted.
In children 3 months of age or older, higher 
doses of MEFOXIN* (100 mg/kg/day and 
above) have been associated w ith  an 
increased incidence of eosinophilia and 
elevated SGOT.
ADVERSE REACTIONS
MEFOXIN* is generally well tolerated. Adverse 
reactions rare ly required cessation of 
treatment and usually have been mild and 
transient 
Local Reactions
Thrombophlebitis has occurred with intra­
venous administration. Some degree of pain 
and tenderness is usually experienced after 
in tra m u scu la r in je c tio n s  using w ater. 
Induration has occasionally been reported.
Allergic
M aculopapular rash, urticaria , pruritus, 
eosinophilia, fever and other allergic reactions 
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can 
appear during or after antibiotic treatment. 
Nausea and vomiting have been reported 
rarely.
Blood
Transient eosinophilia, leukopenia, neutropenia, 
hemolytic anemia, and thrombocytopenia 
have been reported. Some individuals, particu­
la rly  those with azotemia, may develop 
positive direct Coombs tests during therapy 
with MEFOXIN*.
Liver Function
Transient elevations in SGOT, SGPT, serum 
LDH, and serum alkaline phosphatase have 
been reported.
Kidney
Elevations in serum creatinine and/or blood 
urea nitrogen levels have been observed. As 
with the cephalosporins, acute renal failure 
has been reported rare ly. The role of 
MEFOXIN* in changes in renal function tests 
is d iff ic u lt to assess, since factors pre­
disposing to prerenal azotemia or to impaired 
renal function have often been present.
TREATMENT OF OVERDOSE
Other than general supportive treatment, no 
specific antidote is known. MEFOXIN* can be 
eliminated by dialysis in patients with renal 
insufficiency.
Adults with Impaired Renal Function
MEFOXIN* may be used in patients with 
reduced renal function but a reduced dosage 
should be employed and it is advisable to 
monitor serum levels in patients with severe 
impairment.
In adults with renal insufficiency, an initial 
loading dose of 1 g to 2 g should be given. 
After a loading dose, the following recommen­
dations for maintenance dosage may be used 
as a guide:
RENAL CREATININE
FUNCTION CLEARANCE DOSE FREQUENCY
mL/min
Mild>
impairment
Moderate
50-30 1-2 g every 8-12 h
impairment
Severe
29-10 1-2 g every 12-24 h
impairment 9-5 0.5-1 g every 12-24 h
Essentially 
no function <5 0.5-1 g every 24-48 h
In the patient undergoing hemodialysis, the 
loading dose of 1 - 2g should be given after 
each hemodialysis, and the maintenance dose 
should be given as indicated in the Table 
above.
Neonates (Including Premature Infants), 
Infants and Children (See WARNINGS for 
Neonates under ADMINISTRATION in the 
complete monograph.)
P re m a tu re  In fa n ts  
w ith  B o d y  W e ig h ts  
A b o v e  1 5 0 0  g 20-40 mg/kg every 12 h I.V.
N e o n a te s
0- 1 week of age
1- 4 weeks of age
20-40 mg/kg every 12 h I.V. 
20-40 mg/kg every 8 h I.V.
In fa n ts
1 month to 2 years 
of age
20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
C h ild re n 20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
In severe infections, the total daily dosage in 
infants and children may be increased to 
200 mg/kg, but not to exceed 12 g per day. 
MEFOXIN* is not recommended fo r the
therapy of meningitis. If meningitis is sus­
pected, an appropriate antibiotic should be 
used.
DOSAGE AND ADMINISTRATION
MEFOXIN* may be administered intravenously 
or intram uscularly when required. (See 
complete monograph on ADMINISTRATION 
and RECONSTITUTION.)
TREATMENT DOSAGE 
Adults
The usual adult dosage is 1 g or 2 g of 
MEFOXIN* every 6 to 8 hours. Dosage and 
route of administration should be determined 
by severity of infection, susceptibility of the 
causative organisms, and condition of the 
patient. The usual adult dosages are shown in 
the Table below.
Usual Adult Dosage
T y p e  of 
in fe c tio n
D a ily
D o s a g e
F r e q u e n c y  
a n d  R o u te
Uncomplicated 
forms* of in­
fections such as 
pneumonia, 
urinary tract 
infection, soft 
tissue infection
3-4 g 1 g every 6-8 h 
I.V. or I.M.
Moderately 
severe or severe 
infections
6-8 g 1 g every 4 h
or
2 g every 6-8 h I.V.
Infections 
commonly 
needing anti­
biotics in higher 
dosage (e.g. gas 
gangrene)
12 g 2 g every 4 h
or
3 g every 6 h I.V.
"Including patients in whom bacteremia is 
absent or unlikely
Therapy may be started while awaiting the 
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic 
streptococcal infections should be maintained 
for at least 10 days to guard against the risk of 
rheumatic fever or glomerulonephritis. In 
staphylococcal and other infections involving 
a collection of pus, surgical drainage should 
be carried out where indicated.
At present there is in su ffic ie n t data to 
recommend a specific dosage for children 
with impaired renal function. However, if the 
administration of MEFOXIN* is deemed to be 
essential the dosage should be modified 
consistent with the recommendations for 
adults (see Table above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of 
MEFOXIN* is recommended as follows:
Vaginal or abdominal hysterectomy and 
abdominal surgery
2 g administered intramuscularly or intra­
venously just prior to surgery (approximately 
one-half to one hour before initial incision).
The second and third 2g doses should be 
administered at 2-6hour intervals after the 
initial dose.
Cesarean Section
The first dose of 2g should be administered 
intravenously as soon as the umbilical cord 
has been clamped. The second and third 
2 g doses should be given intravenously or 
intramuscularly four hours and eight hours 
after the first dose.
AVAILABILITY
MEFOXIN* is supplied as sterile powder in 
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt 
Storage
MEFOXIN* in the dry state should be stored 
below 30° C.
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Revision of Failed Horizontal Gastroplasty 
by Vertical Banded Gastroplasty
Eighteen patients who had undergone 
horizontal gastroplasty experienced 
postoperative weight gain due to techni­
cal failure (large orifice in 10 patients, 
staple-line disruption in 7 and a large 
pouch in 1). A vertical banded gas­
troplasty was used to correct the 
problem, with a resulting operative mor­
bidity of 38.9%. This included perfora­
tion with peritonitis (five patients) and 
complete outlet obstruction (two 
patients). These complications appear to 
result from poor blood supply to the area 
of the anastomosis necessary in this 
conversion. This study indicates that it is 
not safe to use vertical banded gas­
troplasty for the failed horizontal gas­
troplasty.
Dix-huit patients ayant subi une gas- 
troplastie horizontale ont presente un 
accroissement ponderal postoperatoire 
du a une dgfaillance de technique 
(grande orifice chez 10 des patients, bris 
de la ligne des agrafes chez 7 autres, et 
une grande poche chez le patient res- 
tant). Une gastroplastie en bande ver- 
ticale fut operee pour corriger leur 
probleme, avec un taux de morbidity 
operatoire resultante de 38,9% (perfora­
tion et pgritonite chez cinq patients, et 
obstruction complete chez deux autres). 
Ces complications semblent avoir resulte 
d'une irrigation sanguine insuffisante de 
la region de I'anastomose necessitee par 
une telle conversion. Cette etude indique 
qu'il est imprudent de recourir a la gas­
troplastie en bande verticale dans les cas 
de gastroplastie horizontale defaillante.
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The currently popular operations used to 
treat morbidly obese people are gastric 
bypass1’2 and vertical banded gas­
troplasty.3 These operations give a good 
initial loss of excess weight with minimal 
morbidity. The horizontal gastroplasty 
with either single4 or double staple 
lines5,6 with or without external support 
of the stoma6,7 has been much less suc­
cessful. As a result horizontal gastroplasty 
has been abandoned by most surgeons.
Failure to lose weight or late weight 
gain with horizontal gastroplasty is due 
to technical problems. The stoma or 
pouch can enlarge, and the material used 
to support the stoma can migrate into the 
gastric lumen. Finally, an opening can 
develop in the staple line resulting in poor 
weight loss or weight gain. When the 
horizontal gastroplasty is revised by 
merely reperforming the procedure, 
failure for similar reasons is frequent.5
Roux-en-Y gastric bypass has been 
reported as the best remedial operation 
for the failed horizontal gastroplasty.5 
Prospective randomized trials indicate 
that gastric bypass provides better results 
than horizontal gastroplasty and these 
trials advocate gastric bypass as the oper­
ation of choice for morbid obesity.8,9
Vertical banded gastroplasty has at 
least two potential advantages over 
horizontal gastroplasty. The material 
used for banding rarely migrates into the 
lumen and a small pouch is easily con­
structed without sacrificing the blood sup­
p ly .10 The conversion of a failed
T ab le  1 - P a tie n t C h a ra c te r is tic s
C h a ra c te r is tic M ean  R ange
A g e , y r 3 9 .8  ± 7 .9  2 6  -  5 5
H e ig h t, cm 1 6 6 .7 5  ± 6 .2 5  1 5 2  -  1 9 3
W e ig h t, kg 1 4 0 .8  ± 6 .2  9 5 .5  -  2 0 4 .5
Ideal w eight, kg 6 3 .8  ± 1 .6  5 4  -  81
horizontal gastroplasty to a vertical 
banded gastroplasty, although frequently 
suggested as a safe and logical procedure, 
has not been reported previously.
This paper presents the combined 
experience of the St. Joseph’s Health 
Centre in Toronto and the Royal Victoria 
Hospital in Montreal with 18 cases of 
failed horizontal gastroplasty converted 
to vertical banded gastroplasty.
Patients
Of the 18 patients (14 women, 4 men), 
8 were from Toronto and 10 from Mont­
real. The clinical data are set forth in 
Table I.
Horizontal Gastroplasty
The operations performed were slightly 
different depending on the patient and the 
hospital centre. The technique for the 
Toronto procedure was that described by 
Gomez.7 The Montreal operations 
included the Gomez procedure as well as 
a number of other horizontal techniques 
which placed the stoma at different loca­
tions on the horizontal staple line and 
used different materials to reinforce the 
gastrogastrostomy.6
The patients obtained a mean weight 
loss of 34.1 ± 2.5% (±  SEM) of their 
initial weight down to a mean weight of 
91.8 ± 4.4 kg (Table II). Using a clas­
sification described previously,6 we 
defined a good result as one in which the 
patient has lost more than 25% of the ini­
tial weight and is within 30% of ideal 
body weight, a satisfactory result is used 
for a patient who has lost more than 25% 
of initial weight but is not within 30% of 
ideal body weight and an unsatisfactory 
result is a weight loss of less than 25% 
of the initial body weight. There were five
T a b le  I I— O utco m e o f H o rizo n ta l G a s tro p la s ty  (M e a n  ± S E M )
O u tco m e M e a n R ange
P re o p e ra tiv e  w e ig h t ,  kg 1 4 0 .8  ± 6 .2 9 5 .5  -  2 0 4 .5
A f te r  h orizonta l g a s tro p la s ty , kg
L o w e s t w e ig h t 9 1 .8  ± 4 .4 6 8 .2  -  1 3 6 .4
H ig h es t w e ig h t 1 2 0 .3  ± 5 .7 7 2 .7  -  1 6 0 .5
F o llo w -u p  b e fo re  revis ion, mo 4 5 .1  ± 1 5 .1 1 2  -  6 8
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good, nine satisfactory and four unsatis­
factory results.
The horizontal gastroplasties subse­
quently failed in these 18 patients for 
several reasons — staple-line disruption 
(7 patients), a large orifice due to migra­
tion of the material used to maintain a 
specific size of stoma (10 patients) and a 
poorly positioned orifice (1 patient), 
which caused frequent vomiting despite 
weight gain. With these problems, the 
patients’ mean weight increased to 120.3 
± 5.7 kg, representing a gain of 28.5 ± 
3.1 kg from their lowest postoperative 
weight (Table II). At this point the results 
were classified as good in 1 patient, satis­
factory in 1 and unsatisfactory in 16
patients. The time taken ( ± SD) for these 
problems to develop was 45.1 ± 15.1 
months (range from 12 to 68 months) 
after surgery.
Vertical Banded Gastroplasty
This operation was performed in a 
fashion similar to that described by 
Mason.3 The banded area of the gas­
troplasty was made below the horizontal 
staple line, which usually necessitated an 
anastomosis between the upper and lower 
gastric pouches in order to provide a 
channel along the lesser curvature (Fig. 
1). The results of the vertical banded gas­
troplasty are presented in Table III. The
postoperative problems associated with 
the vertical banded gastroplasty used as 
a revision procedure occurred early 
postoperatively and were major (seven 
patients). Five patients suffered peritoni­
tis from a perforation of the stomach at 
the anastomosis between the upper and 
lower gastric pouches. Four of these had 
abscesses drained surgically with no fur­
ther problems; however, they were seri­
ously ill and required treatment in the sur­
gical intensive care unit for several weeks. 
In the fifth patient, a gastrocutaneous 
fistula developed and did not close for 2 
months. Two patients had severe gastric 
outlet obstruction requiring further sur­
gery to provide adequate drainage from 
the gastric pouch. There were no deaths. 
The mean weight of these 18 patients at 
the time of writing was 87.5 ± 4.7 kg, 
which is 37.4 ± 2.6% less than the ini­
tial weight. There are 5 good results, 12 
satisfactory and 1 unsatisfactory result 
(Table IV) at a mean follow-up after ver­
tical banded gastroplasty of 13.9 ±  6.4 
months (±SD).
Discussion
The patients presented in this paper had 
an initial favourable response to horizon­
tal gastroplasty, but because of staple-line 
disruptions or orifice enlargement, all 
regained most of their weight. This failure 
of horizontal gastroplasty is now well 
established. In a review of 5470 gastric 
partitioning operations, weight gain was 
the most frequent cause of failure in 5% 
to 20% of patients.11 Technical failure 
rates as high as 62% have been reported 
for horizontal gastroplasty.12 The techni­
cal failures relate primarily to stomal size 
or disruption of the staple line. Despite 
reinforcement of the gastrogastrostomy 
as emphasized by Gomez13 and of the 
staple line as emphasized by Brolin and 
R avitch ,14 there are still several 
reports5’9,15’'* of horizontal gastroplasty 
failures. It is important to have a long and 
complete patient follow-up. In the 18 
patients reported here, there were some 
failures as early as 1 year, but others 
occurred as late as 68 months after 
horizontal gastroplasty.
The vertical banded gastroplasty is cur­
rently popular because a small pouch is 
easily constructed, the orifice of the new 
gastric pouch can be externally supported 
and the polypropylene mesh rarely 
migrates through the thicker wall on the 
lesser curvature of the stomach. This 
operation presently has acceptable 
results,3’17-19 although long-term evalua­
tion is only now being reported.10’20 It is 
accepted but not proven as a suitable 
primary procedure for the surgical ther­
apy of morbid obesity.
As a secondary procedure, especially 
for failed horizontal gastroplasty, verti­
cal banded gastroplasty cannot be recom-
F1G. 1—Failed horizontal gastroplasty corrected by vertical banded gastroplasty : A = dou­
ble row of horizontal staples, B = reinforced gastrogastrostomy of horizontal gastroplasty, 
C = double row of vertical staples, D = reinforced pouch outlet of vertical gastroplasty. Insertion 
of gastrogastrostomy (E) was required to complete vertical banded gastroplasty.
Table Ill-O u tc o m e  of Vertica l Banded G astroplasty for Failed 
Horizontal G astroplasty (M ean  +  SEM )
Outcome M ean Range
W eight before vertical banded 
gastrop lasty, kg
1 2 0 .3  ± 5 .7 7 2 .7  -  1 7 0 .5
Current w e ig h t, kg 8 7 .5  ± 4 .7 5 8 .2  -  1 2 6 .4
Loss from  initial w eight, % 3 7 .4  ± 2 .6 1 0 .4  -  6 2 .8
Follow up a fte r  vertical banded 
gastroplasty, mo
1 3 .9  ± 6 .4 6 - 2 6
Tab le IV—Results of G astroplasty Procedures
Horizontal gastroplasty, class
V ertica l banded
Result Best Failed gastroplasty
Good 5 1 5
S atis facto ry 9 1 12
U nsatis factory 4 16 1
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Examinations
The exam ina tion s  o f th e  Roya l C o lle ge  
are held in Septem ber o f each  year. C an ­
d ida te s  w ish in g  to  s it fo r  the exam in a ­
t io n s  shou ld  no te  the fo llo w in g :
1. Every  cand idate  fo r adm iss ion  to  the 
exam ina tion s  m ust su bm it an app li­
ca t io n  for a sse ssm en t o f tra in ing .
2. C and ida tes  in tra in ing  in Canada  
shou ld  app ly fo r p re lim inary  a s se s s ­
m en t o f tra in ing  at le a s t one  year 
before  the date on w h ich  they  expec t 
to  s it  fo r the exam ina tion s , th a t is to  
say  no t later than  Sep tem ber 1 o f the 
preceding year. Cand idates w h o  have 
had train ing outs ide  o f Canada shou ld  
su bm it their in itia l ap p lica tio n  fo r 
a sse ssm en t a t least 18 m on ths 
be fo re  they e x p e c t to  s it  fo r th e  ex a ­
m ina tion s, th a t is by M a rch  1 o f the 
p re ced in g  year. O n ly  can d id a te s  
w h o se  asse ssm en t o f c red e n t ia ls  is 
co m p le te  w ill be accep ted  to  s it  fo r 
the  exam ina tion s.
3 . C an d id a tes  w h o  desire to  s it fo r  an 
exam ina tion , hav ing  com p lied  w ith  
the  above  requ irem ent o f p re lim inary  
a sse ssm en t o f tra in ing , m u st no tify  
th e  Roya l C o lle ge  in w rit in g  o f the ir 
in ten t before February  1 o f the  yea r 
o f th e  exam ina tion . Upon re ce ip t o f 
th is  n o t ice  of in ten t, th e  eva lu a tion  
o f th e  c a n d id a te 's  p e rfo rm a n ce  
during  tra in ing  w ill be added to  the 
p rev iou s ly  com ple ted  a sse ssm en t o f 
creden tia ls . Each cand ida te  w ill then  
rece ive  no tif ica tion  as to  e lig ib ility  
tog e the r w ith  an app lica tion  fo rm  fo r 
adm iss ion  to  th e  exam ina tion  to  be 
co m p le te d  and returned.
4 . T he  fo llo w in g  d o cu m e n ts  m ay be 
ob ta ined  from  th e  Roya l C o lle ge  
o ffice :
(a) App lica tion  fo rm s fo r asse ssm en t 
o f tra in ing;
(b) G enera l in fo rm ation  book le t on 
tra in in g  requ irem ents and exam i­
na tions;
(c) S p e c if ic  requ irem ents fo r tra in ing  
and regu la tion s re lating to  the  
exam ina tion s o f each sp e c ia lty . 
Requests shou ld ind icate the sp e ­
c ia lty  o r spec ia lt ie s  o f in te re s t to  
th e  app licant;
(d) L is t ing  o f sp ec ia lty  tra in ing  p ro ­
g ram s in Canada acc red ited  by 
the  Roya l Co llege .
5 . A d d re s s  a ll enqu ires to:
Dr. R.F. Maudsley, Director, 
Office of Training and Evaluation, 
The Royal Colieqe of Physicians 
and Surgeons of Canada,
74 Stanley,
Ottawa, Canada 
KIM 1P4.
(613) 746-8177.
mended on the basis of our experience. 
It was associated with a 28% incidence 
of pouch perforation with peritonitis and 
an 11 % incidence of gastric obstruction 
requiring further surgical correction. 
These complications are considerably 
higher than those reported in the lit­
erature, and the perforation rate with 
peritonitis is the highest presently 
reported.3'5,8’17,18’20 Mason and col­
leagues21 had previously given a rate of 
6.1% with horizontal procedures, and the 
highest reported rate for gastric bypass is 
4.0%.8'9’17'21 The frequency of perfora­
tion is increased when the operations are 
remedial, with a previously reported inci­
dence of 6.9% for revised horizontal gas­
troplasties.5,21 The reason for these 
major complications of perforation and 
stomal stenosis appears to be inadequate 
blood supply to the pouch (Fig. 1). 
Mason’s group21 and other investigators 
have indicated that this complication is 
due to the precarious blood supply of the 
upper pouch after two operations. In par­
ticular, the horizontal and vertical staple 
lines are associated with poor blood sup­
ply where they interesect. Stomal scarring 
is probably secondary to a localized leak 
or poor healing due to inadequate blood 
supply.
Conversion to a gastric bypass proce­
dure from horizontal gastroplasty can 
also be dangerous if, in so doing, the sur­
geon must use vertical staple lines to cre­
ate a smaller pouch. In creating the 
smaller pouch similar problems can the­
oretically be encountered by compromis­
ing the blood supply to the fundic pouch.
The results of the vertical banded 
procedure in terms of weight loss in this 
group of patients were not uniformly 
good. Thus, from the standpoint of 
weight loss, the vertical banded gas­
troplasty as a revision procedure for the 
failed horizontal gastroplasty was less 
than ideal.
Patients with failed horizontal gas­
troplasty with a small gastric pouch are 
most appropriately treated with Roux-en- 
Y gastric bypass. Sugerman and Wolper5 
have reported a loss of 66 ± 18% of 
excess weight with gastric bypass for 
failed gastroplasty that was comparable 
to the 69 ± 17% obtained when gastric 
bypass was a primary procedure. This 
conversion can be difficult and was 
associated with problems in 21 of the 34 
patients.5 If the gastric pouch is large or 
the patient has an unacceptable result 
after gastric bypass, the intestinal bypass 
of Cleator and Gourlay described in this 
issue of the journal (pages 114 to 116) 
may be considered. In their procedure an 
end-to-end jejunoileal bypass is done with 
25 cm of jejunum anastomosed to 50 cm 
of ileum. The bypassed segment is 
drained into the upper stomach. Diar­
rhea, metabolic problems and bypass 
enteritis were not a problem after this
operation, which leaves a long distal seg­
ment in circuit. Bacterial reflux into the 
bypassed segment is minimized by 
drainage into the stomach.
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Adverse Effect of Blood Transfusions on 
Patient Survival After Resection of Rectal Cancer
Studies have shown that the number of 
units of blood transfused perioperatively 
in patients operated on for colonic 
cancer has a progressively strong nega­
tive influence on survival.
The present study, involving 198 
patients with rectal cancer, was done to 
determine if perioperative blood transfu­
sions had any prognostic significance.
Multivariate regression analysis was 
applied to these patients, operated for 
cure of Dukes' stage A, B or C disease. 
Other variables analysed were age, sex, 
preoperative hemoglobin, albumin and 
lymphocyte values and the timing of 
transfusion.
Perioperative deaths, pre- and post­
operative immunodepression, neopla­
sia in situ, nonresections and stage D 
disease were excluded.
It was found that the number of units 
of blood transfused perioperatively had a 
negative effect on patient survival, that 
was independent of the other analysed 
variables.
It is suggested that blood transfusion 
perioperatively exerts an immunosup­
pressive effect on patients with rectal 
cancer.
Des etudes anterieures ont montre que le 
nombre d'unites de sang transfuse en 
periode perioperatoire, ont une influence 
fortement negative sur le pronostic vital 
des malades ayant subi une resection 
intestinale pour cancer colique.
La presente etude a ete conduite sur 
198 malades souffrant de cancer rectal 
pour determiner si les transfusions peri­
operatoires avaient une signification 
pronostique.
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Les analyses de regression multi- 
variees ont ete appliquges a ces patients 
operes pour cure d'un cancer rectal, de 
stade A, B ou C de Dukes.
Les autres variables etudiees ont ete 
I'age, le sexe, les taux preoperatoires 
d'hemoglobine et d'albumine, la numera­
tion lymphocytaire et le moment des 
transfusions (pre, per ou postoperatoire).
Les criteres d’exclusion ont ete les 
deces perioperatoires, les etats 
d'immuno-depression pre et postoper- 
atoires, les cancers in situ, les interven­
tions & visees non curatives et les 
stades D.
Les resultats ont montre que le 
nombre d'unites de sang transfuse en 
perioperatoire avait un effet negatif sur 
la survie des malades et que cet effet 
deletere etait independant des autres 
variables etudiees.
Ceci suggere que les transfusions san­
guines perioperatoires, exercent un effet 
immuno-depresseur sur les malades 
atteints d'un cancer rectal.
Evidence is increasing that blood trans­
fusions impair the host immune system 
by mechanisms that are not fully under­
stood. This is used to advantage in organ 
transplantation, as demonstrated by 
numerous studies of kidney allografting. 
Graft survival is greatly improved after 
preoperative blood transfusion, the 
benefit seemingly proportional to the 
number of units administered.1-20
However, it has been shown recently 
that perioperative blood transfusions 
have a deleterious effect on host 
resistance to infection and cancer recur­
rence, with decreased survival after 
tumour resection.21-31
In a previous retrospective study,21 
analysing the outcome of 281 patients 
operated on for colorectal cancer, we 
showed that the number of perioperative 
blood transfusions had a highly signifi­
cant proportional negative effect on the 
survival of patients treated for colonic 
cancer, regardless of the other variables 
studied. This negative effect was not 
found when the 74 patients with rectal 
tumours were analysed separately.
We present data on the influence of
perioperative blood transfusions on the 
survival of 198 patients operated on for 
rectal cancer in our institution.
Patients and M ethods
The medical records of 446 patients 
who underwent surgery for rectal cancer, 
between 1951 and 1971 at the hopital 
Notre-Dame in Montreal were reviewed.
Exclusion criteria were death within 1 
month of operation (31 patients), im- 
munodepressive conditions such as previ­
ous neoplasia, diabetes, recent tubercu­
losis, previous or current chemotherapy, 
radiotherapy or corticotherapy (70), 
postoperative adjuvant therapy (17), diag­
nostic or palliative procedure (154), 
insufficient data (5) and Dukes’ stage D 
disease (116).
Rectal cancer was defined as disease 
located below the rectosigmoid angle.
Of primary concern was the number of 
units of whole blood or packed red cells 
that each patient received perioperatively.
The patient population was grouped as 
either transfused or not transfused. The 
number of transfusion units was divided 
into subsets of 0, 1 to 5, 6 to 10 and 11 
or more units, or studied on an individual 
basis. The timing of transfusion was also 
classified—preoperative (within 3 months 
before the operation), peroperative, and 
postoperative (within 1 month after sur­
gery). Other analysed variables were age, 
sex, preoperative values of hemoglobin 
(g/L) and serum albumin (g/L), total 
lymphocyte count, Dukes’ stage (A, B 
and C) of the disease and type of opera­
tion (abdominoperineal resection, an­
terior resection, pull-through or surgical 
polypectomy).Population distribution for each vari­
able was studied by the x2 test and analysis of variance. Correlation between 
variables was submitted to the Pearson 
test. Distribution of the variables was 
studied in accordance with a specific 
criterion such as Dukes’ stage, type of 
surgery, transfused versus nontransfused 
patients, number of blood units given and 
timing of transfusion.
Survival was defined as the time from 
resection to last follow-up or death. In the 
analysis, death was a factor only when it
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was due specifically to rectal cancer; other 
causes of death were classified as cases 
lost to follow-up.
Mantel-Cox log-rank tests were used to 
compare single group and subgroup vari­
ables and to draw actuarial survival 
curves. Simultaneous influence of all 
covariables was tested by Cox’s multivar­
iate regression analysis when the number 
of blood units was studied on an 
individual basis.
Findings
After application of the exclusion 
criteria 198 of the 446 patients were avail­
able for study.
The 198 patients (102 men, 96 women) 
had a mean age of 59.8 ± 10.6 years. The 
mean hemoglobin level, determined 
preoperatively in 190 patients was 124 ± 
22 g/L. The mean serum albumin level 
determined in 120 (61%) patients was 
16.2 ± 14.2 g/L and the lymphocyte 
count in 181 (91%) patients was 2.0 ± 
0.98 x 109/L . Dukes’ stages were 
almost equally represented with a slight 
predominance of stage B (37%) over 
stages A (33%) and C (30%). Abdomino­
perineal resection was performed in 172 
(87%) patients, 10 (5%) had an anterior 
resection, 13 (6.5%) a pull-through oper­
ation and the remaining 3 (1.5%) patients 
underwent surgical polypectomy.
The exact number and timing of trans­
fusions are shown in Table I.
Distribution o f  Variables According to Specific Criteria
Age, sex and preoperative albumin 
levels were equally distributed in all 
groups studied (Tables II to V).
When comparing the variables for 
Dukes’ stage, we found that the total lym­
phocyte count was differently distributed 
in classes A, B and C (Table II). Distri­
bution of the resection types, taken 
individually, was not statistically differ­
ent in this group (p = 0.09). However, 
when comparing the variables for the type 
of surgery (Table III), we found that more 
abdominoperineal resections were per­
formed, compared with all other types of 
operations taken together, when the stage 
was more advanced (p = 0.04).
When the distribution of variables was 
studied in transfused and nontransfused
patients, 100% of those with pull-through 
procedures, 98% with abdominoperineal 
resections, 80% with anterior resections 
and 33% who had surgical polypectomies 
were transfused (p = 0.0001). However, 
the stage of the disease was not a factor 
in the need for transfusion and, as 
expected, there was a striking difference 
in the number of units transfused since 
seven patients did not receive blood 
(Table IV).
Again, when considering the number of 
units transfused, we noted that patients 
who underwent a pull-through operation 
received proportionately more units of 
blood than those who had an 
abdominoperineal or anterior resection of 
the rectum (p = 0.00001) (Table V). 
Preoperative hemoglobin values were 
statistically different according to the 
number of blood units administered 
(p = 0.0003). However, the Pearson 
test indicated a strong and significant 
linear correlation between the preopera­
tive hemoglobin level and the number of 
transfusions preoperatively (r = 0.5, 
p = 0.001) but weak and not significant 
ones for peroperative transfusions 
(r = 0.06, p = 0.1) and postoperative
T a b le  1 - U n its  o f Blood T ra n s fu s e d  P e rio p e ra tive ly Finally, in the subsets relating to the
amount of blood transfused, most of the
T im in g  o f N o o f p a tie n ts U n its  tra n s fu s e d patients who received 1 to 10 units of
t ra n s fu s io n (%  o f  to ta l g ro up) T o ta l M e a n  ± SD blood were transfused during the opera-
P e rio p e ra tive ly * tion and the majority who received more
T ra n s fu s e d 187 (94) 905 4 .7  ± 3.2 than 10 units were transfused postoper-
N o t tra n s fu s e d 7 (4) atively (Table V).
P re o p e ra tive ly*
T ra n s fu s e d 37 (19) 105 2.9 ± 2.2 Survival
N o t tra n s fu s e d 157 (79)
P e ro p e ra tiv e ly
T ra n s fu s e d 188 (95) 5 82 3.1 ± 1.3
Omitting the transfusion variable, we
N o t tra n s fu s e d 10 (5) round, as expected, a significant
P o sto p e ra tive ly* (p =  0.00001) difference with respect to
T ra n s fu s e d 89 (45) 2 30 2.6 ± 2.8 survival (log-rank test) in the follow-up
N o t tra n s fu s e d 105 (53) of Dukes’ stages A, B and C rectal
' E x a c t  no. o f u n its  tra n s fu s e d  d e te rm in e d  in 194  (9 8 % ) patie n ts cancers, at 10 years — 77%, 42% and23% respectively (Fig. 1).
T a b le  II—D istrib u tio n  o f  V a ria b le s  A c c o rd in g  to  Dukes' S tage*
S ta g e
V a ria b le A  (n = 65) B (n -  73) C (n = 60) p value
S ex
M ale 30 43 29
Fem a le 35 30 31 0.2
T y p e  o f re se ctio n
Ab d o m in o p e rin e a l 52 63 57
A n te rio r 4 4 2
P u ll-th ro u g h 6 6 1 0.09
P o ly p e c to m y 3 0 0
A g e , y r 5 9 .6  ± 11 6 0 .6  ± 10.4 59.3 ± 10.5 0.8
P re o p  hem o globin, g/Lt 126 ± 19 122 ± 26 124 ± 17 0.5
P reo p  album in, g / Lt 16 ± 14 14 ± 13 19 ± 14 0.3
P re o p  ly m p h o c y te s , x 109/Lt 2 .2 4 8  ± 1.262 1 .7 3 0  ± 0 .5 6 2 2 .0 4 8  ± 0 .9 3 3 0.01
T ra n s fu s io n s , u n its
P e rio p 4 .3  ± 2.8 5.1 ± 3.7 4 .5  ± 3.1 0.39
P re o p t 0 .2 8  ± 0.97 0 .7 7  ± 1.5 0 .5 2  ± 1 0.07
P ero p 2 .9  ± 1.8 2 .6  ± 1.3 3 .2  ± 1.8 0.3
P o s t o p f 1.1 ± 1.6 1.5 ± 2.5 0 .8  ± 1.9 0 .1 4
' F ig u re s  are m ean s ± sta n d a rd  d e via tio n .
t D a t a  m issing: hem o glob in - 8, album in - 78, ly m p h o c yte  co u n t = 17, pre and p o sto p  tra n s fu s io n  = 4.
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On the other hand, log-rank compari­
son of survival according to the different 
resection types or transfused versus non- 
transfused patients did not demonstrate 
any statistical differences (Figs. 2 and 3).
However, actuarial survival was signifi­
cantly (p = 0.0008) different according 
to the number of blood units patients 
received during the perioperative period. 
At 10 years, for subgroups transfused 
with 0, 1 to 5, 6 to 10 and more than 10 
units, survival was 86%, 53%, 31% and 
14% respectively (Fig. 4).
When multivariate adjustment for the 
seven main variables studied simultane­
ously (Cox’s regression analysis) was
applied to the population, the following 
three variables had a significant predic­
tive value on patient survival: preopera­
tive hemoglobin level (p = 0.001), 
Dukes’ stage (survival was better for stage 
A compared with stages B and C 
[p = 0.0001] and for stage B compared 
with C [p = 0.001]) and the number of 
blood units transfused (p = 0.03) (Table 
VI).
Finally, in an attempt to determine if 
the timing of transfusion had any 
influence on survival, we found that the 
number of peroperative blood transfu­
sions was statistically  significant 
(p = 0.002) when compared w ith
preoperative (p = 0.58) and postopera­
tive units transfused (p = 0.73).
Discussion
The effects of blood transfusion on 
host immunocompetence are of growing 
interest. The effects on renal transplan­
tation, cancer surgery and host bacterial 
infections have been summarized in an 
excellent review by G eorge and 
Morello.32
The immunosuppressive effect of 
whole blood is used as a routine tool to 
enhance allograft survival of transplanted 
cadaver kidneys2-12,15,16,18 and is pro­
portional to the number of units of 
whole blood or packed cells admi­
nistered.9,13,14,17,19,20
On the other hand, there is a growing 
suspicion that blood transfusion may 
have an adverse effect on the outcome of 
patients operated on for cancer and on 
the rate of concomitant bacterial infec­
tions. Retrospective studies have shown 
this to be so in patients operated on 
for colorectal cancer,22,25-27 lung tu ­
mours,23,28 breast cancer29 and soft-tissue 
sarcomas.30 Prospective studies have 
shown that in patients with penetrating 
abdominal trauma and in those who 
undergo elective colorectal operations, 
significantly more infections occurred in 
recipients of blood even after adjustment 
for other risk factors.24,31
In a recently published retrospective 
analysis21 of 281 patients operated on for 
cure of a Dukes’ stage A, B or C colorec­
tal cancer, we concluded that the num­
ber of units of blood transfused perioper- 
atively had a strong negative influence on 
patient survival regardless of the other 
analysed risk factors. However, this 
adverse effect could not be demonstrated 
when patients with rectal cancer were 
studied separately, although they received 
more blood units than those operated on 
for colonic cancer.
We hypothesized that the timing of 
transfusion was important or the biologic 
behaviour of rectal cancer differed from 
that of colonic cancer as suggested by 
Wolmark and colleagues33 and Foster 
and colleagues26 or more simply that the 
number of cases studied was not large 
enough to reach valid statistical conclu­
sions.
This prompted us to enlarge our series 
of rectal cancer patients transfused and 
not transfused.
The present study shows that regard­
less of the stage of the disease, the type 
of surgery, the preoperative hemoglobin 
level and the other variables, the number 
of blood units transfused during the peri­
operative period has a negative effect on 
patient survival (Table VI).
Other risk factors singularly important 
are the stage of the disease and the 
preoperative hemoglobin level (Table VI).
Table II I- -Distribution of Variables According to Type of 
Resection*
Type of resection
Abdominoperineal Other
Variable (n -  172) (n -  26) p value
Sex
Male 91 11
Female 81 15 0.3
Dukes' stage
A 52 13
B 63 10 0.04
C 57 3
Age, yr 60 ± 10.3 58 ± 12.9 0.5
Preop hemoglobin, g/Lt 124 ± 22 120 ± 24 0.4
Preop albumin, g/Lt 15.9 ± 14.2 19.1 ± 14.2 0.3
Preop lymphocytes, * 109/Lt 2.013 ± 1.015 1.914 ± 0.733 0.6
Transfusions, units
Periop 4.5 ± 2.8 5.4 ± 5.1 0.4
Preopt 0.5 ± 1.2 0.5 ± 1.5 0.9
Perop 2.9 ± 1.5 2.8 ± 2.5 0.7
Postopt 1 ± 1.8 2 ± 3.2 0.1
'Figures are means ± SD.
tData missing: hemoglobin -  8, albumin -  78, lymphocyte count -  17, pre and postop transfusion
-  4.
Table IV--Distribution of Variables According to Transfused 
Versus Nontransfused Groups*
Variable
Transfused 
(n -  191)
Nontransfused 
(n = 7) p value
Sex
Male 98 4
Female 93 3 1.0
Dukes' stage
A 62 3
B 72 1 0.4
C 57 3
Type of resection
Abdominoperineal 169 3
Anterior 8 2
Pull-through 13 0 0.0001
Polypectomy 1 2
0.6Age, yr 59.7 ± 10.4 63.1 ± 16.3
Preop hemoglobin, g/Lt 123 ± 22 131 ± 13 0.4
Preop albumin, g/Lt 16.4 ± 14 19.2 ± 18 0.6
Preop lymphocytes, x 109/Lt 2.009 ± 0.995 1.738 ± 0.429 0.5
Transfusions, units
Periop 4.8 ± 3.2 —
Preopt 0.56 ± 1.3 - 0.0001
Perop 3 ± 1.6 -
Postopt 1.2 ± 2.1 —
'Figures are means ± SD.
tData missing: hemoglobin - 8, albumin -  78, lymphocyte count -  17, pre and postop transfusion
= 4.
VOLUME 31, NO. 2, M ARCH 1988 /  THE CANADIAN JOURNAL OF SURGERY 123
It should be noted, however, that the 
Pearson test indicated a strong and sig­
nificant correlation only between the 
preoperative hemoglobin level and the 
number of transfusions given preopera- 
tively not between peroperative and 
postoperative blood units administered.
The data also indicate that the timing 
of transfusions may be important since 
the number of units administered 
peroperatively had a prognostic value 
(p = 0.002). On the other hand, it should 
be noted that most (95%) of the patients 
were transfused peroperatively (Table I), 
and, of a total of 905 units of blood, 582 
were administered during the operation.
It could be argued that the number of 
units transfused relates to the type of 
resection, and the form of surgery like­
wise is related to the stage of the disease. 
Hence, the influence of the number of 
blood units administered could be related 
to the Dukes’ stage. Actually, the mean 
number of transfusions was almost the 
same, regardless of Dukes’ stage or the 
type of surgery. The patients receiving the 
most blood units (six and more) were 
those who underwent a pull-through 
procedure, even though those operations 
were performed mostly for Dukes’ A and 
B disease. The opposite should have been 
the case if the transfusion influence was 
really related to the stage of the disease 
through the type of resection.
It is well known that for equivalent 
stages, rectal cancer has a worse progno­
sis than colonic cancer. This has been 
attributed to a difference in biologic 
behaviour between the two.26’33 On the 
other hand, more blood transfusions are 
needed during the surgery for rectal than 
for colonic cancer. We are currently 
studying a population of patients oper-
Table V—Distribution of Variables According to Number of Blood Units Transfused*
Blood transfused, units
0 1 to 5 6 to 10 >10
Variable (n -  7) (n = 131) (n -  45) (n -  11) p value
Sex
Male 4 70 20 5
Female 3 61 25 6 0.7
Dukes' stage
A 3 47 10 3
B 1 45 19 7 0.2
C 3 39 16 1
Type of resection
Abdominoperineal 3 118 41 6
Anterior 2 6 1 1 0.00001
Pull-through 0 6 3 4
Polypectomy 2 1 0 0
Age, yr 63 ± 16.3 60 ± 9.7 58.8 ± 11.5 bb.1 ± 11.6 0.2
Preop hemoglobin, g/Lt 131 ± 13 128 ± 24 112 ± 24 115 ± 20 0.0003
Preop albumin, g/Lt 19 ± 18 16 ± 13 12.7 ± 13 28 ± 17 0.1
Preop lymphocytes, x 109/Lt 1.738 ± 0.429 2.071 ± 1.087 1.786 ± 0.668 2.181 ± 0.910 0.3
Transfusions, units
Preopt - 0.2 ± 0.7 1.5 ± 1.8 1.3 ± 1.9
Perop - 2.5 ± 1 4 ± 1.7 5.5 ± 2 0.00001
Postopt - 0.5 ± 0.9 1.8 ± 1.5 7.2 ± 3.8
‘ Figures are means ± SD.
tData missing: hemoglobin -  8, albumin -  78, lymphocyte count = 17, pre and postop transfusion -  4.
FIG. 1—Survival for Dukes’ stage A (65 patients), B (73 patients) and C (60 patients) rec­
tal cancers (log-rank analysis) shows significant difference (p = 0.00001); 10-year survival rates 
for stages A, B and C are 77%, 42% and 23% respectively.
FIG. 2—Survival for abdominoperineal (AP, 172 patients) versus other types (O, 26 patients) 
of rectal cancer resection. Log-rank analysis showed no significant difference (p = 0.4).
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ated on for colonic and rectal cancer to 
determine if the negative transfusion 
effect can account for the inferior prog­
nosis of the rectal tumour, generally 
attributed to its localization.
Whatever the mechanism of this 
deleterious transfusion effect it is tempt­
ing to correlate it to the same immuno­
logic effect that enhances allograft sur­
vival in renal transplantation.34-36
Randomized prospective studies using 
whole and leukocyte-free or autologous 
blood are needed to prove that 
hypothesis.
We thank Francine Fugere, Johanne Trahan 
and Guy Jean for their technical assistance in 
compiling the data. The statistical analysis was 
done by Les Services a la recherche JTD Inc., 
Montreal.
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Analysis of a Protocol 
for an Autologous Blood Transfusion 
Program for Total Joint Replacement Surgery
This retrospective study analysed an 
autologous blood transfusion program for 
total joint replacement surgery. A group 
of 99 patients receiving autologous 
blood transfusion was compared with a 
control group of 55 patients. One-unit 
phlebotomies were done 14 and 7 days 
before surgery. The whole blood was 
transfused intraoperatively. Preoperative 
hemoglobin values were within the normal 
range for all patient groups except the 
female autologous blood group for which 
the mean value was 122 ± 11.3 g/L.
Due to perioperative hemodilution, the 
postoperative hemoglobin values were 
substantially lower than preoperative 
values for all groups. Mean intraopera­
tive blood loss was similar for the 
autologous and control groups (650 to 
750 ml). IMo adverse reactions were 
associated with the autologous transfu­
sions and 74%  of the autologous group 
received autologous blood only. From 
this analysis a 3-week, three-unit 
preoperative collection was proposed for 
future use. A  standardized protocol will 
allow logistical ease and implementation 
of the program for various surgical 
procedures.
Cette 6tude retrospective se penche sur 
un programme de transfusion de sang 
autologue utilise lors des arthroplasties
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totales de la hanche. Un groupe de 99 
patients qui ont recu une transfusion de 
sang autologue a ete compare a un 
groupe temoin de 55 patients. Des phle­
botomies d'une unite de sang furent pra- 
tiquees 14 et 7 jours avant I'interven- 
tion. Des transfusions de sang entier 
furent effectuees durant I'operation. 
L'hemoglobinemie preoperatoire s'est 
reveiee a I'interieur des limites de la nor- 
male pour tous les groupes, sauf pour 
les femmes du groupe recevant du sang 
autologue, dont la valeur moyenne s'eta- 
blissait a 122 ± 11.3 g/L. A cause de 
I'hemodilution peroperatoire, I'hemoglobi- 
nemie postoperatoire etait beaucoup plus 
basse que la mesure preoperatoire, et 
ceci pour tous les groupes. La deperdi­
tion sanguine moyenne durant I'operation 
a ete semblable pour le groupe ayant 
recu du sang autologue et pour le groupe 
temoin (de 650 a 750 ml). Aucune reac­
tion indesirable n'a ete reliee aux transfu­
sions de sang autologue et 74%  de ce 
groupe n'ont recu que du sang autolo­
gue. A partir de cette analyse, une col- 
lecte de trois unites de sang repartie sur 
3 semaines est suggeree pour I'avenir.
Un programme standardise offrira une 
flexibilite logistique et permettra la mise 
en oeuvre de ce programme pour diver- 
ses interventions chirurgicales.
The first reports of the use o f autologous 
blood transfusion for orthopedic surgery 
were by Miller,’ in 1885, for a hip ampu­
tation and by Duncan,2 in 1886, for a leg 
amputation. The transfusion method was 
intraoperative blood salvage and reinfu­
sion, which is one of three clinically 
applicable forms of autotransfusion, the 
others being preoperative blood collection 
and storage, and hemodilution and 
autotransfusion.
Recently, preoperative blood collection 
and storage has been used in elective total 
joint replacement surgery.3"8 In these 
reports, blood storage has been as fresh 
whole blood,4’6 a mixture of fresh whole 
blood and frozen packed cells,5,8 a mix­
ture of fresh whole blood and frozen 
whole blood,3 and all units as frozen 
whole blood.7 The protocol for autolo­
gous transfusion was either individualized 
or only partly standardized to a pre-set 
schedule. The number of units collected 
per patient therefore varied greatly within 
each report. No reported programs have 
standardized all o f the following: the 
number of units to be collected preoper- 
atively, the preoperative timing of the 
phlebotomies, the storage of the collected 
units as fresh whole blood and the rou­
tine intraoperative transfusion of the 
collected units of blood. Analysis o f a 
program designed with these four stan­
dardizations and of logistic ease for 
patients, surgeons, consulting physicians, 
anesthetists and blood-bank personnel 
would provide useful information for 
future planning for autologous blood 
transfusion programs. At the Calgary 
General Hospital, preoperative storage of 
two units of whole blood to be transfused 
intraoperatively has been in effect since 
1977 for patients scheduled to undergo 
total joint replacement. This retrospective 
study analyses the autologous transfusion 
program for elective total joint surgery 
from 1982 to 1986 inclusive.
Program Design and Methods
This program was designed as a stan­
dardized protocol for logistic ease.
• Having decided to undergo surgery, 
patients are invited to participate in the
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autologous transfusion program if they 
weigh more than 45 kg and have no his­
tory of ischemic heart disease, cerebrovas­
cular accident or chronic anemia.
• The family practitioner or internist 
assesses the patient and affirms that the 
hemoglobin level is greater than 120 g/L.
• The examining physician sends the 
director of the blood bank a letter verify­
ing medical clearance and requests 
arrangements be made for phlebotomies 
at the hospital hematology clinic approx­
imately 14 and 7 days before the sched­
uled surgery (the second phlebotomy is 
always done more than 72 hours before 
the scheduled surgery).
• Patients are instructed to take iron 
and vitamin B supplements from the time 
of the first phlebotomy (ferrous gluconate 
300 mg orally three times daily and Stress 
Caps T orally daily).
• The units of whole blood are typed 
and screened and stored with citrate phos­
phate dextrose adenine - 1 (CPDA-1) 
solution as a preservative at 4°C in the 
hospital blood bank.
• When the patient is admitted for sur­
gery the collected autologous blood is 
cross matched.
• The autologous whole blood is trans­
fused intraoperatively, and if for some 
reason it is not transfused it is discarded.
This program is designed to permit an 
interval of 1 month from initial consent 
to completion of surgery. From 1982 to 
1986 inclusive, 99 patients who underwent 
total joint replacement surgery (95 total 
hip and 4 total knee) were in the autolo­
gous transfusion program. One surgeon 
performed the operation in 87 of these 
patients. During the same period, the 
same surgeon performed 55 total joint 
replacements on patients who were not in 
the autologous transfusion program. 
They were used as a control group: they 
included patients eligible for the autolo­
gous transfusion program but inadver­
tently not so informed, patients who did 
not meet the appropriate hemoglobin, 
weight and medical history criteria, 
patients whose altered operation sched­
ule did not permit the right timing for the 
phlebotomies and patients whose blood 
clotted at the time of phlebotomy or
whose antecubital veins were too small. 
Both groups of patients were compared 
as to sex, age, preoperative and postoper­
ative hemoglobin levels, estimated 
intraoperative blood loss, transfusion 
morbidity and total transfusion require­
ments.
Comparison of preoperative and post­
operative hemoglobin levels was consi­
dered of questionable value. A change in 
hemoglobin could be due to perioperative 
hemodilution. To study this further, the 
preoperative hemoglobin levels were used 
in a calculation to correct for any change 
in hematocrit from preoperative to post­
operative samples (Table I). An apparent 
change would show the calculated 
hemoglobin value equal to the actual 
measured postoperative hemoglobin 
value. The calculated hemoglobin was 
equal to preoperative hemoglobin multi­
plied by postoperative hematocrit and 
divided by the preoperative hematocrit.
Estimated mean intraoperative blood 
loss plus the standard deviation of this 
mean plus an estimated 100 ml postoper­
ative loss was used in estimating the 
potential blood transfusion requirements 
of the surgical procedure. With standard 
normal population statistics, the mean 
plus the standard deviation of the mean 
equals a value equal to or greater than 
that of 84% of the population. Likewise, 
the mean plus two standard deviations 
equals a value that will be greater than or 
equal to that in 97.7% of the popula­
tion .9 These statistics were used in 
predicting the blood requirements for 
patients in the study. The Student’s /-test 
was used to analyse differences in the 
findings. The significance level used was
p = 0.01.
Findings
The sex and ages of the patients in the 
two groups are shown in Table II.
Hemoglobin values were obtained for 
all patients preoperatively and on the day 
after surgery. Preoperative hemoglobin 
values were within the limits of the nor­
mal for the hospital (male 135 to 180 g/L, 
female 125 to 164 g/L) except in the 
group of women who had autologous 
transfusions, whose values were below the 
normal range (Table I). Preoperative and 
postoperative hemoglobin values for the 
control group were significantly higher in 
all patients than for the autologous 
group. Postoperative hemoglobin values 
for both sexes of both groups were sig­
nificantly (p <  0.01) lower than the 
preoperative values (Table I). The calcu­
lated hemoglobin value was not signifi­
cantly different from the measured 
postoperative hemoglobin within any 
group. The hemoglobin of any patient 
who received only the intraoperative 
autologous transfusions tended to return 
to preoperative values (determined by the 
hematocrit or hemodilution) during the 
hospital stay (Fig. 1).
Intraoperative blood loss, ranging from 
650 to 750 ml, was similar for both sex 
and group (Table I).
Transfusion reactions (increased tem­
perature) occurred in only two patients; 
one who received autologous and 
homologous transfusions and in a patient 
who received homologous transfusion 
alone. In the autologous group, 3% did 
not receive autologous blood; 5% 
received only one unit of autologous 
blood (only one unit collected or given) 
(Table III). Ninety-one percent of patients
Table II--Autologous and Control Groups: Ages
Group No. Age, yr (mean + SD) Age range, yr
Autologous
Male 42 64 ± 9.1 37 -  78
Female 57 62 ± 12.2 26 -  87
Control
Male 21 67 ± 9.6 54 -  83
Female 34 70 ± 12.1 35 -  84
Differences were not significant.
Table I—Autologous and Control Groups: Hemoglobin and 
Estimated Blood Loss (Mean ± SD)
Hemoglobin, g/L
Group Preop Postop Calculated* Blood loss, ml
Autologus
Male 138 + 9.3 124 ± 11.8 122 ± 13.84 650 ± 238
Female 122 ± 11.3 112 ± 13.3 115 ± 11.94 750 ± 311
Control
Male 144 ± 17.14 129 ± 15.5 127 ± 15.5 650 ± 224
Female 134 ± 14.1t 119 ± 12.14 118 ± 12.6 700 ± 33
‘ Calculated hemoglobin - preoperative hemoglobin x postoperative hematocrit + preoperative hematocrit.
tFor 1984 patients only.
^Significantly higher than autologous group values, p <  0.01.
All calculated hemoglobin values not significantly different from postoperative values within a group. All blood loss estimates not significantly different.
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in the autologous group received the two 
units of whole blood while in hospital and 
26% received extra packed-cell transfu­
sions during their hospital stay. Conse­
quently, requirements were met with 
autologous blood only in 74% of 
patients. Also, in the autologous group, 
transfusion requirements were met with 
two units or less of either autologous or 
homologous transfusions in 74%, with 
three units or less in 82% and with four 
units or less in 95% (Table III). The 
results were similar for the control group. 
The average number of units given in the 
autologous group was 2.48 compared 
with 2.25 for the control group.
Discussion
This retrospective study demonstrated 
that an autologous transfusion program 
designed to have two units of whole blood 
available for intraoperative transfusion is 
feasible and sustains an intraoperative
blood loss of approximately 650 to 750 
ml in major orthopedic surgery. Age 
alone does not appear to exclude patients 
from entering the program as 30% were 
more than 70 years old, and other 
investigators3-8'10 have not applied age 
restrictions. In addition, blood donations 
by healthy people aged 66 years and older 
are carried out without any difference in 
immediate or short-term reactions when 
compared with donors 55 to 65 years 
old.11 Both men and women had signifi­
cantly (p < 0.01) lower hemoglobin levels 
preoperatively than the control group; 
however, the difference between the con­
trol and autologous group values was 
equal to (women) or less than (men) the 
drop in hemoglobin noted in healthy sub­
jects who underwent a one-unit phlebot­
omy followed by iron supplementation 
and reassessment of their hemoglobin 
level at 2 weeks.10 Therefore, even with 
the second phlebotomy 7 days after the 
first, in this study patients were able to
maintain their hemoglobin levels equally 
well. It is well known that repeated phle­
botomies of greater frequency and larger 
total volume than we report cause no 
adverse effects if sufficient time elapses 
to allow correction of the hemoglobin 
level, and the patient is provided with ade­
quate iron supplementation.12’13 Phlebot­
omy can stimulate red-cell production 
three to five times that of normal.12 
Therefore, in this study, the cause of the 
lower preoperative hemoglobin level in 
the autologous group compared with the 
control group could be due partially to 
insufficient time for optimal hematopoi­
esis or to inadequate iron supplementa­
tion, which was based solely on patient 
compliance. The 2 weeks from initial 
phlebotomy to surgery are inadequate for 
complete recovery of hemoglobin levels 
especially from two phlebotomies. The 
literature suggests that 3 weeks are ne­
cessary for hemoglobin to return to 
the pre-phlebotomy value.10 Patients 
depositing between 1 and 10 units of 
blood preoperatively, over a period of 2 
to 20 weeks have shown no significant 
difference in preoperative hematocrit 
compared to a control group of patients 
who did not deposit blood.3
The postoperative drop in hemoglobin 
value could be due to either transfusion 
of blood that had less hemoglobin per 
blood cell or hemodilution from intra­
venous fluids. The former would not be 
a significant factor in the autologous or 
homologous transfusions; therefore, 
hemodilution was thought to be the cul­
prit. The hemodilution was also demon­
strated by the trend for hemoglobin and 
hematocrit levels to return to preopera­
tive values during the patient’s hospital 
stay. Intravenous fluid hemodilution 
takes time to correct, the interval depend­
ing on the concentration of sodium,14 
which may be increased if saline was used 
intraoperatively.
In our autologous transfusion pro­
tocol, the preoperative hemoglobin level 
is essentially maintained, in the majority 
of patients, both during the surgery and 
postoperatively, by the intraoperative 
transfusion of two units of whole blood.
Example 1. - Postoperative Hemodilution
Example 2. - Postoperative Hemoconcentration
FIG. 1—In-hospital hemoglobin levels for patients receiving only intraoperative autolo­
gous blood, x = measured hemoglobin value, o = hemoglobin value corrected for hemodilution 
by using hematocrit.
Table III—Autologous and Control Groups: Transfusion Data
Units transfused Mean
units/
Group 0 1 2 3 4 5 6 patient
Autologous 2.48
Autologous 3 (3) 5 (5) 91 (100)
blood only 
(cumulative 
frequency, %)
All transfusions 2 12) 2 (4) 69 (74) 18 (82) 13 (95) 4 (99) 1 (100)
(cumulative 
frequency, %)
Control 2.25
Packed red cells 4 (7) 6 (19) 30 (73) 7 (85) 5 (95) 1 (96) 2 (100)
(cumulative 
frequency, %)
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This quantity could replace an average 
blood loss of 650 to 750 ml for the total 
joint procedures in both the autologous 
and control groups. Mean blood loss plus 
the standard deviation of the mean plus 
100 ml postoperative loss equals a two- 
to three-unit volume for all groups. The­
oretically, in 84% of patients three units 
or less should replace blood lost, as con­
firmed by the data of this study.
The intraoperative blood loss of 650 to 
750 ml in our series is markedly lower 
than that reported in the literature for 
other autologous blood transfusion 
studies in total joint replacement.3' 5 As 
well, the others also had a lower percen­
tage of patients receiving only autologous 
blood. In this study, patients in the 
autologous group having total joint sur­
gery required less autologous blood and 
less added homologous transfusion per 
patient and at the same time met the 
transfusion requirements of a higher per­
centage of patients by autologous trans­
fusion alone than any reported work for 
total joint surgery.
The number of units to be collected 
should be determined on the basis of 
blood loss for a particular procedure. A 
3-week interval from initial phlebotomy 
to surgery would help in restoring the 
patient’s hemoglobin to a normal level 
preoperatively by increased erythropoie- 
sis, assisted by iron medication. Using 
CPDA-1 as a preservative, blood may be 
stored for 35 days making it possible to 
collect five units of autologous blood 
preoperatively. In analysing our protocol, 
a change to a 3-week, three-unit preoper­
ative collection, while maintaining the 
oral iron and B vitamin supplementation, 
could allow 84% of patients to receive 
only autologous blood. If prudent guide­
lines for further transfusions were estab­
lished, a statistical estimate of 97.7% 
(mean ± SD) of patients could receive
only autologous blood; that is, the statis­
tics of four units or less could perhaps be 
achieved with three units.
In assessing the need for n&.isfusions, 
we noted that the average total units of 
transfusion per patient was higher for the 
autologous than the control group, solely 
owing to the fact that the control group 
did not routinely receive two units of 
blood intraoperatively.
Febrile transfusion reactions were 
observed in 2 (2.47%) of 81 patients 
receiving a homologous transfusion. An 
autologous transfusion program, met by 
autologous blood alone, would eliminate 
these reactions and other potential post­
transfusion complications, such as hepa­
titis, acquired immune deficiency syn­
drome, toxoplasmosis and cytomegalovi­
rus infection.
Conclusions
An autologous transfusion program is 
feasible if the protocol is standardized for 
the number of units to be collected 
preoperatively for a specific procedure, 
preoperative collection times, the storage 
of these collected units as fresh whole 
blood and routine intraoperative transfu­
sion of the collected units of blood. The 
logistics with this protocol are simple for 
patients, surgeons, consulting physicians, 
anesthetists and blood-bank personnel. 
Standardization of a program also 
ensures no mistake as to who introduces 
the autologous program to the patient, 
what guidelines are used to exclude 
patients from the program, who does the 
medical assessment of the patient, who 
assesses the phlebotomies, on which days 
the phlebotomies are done, what sup­
plementation the patient should take, the 
in-hospital arrangements for intraopera­
tive transfusion and the use of nontrans- 
fused autologous blood.
The protocol for the autologous pro­
gram in this study was completely success­
ful for 74% of patients who received only 
autologous blood. Using as guidelines the 
calculated blood loss of the total joint 
procedure and the time needed for 
increased hematopoiesis to correct the 
loss by phlebotomy, it is concluded that, 
for total joint replacement, a 3-week, three- 
unit preoperative collection protocol 
would improve the percentage of patients 
receiving only autologous blood as well 
as the preoperative hemoglobin level and 
the ongoing erythropoiesis at the time of 
surgery.
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Relationship Between Deep-Vein Thrombosis 
in the Calf and Fatal Pulmonary Embolism
Deep-vein thrombosis of the lower limb 
is common, yet the importance of iso­
lated calf deep-vein thrombosis is poorly
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understood and the treatment is con­
troversial.
This retrospective study documented 
that 13% of fatal pulmonary emboli 
originated only from calf deep-vein 
thrombosis. This rate is similar to that in 
another study (15%), suggesting that 
isolated calf deep-vein thromboses do 
produce fatal pulmonary emboli.
La thrombose veineuse profonde d'un 
membre inferieur est frequente. N6an-
moins, on comprend mal ('importance 
d'une thrombose veineuse isolee du mol- 
let et son traitement fait I'objet de dis­
cussion.
Cette etude retrospective montre que 
13% des embolies pulmonaires fatales 
originaient d'une thrombose veineuse 
profonde du mollet. Ce taux est sembla- 
ble a celui d’une autre etude (15%), ce 
qui indique que les thromboses veineu- 
ses profondes du mollet produisent 
effectivement des embolies pulmonaires 
fatales.
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Lower limb venous thrombosis usually 
occurs in patients treated primarily for 
unrelated conditions. It is a common 
complication of orthopedic procedures 
and can be fatal. Thromboses in the veins 
of the proximal thigh or pelvis are consi­
dered dangerous,1-3 and most physicians 
advocate anticoagulant therapy,4 
whereas many physicians believe that 
asymptomatic calf deep-vein thrombosis 
(discovered on routine follow-up for 
unrelated conditions, commonly ortho­
pedic) is unimportant and needs no treat­
ment.5 This study was conducted to 
investigate the source of thrombosis in 
cases of fatal pulmonary embolism.
Method
A retrospective chart review was con­
ducted of patients who died of pulmonary 
embolism at the Ottawa General and 
Ottawa Civic hospitals over a 5-year 
period. All were admitted to hospital for 
problems other than venous thrombosis, 
the embolism occurring as a complica­
tion. Only deaths considered to be caused 
by pulmonary embolism were studied. 
Cases in which autopsy findings failed to 
identify the cause of death or location of 
the deep-vein thrombosis were excluded.
Results
Pulmonary embolism was listed as the 
cause of death on the charts of 152 
patients; in 70 of these, autopsy was done, 
and 59 registered autopsies failed to rev­
eal the source of embolism. Autopsy find­
ings confirmed pulmonary embolism as 
the cause of death and identified the 
source of embolism in 23 patients, who 
formed the basis for this study. Sites of 
thrombi were: pelvic veins 7, thigh veins 
13 and calf veins 3.
Discussion
Lotke and colleagues3 stated that 
deep-vein thrombosis in the calf, whether 
large or small, is unlikely to produce 
symptomatic emboli, and therefore anti­
coagulation is unnecessary. They also 
stated that thrombi limited to the calf 
rarely form emboli.3 This is contrary to 
the statement by Browse and Thomas1 
that emboli can arise from any thrombus 
and the calf, being the most common site 
for thrombus, is therefore the most com­
mon source of emboli. However, they 
believed that lethal emboli originated in 
the femoroiliac segments. In the opinion 
of Lowe,4 calf thrombi are important 
and “ thrombi proximal to the popliteal 
vein or greater than 5 cm in length in the 
calf are significant because of immediate 
risk of embolism and long term possibil­
ity of venous hypertension .. .the 
remainder, clots of less than 5 cm in 
length in the calf veins are ‘not signifi­
cant’ and may be observed by continu­
ing I125 scanning” . These were arbitrary
criteria. Hirsh and associates6 believed 
that if one chooses not to treat a calf 
deep-vein thrombosis then the patient 
must be followed up clinically as 20% of 
such thromboses extend into the thigh. 
This concept is supported by others.1'4-7’8 
But are clots confined to the calf veins 
capable of producing pulmonary emboli, 
especially fatal pulmonary emboli? Harris 
and colleagues2 stated, “ there is substan­
tial evidence that it is the thrombi that 
form in the veins of the thigh or iliac 
region that are the principal sources of 
major pulmonary emboli” . This remark 
leaves open the possibility of a small per­
centage originating only in calf veins, as 
does the conclusion reached by Moser and 
LeMoine9 that calf deep-vein thrombosis 
poses a low risk of embolism. McKenna 
and colleagues10 in a prospective study 
of patients scheduled to undergo total 
knee replacements used iodine-125- 
labelled fibrinogen scanning and phlebo­
graphy to show isolated calf vein 
thrombi in 10 patients, 6 of whom 
had pulmonary emboli documented on a 
lung scan. In another study of 30 total 
knee replacements, 16 patients had veno- 
graphic evidence of thrombosis, resulting 
in three pulmonary emboli. In these three, 
the thromboses were located in the calf 
veins and only one extended into the 
popliteal and femoral veins.11 The 
authors stated that their study showed 
“ an association between thrombosis of 
the calf veins... and pulmonary embolism 
in patients who have had total knee 
replacements” .
Are some emboli from calf veins fatal? 
Browse and Thomas1 stated “ the effect 
of an embolus depends both upon its size 
and the cardiovascular state of the 
patient. Undoubtedly size is the most 
important factor in a fit person, but one 
or many small emboli can have a very 
serious effect on the pulmonary circula­
tion, especially if the heart is weak; hence 
the potential danger of calf thrombosis 
must not be ignored.” Very large emboli 
straddle the pulmonary artery bifurcation 
and cause rapid clinical deterioration. 
Slightly smaller emboli blocking one pul­
monary artery or a secondary lobar artery 
result in less rapid changes. Multiple small 
pulmonary emboli produce pulmonary 
hypertension leading gradually to cardiac 
failure or fatal arrhythmia. Sevitt and 
Gallagher12 performed autopsies in 74 
cases of death from pulmonary embolism 
to investigate the size (length and 
diameter) and number of the pulmonary 
emboli and also to locate the origin, 
which was: the iliofemoral veins in 61, the 
inferior vena cava in 2 and the calf veins 
in 11 cases. The rate of fatal pulmonary 
emboli from thrombi in the deep veins of 
the calf in this study was 15% (11 of 74), 
a figure remarkably close to the 13% (3 
of 23) found in our series. Most deep-vein 
thromboses are asymptomatic so the
likelihood of an associated fatal pulmo­
nary embolism still remains unanswered. 
Most pulmonary emboli are asympto­
matic. The majority of symptomatic pul­
monary emboli are not fatal and in those 
that are, only 13% to 15% originate in 
the veins of the calf.
In my opinion the patient at most risk 
of a fatal pulmonary embolism from 
deep-vein thrombosis in the calf is the 
elderly patient with limited cardiorespira­
tory reserve in whom a small embolism, 
or multiple small emboli, can trigger a 
fatal arrhythmia. If there is no contrain­
dication, full heparinization for 1 week 
followed by oral anticoagulation for 3 
months is recommended. Low-dose Cou­
madin, as suggested by Harris and 
colleagues2 is a safe alternative.
Until the exact rate of fatal pulmonary 
emboli arising from isolated calf deep- 
vein thrombosis is known, one cannot 
compare the risk of heparinization with 
that of observation; nevertheless, these 
veins must be recognized as a source of 
fatal pulmonary emboli.
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Correction
The November 1987 issue of the Jour­
nal contains an error in the article by Dr. 
M. Robinette. On page 407, in Case 1, 
under discussion, the sentence “ Ureteral 
‘danger areas’ are: the inferior mesenteric 
vessels (during ligation), the ovarian fossa, 
the rectovesical pouch, the ureterosacral 
ligaments . . .”  should read “ Ureteral 
‘danger areas’ are: the inferior mesenteric 
vessels (during ligation), the ovarian fossa, 
the rectovesical pouch, the uterosacral liga­
ments . . We apologize to Dr. Robinette 
and to our readers for this error.
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Thoracic Outlet Syndrome 
With Congenital Pseudarthrosis of the Clavicle: 
Treatment by Brachial Plexus Decompression, 
Plate Fixation and Bone Grafting
Although a number of cases of congeni­
tal pseudarthrosis of the clavicle have 
been described in the literature, they pro­
vide little direction for the treatment of 
this condition when it is associated with 
thoracic outlet syndrome. The authors 
describe their experience with such a 
case in a 20-year-old woman. Symptoms 
of pain in the ulnar distribution of the 
right forearm and discoloration of the 
hand with abduction of the extremity 
had developed over 3 years. The radial 
pulse was obliterated by abduction of 
the arm. Exploration of the brachial 
plexus revealed a constricting band aris­
ing from the distal fragment of the clavi­
cle running to the first rib which, 
together with the mass of the pseudar­
throsis, comprised the thoracic outlet. 
The patient was successfully treated by 
division of the fibrous band, reduction of 
the clavicle, internal fixation with a plate 
and iliac crest bone grafting. At follow­
up the patient had a full range of motion 
in the shoulder and was asymptomatic.
Meme si on retrouve un certain nombre 
de cas de pseudarthrose congenitale de 
la clavicule dans la litterature, on y 
decouvre peu de directives quant au trai- 
tement de cette affection lorsqu'elle est 
associee a un syndrome du defile 
thoraco-brachiale. Les auteurs ddcrivent 
comment ils ont fait face d un cas sem- 
blable chez une femme de 20 ans. Sur 
une periode de 3 ans, elle vit apparaitre 
une douleur dans la region cubitale de 
I'avant bras droit, accompagnee d'une 
decoloration de la main avec abduction
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de I’extremite. Le pouls radial disparais- 
sait a I'abduction du bras. A I'exploration 
du plexus brachial, on a observe un 
retrecissement partant du fragment distal 
de la clavicule et allant jusqu'a la pre­
miere cote; cette bande, ajoutee a la 
masse de la pseudarthrose, venant 
entourer la traversee thoraco-brachiale.
La patiente fut traitee avec succes par 
division de la bande fibreuse, reduction 
de la clavicule, fixation interne a I'aide 
d'une tige et greffe osseuse de la Crete 
iliaque. A I'examen de controle, la 
patiente avait recouvre une pleine ampli­
tude des mouvements de I'epaule et etait 
asymptomatique.
In 1984 Bargar and colleagues1 reported 
the first case of thoracic outlet syndrome 
associated with congenital pseudarthro­
sis of the clavicle. A 28-year-old woman 
had complete relief of her symptoms fol­
lowing resection of the pseudarthrosis and 
the middle 3 cm of her clavicle. Wood2 
reported a patient who had subclavian 
vein thrombosis secondary to a congeni­
tal pseudarthrosis of her right clavicle, 
also treated by claviculectomy. The 
patient had a good functional result. 
Cases of thoracic outlet syndrome 
associated with ununited clavicular frac­
tures have been reported by Watson- 
Jones,3 Ghormley and associates4 and 
Pipkin.5 In Pipkin’s case the patient had 
fractured her clavicle at ages 4 and 7 years 
and vascular compromise developed sud­
denly 32 years later.
Many unsolved issues surround both 
the etiology and treatment of congenital 
pseudarthrosis of the clavicle. Since 
Fitzwilliams6 first described congenital 
pseudarthrosis of the clavicle in 1910, 83 
unilateral right-sided cases, 10 bilateral 
cases, 4 left-sided cases (two associated 
with dextrocardia, one with a large cer­
vical rib and one unspecified) have been 
reported in the literature.7-19 However, 
medical literature provides little direction 
for the treatment of congenital pseudar­
throsis of the clavicle when it is associated
with thoracic outlet syndrome. We 
recently treated such a patient in one stage 
by brachial plexus exploration and 
decompression combined with plating 
and bone grafting of the clavicular 
pseudarthrosis. To our knowledge this 
method of treatment, which was success­
ful, has not previously been reported.
Case Report
A 20-year-old woman, who was right 
handed, presented to the Upper Extremity 
Clinic with right upper limb complaints. Dur­
ing the previous 3 years she had experienced 
aching discomfort about her right shoulder and 
pain along the ulnar aspect of her right hand 
and forearm; the pain was burning in nature 
and aggravated by carrying luggage or lifting 
the arm above 90°. The dorsum of her hand 
became discoloured at times. Motor weakness 
or loss of sensation had not occurred. She was 
aware that her right clavicle was foreshortened, 
with a swelling in its middle third; her parents 
had been informed, in the patient’s early child­
hood, that the mass was caused by a congeni­
tal pseudarthrosis of the clavicle. Since the 
mass was painless and did not present a cos­
metic or functional deformity, no treatment 
was indicated at that time.
On examination there was a 2-cm decrease 
in the sternoacromial distance on the right com­
pared with the left, and a firm, slightly tender 
mass was present over the middle third of the 
right clavicle. The two clavicular ends were pal­
pable with the sternal portion lying superior 
to the acromial segment. Movement was 
elicited at the site of the pseudarthrosis. Pas­
sive or active abduction of the right shoulder 
to 90° decreased radial artery pulsation and 
resulted in cyanosis on the dorsum of her hand 
and a burning pain along the ulnar aspect of 
the hand and forearm. There was no audible 
bruit in the supraclavicular or axillary region. 
Full range of motion was present in both the 
glenohumeral joint and cervical spine. An x- 
ray film confirmed the presence of a pseudar­
throsis in the middle third of the clavicle (Fig. 
1).
With the clinical confirmation of thoracic 
outlet syndrome associated with congenital 
pseudarthrosis of the clavicle neither arteriog­
raphy nor venography was performed. We 
decided to explore the brachial plexus with the 
objective of decompressing the thoracic out-
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let. We also wished to treat the clavicular 
pseudarthrosis in such a manner that brachial 
plexus compression would not recur and shoul­
der strength would be maintained.
Through a transverse incision over the clavi­
cle the proximal (sternal) end of the bone was 
found to lie above the distal (acromial) aspect 
and was directed posteriorly into the brachial 
plexus, decreasing the size of the thoracic out­
let. There was a thick fibrous band arising from 
the medial tip of the acromial fragment, attach­
ing to the first rib and further constricting the 
thoracic outlet. The brachial plexus was decom­
pressed by excision of the fibrotic band and 
reduction of the clavicle; it was not necessary 
to remove the first rib. The sclerotic ends of 
the pseudarthrosis were trimmed, removing the 
covering fibrocartilage. A chevron-type cut was 
made in the distal (acromial) fragment to key 
into a reverse cut in the sternal fragment; both 
ends were cut back to bleeding bone. Good sta­
bility was obtained by a contoured eight-hole 
3.5-mm DC plate (Synthes [Canada] Ltd., Mis­
sissauga, Ont.) that was applied to the superior 
aspect of the clavicle. Iliac bone graft was
packed about the plate and at the pseudarthro­
sis site. Postoperatively, the woman wore a 
Velpeau-type support for 6 weeks after which 
time the shoulder was mobilized with phys­
iotherapy supervision. Two years postopera­
tively there was solid union of the pseudarthro­
sis and resolution of the thoracic outlet 
syndrome (Fig. 2). The patient had a full range 
of abduction and forward flexion (Fig. 3).
Discussion
Congenital pseudarthrosis of the clavi­
cle is rare.7’8,10'13'14'19 It can be distin­
guished from  birth traum a,8 which 
presents as a painful greenstick fracture 
that shows evidence of callus formation 
and usually heals. The lesion is a painless 
transverse mobile pseudarthrosis and may 
occasionally be part of the spectrum of 
the syndrome of cleidocranial dysostosis. 
Congenital pseudarthrosis of the clavicle 
is not related to congenital pseudarthro­
sis of the tibia,20 nor is it associated with
FIG. 1—Anteroposterior view showing congenital pseudarthrosis of right clavicle. Prox­
imal (sternal) fragment lay superiorly and was directed posteriorly, compromising and constricting 
thoracic outlet.
FIG. 1—Postoperative anteroposterior view 1 year after debridement of pseudarthrosis, 
reduction of clavicle, application of 3.5-mm DC plate and autogenous iliac crest bone grafting. 
Clavicle has united.
neurofibromatosis. In contrast, congen­
ital pseudarthrosis of the tibia is 
associated with neurofibromatosis in 40% 
of cases21 and can present with varying 
degrees of severity including a pre­
fracture state consisting of bowing, 
medullary canal sclerosis, diaphyseal con­
striction or cystic changes.20 Pseudar­
throsis in the clavicle generally heals 
rapidly with excision and bone 
grafting.8' 10'12,13'15'17’18
The etiology of congenital pseudarthro­
sis of the clavicle is obscure. Because of 
the predominance of right-sided lesions 
(or left-sided lesions associated with dex­
trocard ia), Lloyd Roberts and 
colleagues14 suggested that “ the lesion is 
sometimes due to pressure upon the 
developing clavicle by the subclavian 
artery which is normally at its highest 
level on the right side” . They speculated 
that this pressure may prevent ossification 
of the middle third of the clavicle. Other 
anatomic variations, such as vertically 
positioned or elevated first ribs or the 
presence of a cervical rib, may push the 
subclavian artery against the middle third 
of the clavicle, the area where congenital 
pseudarthrosis occurs. In the developing 
fetus, the impact of arterial pulsation may 
cause resorption of bone. Others7 have 
suggested that the condition results from 
a failure of fusion of the two ossification 
centres of the clavicle, but this was not 
proven by embryologic studies.10
Most authors advocate nonoperative 
treatment for congenital pseudarthrosis 
of the clavicle unless there is intolerable 
pain or a serious cosmetic deformity. Sug-
FIG. 3—(a) Patient 1 year postoperatively. 
Brachial plexus was explored through trans­
verse incision along clavicle, (b) Patient had 
full range of shoulder motion, no pain, nor­
mal strength and no further symptoms or signs 
of thoracic outlet syndrome.
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gested treatments for sym ptom atic  
patients have included observation,11'13'19 
excision o f  the pseudarthrosis combined 
with bone grafting,7’9'12’15'16’18 internal 
fix a tio n  w ith an in tram edullary  
p j n i,4 ,i o ,i3 ,i6 ,2 i ancj partial1 and total 
claviculectomy.3
Our patient, who was asymptomatic 
for many years, presented with symptoms 
related to the development o f  thoracic 
outlet syndrome in association with con­
genital pseudarthrosis o f the clavicle. This 
association has previously been reported 
only twice in the medical literature.1'2 A 
fibrous band arising from the medial tip 
o f the distal (acromial) fragment to the 
first rib constricted the brachial plexus. 
The proximal (sternal) fragment was 
directed posteriorly into the brachial 
plexus, further reducing the size o f the 
thoracic outlet.
In our opinion internal fixation o f the 
fragments using a plate was important 
both to prevent redisplacement o f  the 
fragments into the brachial plexus and to 
encourage sound union o f  the clavicle.
The bone was o f sufficient quality to per­
mit excellent fixation using 3.5-mm cor­
tical screws. Intramedullary nailing would 
have been difficult due to sclerosis o f  the 
bone ends. We believe the results we 
obtained with reconstruction of the clavi­
cle are superior with respect to cosm esis 
and strength to those that would have 
been possib le w ith claviculectom y. 
W ood2 has reported mild weakness o f  
the pectoral girdle following claviculec­
tomy. We wished to avoid shoulder weak­
ness in our young, active patient.
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Multiple Giant Fibroadenomas 
in an Adolescent Female Breast
Fibroadenomas are the commonest 
breast masses requiring surgery in the 
adolescent female, but multiple and giant 
tumours are rare. This case report 
describes the history and management 
of a teenager who had multiple giant 
fibroadenomas in one breast, eventually 
requiring mastectomy and recon­
struction.
The literature is reviewed. Tumours in 
this age group are almost always benign, 
even the giant and phyllodes tumours. 
Malignant tumours are extremely rare. 
Management should involve excision 
with skin reduction if necessary. The 
breast should be preserved if at all pos­
sible.
Les fibro-adenomes sont les tumeurs 
mammaires qui, chez I’adolescente,
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necessitent le plus souvent la chirurgie; 
les tumeurs multiples et les tumeurs 
geantes sont rares. On decrit ici les ante­
cedents et le traitement d'une adoles- 
cente porteuse de fibro-adenomes geants 
multiples du sein qui, eventuellement, 
necessiterent une mastectomie et une 
operation de reconstruction.
La literature medicale est passee en 
revue. Ches les femmes de cet age, les 
tumeurs sont presque toujours benignes, 
meme les tumeurs geantes et les 
tumeurs phyllodes. Les tumeurs malignes 
sont extremement rares. Le traitement 
implique excision et chirurgie de reduc­
tion lorsque ceci est necessaire. Le sein 
est conserve lorsque cela est possible.
The adolescent female with a breast mass 
represents only a small proportion o f  
patients seen in general surgical practice. 
Although fibrocystic problems do occur, 
fibroadenomas are the commonest surgi­
cal condition in the area. Generally, the 
diagnosis is simple, as is the surgery. 
However, giant and multiple tum ours, 
although quite uncommon, can present 
serious management problems.
Case Report
A 14-year-old girl was seen regarding a left 
breast mass that she discovered herself. She had 
never taken oral contraceptives nor been preg­
nant. Menarche was at 12 years of age. Nee­
dle biopsy of the mass (2 cm in diameter) in 
the upper breast confirmed a fibroadenoma. 
She was seen 3 months later and now had two 
masses, 1.5 cm and 3.5 cm in dimension, in 
different quadrants of the left breast. A month 
later when admitted for scheduled biopsy the 
entire left breast was swollen with superficial 
venous dilatation, redness and increased 
warmth. Five tumours were palpable in the 
breast, and the two larger ones were removed 
using a superior circumareolar incision. On 
pathological examination these were found to 
be pericanalicular fibroadenomas. When seen 
2 months postoperatively, a number of new 
masses had developed and 1 year later about 
half the breast was occupied by tumour. 
Tumour growth then seemed to have stopped 
for 2 years and no masses developed in the right 
breast.
She was lost to follow-up for a year, but 
when seen again at the age of 17 years the left 
breast had become greatly enlarged and pain­
ful, with countless masses. It was almost twice 
the size of the right breast. There was redness, 
thinning of the skin and persistent venous dila-
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noma is different pathologically from that 
of the adult, being more floridly glandu­
lar and usually larger. These tumours can 
grow rapidly over a period of months, 
with superficial venous dilatation, redness 
and warmth;3 the cause is unknown, but 
it is not suggestive of an underlying malig­
nant condition. Hormonal influences 
have been postulated but not proven. In 
general, even for giant tumours, conser­
vation of the breast has been recom­
mended if at all possible. Removal of 
giant tumours with a skin reduction, using 
a Makissok-type mammoplasty, has been 
suggested, thereby reducing breast defor­
mity from redundant skin.4
Multiple giant tumours have been 
reported by Gogas and colleagues,5 San- 
dison and Walker,2 Ashikari and col­
leagues,6 Wulsin3 and Nambiar and 
Kutty;7 they are uncommon with no 
more than 10 cases being described. Dis­
tinguishing these cases from virginal 
hypertrophy clinically may be difficult 
because the latter may present as a nodu­
lar breast and also be unilateral. 
However, superficial venous dilatation 
occurs only with the large fibroadenomas, 
not in virginal hypertrophy.6 Diffuse 
fibroadenomatosis presents in a fashion 
similar to multiple fibroadenomas and is 
also difficult to distinguish from virginal 
hypertrophy. Only one case in the litera­
ture has described bilateral multiple 
fibroadenomas in an adolescent (18 years 
old) serious enough to require bilateral 
mastectomy.2 Also, there is only one 
case report of a subcutaneous mastec­
tomy and silicone implant for a giant 
fibroadenoma in an adolescent,6 the 
treatment of choice if mastectomy is 
necessary.
In widely spaced, rather than con­
fluent, multiple fibroadenomas, separate 
removal of each tumour can result in 
unsightly breast scarring but this may be 
preferable to a mastectomy; each case 
needs individual planning.
All cases of unusual pathologic fea­
tures, such as phyllodes tumours, call for 
appropriate consultation to avoid 
unnecessarily extensive surgery of the 
breast in these young women.
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logical study. Br J  Surg 1974; 61: 113-117FIG. 2—Portion of gross specimen illustrating extensive involvement by multiple tumours.
tation. The nipple was now considerably lower 
than that on the right breast (Fig. 1).
A subcutaneous mastectomy was performed 
with the immediate implantation by a plastic 
surgeon of a subpectoral tissue expander for 
reconstruction. Pathological examination 
showed that the breast was almost completely 
replaced by innumerable fibroadenomas (Fig. 
2), mainly pericanalicular (Fig. 3), variable in 
type and up to 5 cm in size. The nipple-areolar 
skin was banked in the labia for further use. 
She had no recurrent problems when seen 6 
months later at which time a permanent sili­
cone prosthesis was inserted.
Discussion
This patient represents an interesting 
problem in breast disease. With the 
advent of conservation in breast cancer 
surgery, fewer mastectomies are being 
performed. In this case mastectomy 
would seem a mutilating procedure for 
benign disease. However, with the pain, 
weight and the total involvement of the 
breast, there was no alternative. In 
general, almost any tumour of the adoles­
cent breast can be removed with a rim of 
normal tissue, thus preserving most of the 
breast tissue, avoiding recurrence and 
providing acceptable cosmesis.
FIG. 1—Appearance of enlarged, nodular 
breast just before mastectomy.
Fibroadenomas are the commonest 
tumours in adolescent breasts, and at least 
25% are bilateral.1 A few of these, less 
than 5%,2 are giant tumours. In the 
literature, the definition of a giant tumour 
varies from one having a diameter greater 
than 5 cm to a mass weighing more than 
500 g; less than 50 such tumours have 
been reported. At one time, a giant 
tumour was classified as a cystosarcoma, 
but this diagnosis is no longer valid as 
most of these tumours are benign and 
most are fibroadenomas. In one series 
and literature review of phyllodes 
tumours of the breast, from 1927 to 
1954,3 none were shown to behave in a 
malignant fashion. Juvenile fibroade­
FIG. 3—Photomicrograph of representative 
fibroadenoma showing pericanalicular pattern 
(hematoxylin and eosin, original magnification 
x 400).
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Action
In vitro studies indicate that the bacterial action of CLAFORAN (cefotaxime sodium) 
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in the diseases listed below.
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rhea caused by N. gonorrhoeae including penicillin resistant strains. 
B ac te re m ia  /  S e p tic e m ia : caused by Escherichia coli, unspecified Klebsiella 
stra ins and Serratia marcescens.
S k in  in fe c t io n s : caused by Staphylococcus aureus (penicillinase and non­
penicillinase producing, S. epidermidis, Group A streptococci, Escherichia coli, 
Proteus mirabilis and indole positive Proteus.
In tra -a b do m in a l in fe c tio n s : caused by Escherichia coli, and unspecified Kleb­
siella species.
G yne co log ica l in fe c t io n s : including pelvic inflammatory disease, endometritis 
and pelvic cellulitis caused by E. coli, Group A streptococci and Staphylococcus 
epidermidis, anaerobic bacteria including unspecified Peptococcus and Peptostrep- 
tococcus strains and some strains of Bacteroides fragilis. In several cases although 
clin ica l cures were achieved, bacterio logical follow up was not available. 
Clinical experience with CLAFORAN in anaerobic infections is lim ited. CLAFORAN 
has been used with some success in wound and intra-abdominal infections against 
som e strains of unidentified Bacteroides and anaerobic cocci.
CLAFORAN has been shown to be active against some strains of Pseudomonas. 
In the treatment of infections encountered in  im munosuppressed and granulo­
cytopenic patients, results of therapy with CLAFORAN have not been impressive. 
CLAFORAN should not be considered in the treatment of enterococcal infections, 
i.e. Streptococcus taecalis.
Specimens for bacterio logic culture should be obtained prior to therapy in order 
to  isolate and identify the causative organisms and to determine their suscep 
tib ilities  to CLAFORAN. Therapy may be instituted before results of susceptibility 
studies are known; antib iotic treatment should be re evaluated once these results 
becom e available.
P rophy lac tic  U s e : The administration of CLAFORAN perioperatively (preoperative- 
ly, intraoperatively and postoperatively) may reduce the incidence of certain infec 
tions in patients undergoing elective surgical procedures (e.g. abdominal or vaginal 
hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified 
as contaminated or potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased 
risk of infection, intraoperative (after clamping the umbilical cord) and postoperative 
use of CLAFORAN may also reduce the incidence of certain postoperative infections. 
Effective use for elective surgery depends on the time of administration (see Dosage 
and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation 
by mechanical cleansing as well as with a non absorbable antibiotic (eg. neomycin) 
is  recommended.
If there are signs of infection, specimens for culture should be obtained for iden­
tifica tion of the causative organism so that appropriate therapy may be instituted.
Contraindications
CLAFORAN is contraindicated in patients who have shown hypersensitivity to 
cefotaxime sodium, the cephalosporin or the penicillin groups of antibiotics.
Warnings
Before therapy with CLAFORAN is instituted, it must be carefully determined whether 
the  patient has had previous hypersensitivity reactions to cefotaxime, 
cephalosporins, penicillins or other drugs CLAFORAN should be given with caution 
to  patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including 
CLAFORAN should be administered w ith  caution to any patient who has 
demonstrated some form of allergy, particularly to drugs. If an allergic reaction 
to  CLAFORAN occurs, the drug should be discontinued and the patient treated 
w ith  the usual agents (e.g. epinephrine, antihistamine, pressor-amines or 
corticosteroids).
Pseudomembranous colitis has been reported with the use of cephalosporins 
(and other broad spectrum antib iotics); therefore, it is im portant to consider its 
diagnosis in patients who develop diarrhea during the administration of CLAFORAN. 
T h is  colitis can range from m ild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as CLAFORAN, alters the nor­
m al flora of the colon and may perm it overgrowth of Clostridium difficile or other 
Clostridia. It has been established that a toxin produced by Clostridium difficile 
is  one primary cause of antib iotic-associated colitis.
M ild  cases of co litis may respond to discontinuation of CLAFORAN and replace­
ment with a suitable specific antibiotic. Moderate to severe cases should be manag­
ed with fluid, electrolyte and protein supplementation as indicated. When the colitis 
is not relieved by discontinuance of CLAFORAN administration or when it is severe, 
an antibiotic specifically effective in antibiotic-associated pseudomembranous colitis 
(e.g. vancomycin) or ether suitable therapy may be indicated. Other possible causes 
of colitis should also be considered (see A ve rse  Reactions).
Precautions
CLAFORAN (cefotaxime sodium) should be prescribed with caution in individuals 
w ith  a history of lower gastrointestinal disease, particularly colitis.
The safety of CLAFORAN in pregnancy has not been established. Consequently, 
use of the drug in pregnant women requires that the likely benefit from the drug 
be weighed against the possible risk to the mother and fetus.
Use of CLAFORAN in women of child bearing potential requires that the anticipated 
benefits be weighed against the possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be 
exercised when the drug is  administered to nursing mothers.
Prolonged use of CLAFORAN may result in the overgrowth of nonsusceptible 
organisms. Constant evaluation of the patient's condition is essential. If super­
infection occurs, therapy should be discontinued and appropriate measures taken. 
A lthough CLAFORAN rarely produces alterations in kidney function, evaluation 
of renal status is recommended, especially in severely ill patients receiving high 
doses.
Patients w ith  markedly impaired renal function shou ld  be placed on the  special 
dosage schedule recommended under Dosage and Administration, because nor­
mal dosage in these individuals is likely to produce excessive and prolonged serum 
antibiotic concentrations.
Positive direct Coomb’s test is known to develop in individuals du ring  treatment 
w ith the cephalosporin group of antibiotics, including cefotaxime sodium .
In laboratory tests a false positive reaction to g lucose may occur w ith  reducing 
substances but not with the use of specific glucose oxidase methods. 
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence a re : 
H yp e rsen s itiv ity  (1.8%): Rash, pruritus, fever. Loca l (5%); Injection site in flam ­
mation with intravenous administration. Pain, induration and tenderness after in ­
tramuscular injection. G as tro in tes tin a l (1.7%): Co litis diarrhea, nausea and 
vom iting. Symptoms of pseudomembranous co litis  can appear during  or after 
CLAFORAN treatment. H e m ic  and  Lym pha tic  S ys tem  ( < 1 % ) :  M ild , reversi 
ble leukopenia, granulocytopenia and thrombocytopenia have been reported. Some 
patients developed positive direct Coomb's test during treatment w ith  CLAFORAN. 
G en ito u r in a ry  S ystem  ( <  1% ): Moniliasis, vaginitis. L iver ( <  1% ): Transient 
elevations in SGOT, SGFT, serum LDH and serum alkaline phosphatase levels 
have been reported. K idney ( <  1% ): Increased serum  creatinine and BUN have 
occasionally been observed. C en tra l N e rvous System  (0 .2% ); Headache. 
Symptoms and Treatment of Overdosage 
Since no case of overdosage has been reported to date with CLAFORAN, no 
specific information on symptoms or treatment is  available. Treatment of over­
dosage should be symptomatic.
Dosage and Administration
CLAFORAN (cefotaxime sodium ) may be administered intram uscularly or in ­
travenously after reconstitution (see Table with recommended mode of reconstitution 
according to route of administration).
Dosage
Adults
The dosage of CLAFORAN should be determined by susceptibility o f the causative 
organisms, severity of the infection and condition of the patient.
Guidelines for Dosage of CLAFORAN (cefotaxime sodium)
Type of Infection
Daily Dose
(g) Frequency and Route
Uncomplicated
Gonorrhea
1 1 g IM  (s ing le  dose)
Uncomplicated
infections
2 1 g every 12 hours 
IM or IV
Moderately 
severe to severe 
infections
3-6 1-2 g every 
8 hours IM  or IV
Very severe 
infections (e.g. 
septicemia)
6-8 2g every 
6-8 hours IV
Life-threatening
infections
up lo  12 2g  every 
4 hours IV
To prevent postoperative infection in contaminated or potentially contaminated 
surgery, recommended doses are as follows.
(a) 1 g IM or IV administered V2 to IV 2 hours p rio r to the initia l surg ical incision 
to ensure that adequate antib iotic levels are present in the serum  and tissues 
at the start of surgery
(b) 1 g IM or IV administered 11/2  to 2 hours following the first dose; for lengthy 
operative procedures, additional intraoperative doses may be adm inistered, if 
necessary, at appropriate intervals (IV 2 to 2 hours) during surgery
(c) 1 g IM or IV administered with in 2 hours following com pletion of surgery 
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period. 
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord  is  clamped. 
The second and third doses should be given as 1 g IM or IV at 6 and 12 hours 
after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recom m ended:
Neonates: 0-1 week of age 50 m g /  kg IV q 12 h
1-4 weeks of age 50 m g / kg IV q 8  h
infants and children (1 m onth to  12 years): For body weights less than 50 kg, 
the recommended daily dose is  50 to 100 mg / kg IM or IV of body  weight d iv id­
ed into 4 to 6 equal doses, or up to 180 m g / kg / day for severe infections. 
For body weights 50 kg or more, the usual adu lt dosage shou ld  be used. 
The maximum daily dosage should not exceed 12 grams.
Administration of CLAFORAN should be continued for a m in im um  of 48 to 72 
hours after the patient defervesces or after evidence of bacteria l eradication has 
been obtained; a m inim um  of 10 days of treatment is recom m ended for infec­
tions caused by Group A beta-hemolytic streptococci in order to  guard against 
the risk of rheumatic fever or glomerulonephritis; frequent bacterio logic and clinical 
appraisal is necessary during therapy of chronic urinary tract in fections and may 
be required for several m onths after therapy has been completed; persistent in ­
fections may require prolonged treatment. Doses less than those  recommended 
should not be employed.
Dosage for Patients with Impaired Renal Function
In patients w ith estimated creatinine clearance of less than 20  m L  / m in  / 1.73m2 
the dose of CLAFORAN should be halved (see Precautions).
If serum creatinine values alone are available, the following fo rm u la  (based on 
sex, weight, and age of the patient) may be used to convert these values into 
creatinine clearance.
M a le s : Weight (kg) x  (140 -  age) Females: 0.85 x above value 
72 x  serum creatinine
Administration
In tra m u s c u la r: CLAFORAN should be injected well within the body of a relatively
large muscle such as the upper outer quadrant of the buttock (i.e. g luteus max- 
imus); aspiration is necessary to avoid inadvertent in jection in to  a b lood vessel. 
In tra v e n o u s : The intravenous route is preferable for patients w ith  bacteremia, 
bacterial septicemia, or other severe or life-threatening infections, or for patients 
who may be poor risks because of lowered resistance resulting from  such 
debilitating cond itions as malnutrition, trauma, surgery, diabetes, heart failure, 
or malignancy, particularly if shock is present or im pending.
For bolus adm inistration a solution containing 1 or 2 g of CLAFORAN can be 
injected over a period of 3 to 5 minutes. Using an in fusion system, it m ay also 
be given over a longer period of time through the tub ing  system by w h ich  the 
patient may be receiving other intravenous solutions. Butterfly* or scalp vein type 
needles are preferred for this type of infusion. However, during in fusion of the 
solution containing CLAFORAN, it is advisable to discontinue tem porarily the ad­
ministration of other solutions at the same site.
Reg'd TM of Abbott Laboratories.
Reconstitution
For In tra m u s c u la r U s e : CLAFORAN should be reconstituted with Sterile Water 
for Injection or Bacteriostatic Water for Injection in accordance w ith  the vo lum es 
recommended in the following table.
Reconstitution Table
Intramuscular
Volume to be 
Added to 
Vial (mL)*
Approximate 
Available 
Vol. (mL)
Approx. Average 
Concentration 
(mg/mL)
500 m g vial 2 2.2 230
1 g vial 3 3.4 300
2 g vial 5 6.0 330
‘ shake to dissolve.
For d ire c t in tra ve n o u s  in jec tion  (b o lu s ) and  /  o r  c o n t in u o u s  in tra v e n o u s  
in fu s io n ; 500 mg, 1 and 2 g vials shou ld  be reconstituted w ith  at least 10 mL 
of Sterile Water for Injection. Reconstituted so lution may be further d ilu ted with 
50 to 1000 m L of the fluids recommended for IV in fusion.
Reconstitution Table
Volume to be Approximate Approx. Average
Added to Available Concentration
Intravenous Vial (mL)* Vol. (mL) (mg/mL)
500 mg via llO 10.2 50
1 g vial 10 10.4 95
2 g vial 10 11.0 180
'shake to dissolve.
S o lu tio n s  fo r  IV In fu s io n : CLAFORAN is  com patib le w ith  the fo llow ing in fu­
sion f lu id s :
-  Sterile Water for Injection
-  0.9% NaCI in jection
-  5%  dextrose in jection
-  0.9% NaCI and 5%  dextrose in jection
-  0.45% NaCI and 5%  dextrose in jection
-  0 .2%  NaCI and 5 %  dextrose in jection
-  Sodium Lactate injection
-  5%  dextrose and 0.15% KCI injection
-  Plasma-Lyte 56 Electrolyte Solution in 5 %  dextrose injection
-  Ringer's in jection
-  Lactated Ringer's solution
-  Lactated Ringer’s with 5%  dextrose injection 
CLAFORAN is  also compatib le with lignocaine 1%.
A solution of 1 g of CLAFORAN in 14 m L of Sterile Water for Injection is  isotonic. 
S ta b ility  o f S o lu tio n
S to ra g e : Solutions of CLAFORAN range from  light yellow to  amber, depending 
on concentration and the diluent used. The so lutions tend to darken depending 
on storage conditions and should be protected from elevated tem peratures and 
excessive light.
"R e g 'd  TM  of Baxter-Travenol Laboratories.
CLAFORAN reconstituted in the original via l as described under Reconstitution 
maintains satisfactory potency for 24 hours at room temperature (25°C) and for 
48 hours under refrigeration (0-5°C). Only freshly prepared reconstituted so lu­
tions may be further diluted with 50 to 1000 m L of the recom m ended infusion 
flu ids in V ia fle x " intravenous bags. Such so lutions m aintain satisfactory poten­
cy for 24 hours at room temperature (25°C) and for 72 hours under refrigeration 
(0-5°C). Any unused solutions should be discarded.
CLAFORAN reconstituted with 1% lignocaine m aintains satisfactory potency for 
up to  24 hours at room temperature and 48 hours under refrigeration (reference 
to lignocaine restrictions is  advisable).
CLAFORAN solutions exhibit m axim um  stability in the pH 5-7 range.
S pe c ia l In s t r u c t io n s : Parenteral drug products shou ld  be inspected visually 
for particulate matter and discoloration p rio r to adm inistration. Solutions of 
CLAFORAN range from light yellow to  amber, depending on concentration and 
diluent used. The dry powder as well as so lutions tend to darken, depending 
on storage conditions.
In c o m p a tib il it ie s :  Solutions of CLAFORAN m ust not be adm ixed with 
am inoglycoside solutions. If CLAFORAN and am inog lycosides are to  be ad­
ministered to  the same patient, they m ust be adm inistered separately and not 
as a mixed in jection.
Solutions of CLAFORAN should not be prepared w ith  diluents having a pH above 
7.5 such as Sodium  Bicarbonate Injection.
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, 
in via ls containing 500 mg, 1.0 and 2.0 g o f cefotaxime sodium  (expressed as 
acid on a dry basis).
S to ra g e ; CLAFORAN in the dry state shou ld  be stored at room temperature, 
protected from light and heat.
Product monograph available on request 
Reference
Jones R.N. et a l. : Antib iotic Prophylaxis of 1036 Patients Undergoing Elective 
Surgical Procedures. The American Journa l of Surgery, 1987; 153; 341-346.
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CLASSIFIED ADVERTISING
As a further service to its readers the Canadian Journal o f  Surgery is pleased to accept suitable classified advertisements. The deadline is 1 month before issue 
date. Regular classified rates (for each insertion): $42.00 for the first 40 words or less, additional words 55C each (additional $16.00 for frame). Special Display 
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MICROSURGICAL COURSE — The Department of 
Surgery, McMaster University, Hamilton, Ontario, 
is now offering one week, on-going courses in 
microsurgery, using animal facilities and video­
tapes. These courses are for anyone interested in 
small vessel anastomosis, nerve repairs, vas and 
fallopian tube reconstructions. The laboratory is 
organized to guide you through the basic microsur- 
gical techniques to more advanced tasks with the 
help of an assistant on a one-to-one basis. Please 
call: Dr. A. Thoma, (416) 523-0019 for further in­
formation. — S88-09
CLINICAL BURN FELLOWSHIP: ON -  Available 
July 1, 1988 for six months or twelve months. 
Regional Adult Burn Centre treating 1 20 patients 
per year, clinical research. New ultramodern burn 
centre, very well staffed, extensive research fund­
ing. Please contact: Dr. Walter J. Peters, Ste. 224, 
Turner Wing, Wellesley Hospital, 160 Wellesley 
St. E., Toronto, ON M4Y 1J3. -S88-12
CHIEF, DIVISION OF ORTHOPEDICS: ON -  The
Ottawa Civic Hospital, a 922-bed teaching and 
research facility closely associated with the 
University of Ottawa Faculty of Health Sciences 
is seeking a new Chief for the Division of Ortho­
pedic Surgery. The Division has 86 beds, 8 staff 
members and a Royal College Training Program. 
Spinal surgery has been a major clinical and 
research focus. A regional trauma program is
planned and will be an area for future develop­
ment. The hospital is expanding its basic and clin­
ical research activities and applicants should have 
a strong academic background. In accordance 
with Canadian immigration policies, initial prefer­
ence for this position will be given to Canadian 
citizens and permanent residents of Canada. 
Applicants should reply with their curriculum vitae 
and the names of three references to: Dr. J.D. 
Grimes, Vice President, Clinical and Research 
Administration, Ottawa Civic Hospital, 1053 
Carling Ave., Ottawa, ON K1Y 4E9. -S88-16
ORTHOPEDISTS: US — Fargo Clinic — MeritCare, 
one of the nation's largest multispecialty clinics, 
is seeking several additional orthopedists. The 
present department of five will be expanded to 
meet the needs of our community as we complete 
construction of the comprehensive orthopedic and 
rehabilitation facility. Two PA's and a family phy­
sician assist in musculoskeletal evaluations. Ad­
ditional training in pediatrics, spine, and sports 
medicine welcome but not required. Competitive 
compensation and benefits. Tri-college communi­
ty of 130 000 near western Minnesota lakes 
region. Call: Dr. Dave Wiest or Dr. Chuck Ander­
son, 1-800-437-4010 or send cv in confidence to: 
Dr. Anderson, Box 2067, Fargo, ND 58123.
-S88-13
GENERAL SURGEON: NWT -  required for ex­
panding northern community. One active surgeon
on staff. Expansion of surgical work will occur 
with opening of new hospital shortly. This post is 
both challenging and lucrative. The city has ex­
cellent facilities and schools. Please forward en­
quiries to: Family Medical Clinic, PO Box 1559, 
Yellowknife NWT X1A 2P2. -S 88-06
GENERAL/THORACIC SURGEON: US -  Well es­
tablished group in Philadephia area community 
hospital is seeking a BC/BE associate to provide 
general/thoracic surgery (no open heart). Please 
send cv to: Box S116 CJS -S 88-15
RESIDENCY IN 
CARDIOVASCULAR  
A N D THORACIC SURGERY
Opening available July 1, 1988 and 1 989 for three- 
year training program in busy adult (600) and pedri- 
atric (1 50) cardiac surgery program including arrhyth­
mia surgery, heart and heart/ lung transplantation, and 
vascular and thoracic surgery. Outstanding facilities 
and fully accredited program at a major Canadian 
university. ABS certification or eligibility required. If 
not graduate of North American medical school, 
MCCQE required. Please reply to:
Patricia A. Penkoske, MD
Department of Surgery
Room 2D2.09 Walter MacKenzieCenter
University of Alberta
Edmonton, AB
T6G 2R7
Tel: (403) 432-8057 S88-01
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is virtually lint free and non-ffaying to minimize the risk 
of potential infections and foreign reactions 
that could enhance scar formation1 ;
adheres less to wounds and causes less disruption 
of exposed and friable dermal capillary beds'; 
provides a drier wound site because it is 56% 
and 26% more absorbent than 8 & 12 ply cotton gauze 
sponges respectively1 ;
is more economical in use than cotton gauze sponges 
and has shown overall sponge savings of 10 to 25% and more 
in Canadian hospitals, not including savings 
on non-adhering dressings, combine pads, post-op sponges 
and nursing time.
Oinniot
onYluQauje
aponqea.
NU GAUZE* sponges are totally 
Canadian made, are used 
in the majority of Canadian 
hospitals and exported 
to many countries.
Reference: 1. Birdsell DC, Davidson JSD: A Report on Clinical Trials of NU GAUZE*
Rayon Sponges, Including In Vitro and In Vivo Comparisons with Conventional Cotton Gauze 
Sponges. July 1986,
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